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CHAPTER 1 
Introduction. 

Systemic lupus erythematosus (SLE) is an auto-immune disease which may affect 
any organ of the body. The course of the disease is unpredictable and is characterized 
by exacerbations and remissions (1). Nephritis is one of the most serious 
manifestations of the disease, and is found in about half of the patients. In 20% of 
the cases nephritis leads to end stage renal disease (2). 
The diagnosis of SLE is based on a combination of disease manifestations and 
serological findings (1). In SLE a wide variety of auto-antibodies can be found. 
Especially antibodies against nuclear antigens are formed, but also antibodies directed 
against other auto-antigens for instance cytoplasmic antigens, cell membrane 
determinants, immunoglobulins and clotting factors (1). A major group of auto-
antigens recognized by anti-nuclear antibodies are located within chromatin. 
Chromatin is the compact fiber in which the eukaryotic DNA is packed. In inactive 
chromatin, DNA is complexed to histones forming nucleosomes. In a nucleosome 
four pairs of the histone proteins H2A, H2B, H3 and H4 form the histone octamer. 
Two superhelical turns of 146 bp of DNA are wound around this octamer. Histone 
HI and a linker stretch of 60 bp of DNA connect neighboring nucleosomes like 
beads on a string (3). In active chromatin, DNA is unfolded from the nucleosomes 
and gene transcription and DNA replication take place. As outlined in the table in 
various auto-immune diseases antibodies to nucleosomal antigens, transcriptional 
complexes and DNA replication/repair complexes can be found. A selection of these 
anti-chromatin antibodies and their association with autoimmune diseases is given in 
the table (next page). 
Many of the nuclear antigens which serve as a target in auto-immune diseases, are 
complexes of proteins and nucleic acids which are involved in distinct nuclear 
functions. Often a set of auto-antibodies against the individual components of a 
complex tends to be produced tandemly. For instance the nucleosome is a frequent 
auto-immune target in SLE, yielding antibodies to DNA, histones and nucleosomes. 
This phenomenon is also found with other autoantibodies, e.g. those against small 
nuclear ribonucleoprotein (snRNP) autoanti gens such as Ul, U2, U4-6 and U5 
snRNPs, where antibodies may be directed against the U-RNA and the various 
proteins of the particle (15). 
Amongst the anti-nuclear antibodies found in SLE, those directed against double 
stranded DNA and against the Sm protein are specific for the disease (16). Auto-
antibodies have been held responsible for many of the disease manifestations and 
there is evidence that anti-dsDNA antibodies are pathogenic for the development of 
nephritis. Firstly, a rise in titer of anti-dsDNA antibodies is found preceding renal 
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Anti chromatin antibodies and their relation with disease 
auto-antigen 
nucleosomal antigens 
DNA 
histones 
nucleosomes 
transcription complexes 
RNA polymerase I 
RNA polymerase II 
RNA polymerase III 
Ku antigen 
DNA replication/repair complexes 
PCNA3 
disease association 
SLE 
SLE, DIL1, RA2, Juvenile 
RA 
SLE, DIL, scleroderma 
Scleroderma 
Scleroderma 
Scleroderma 
SLE, Scleroderma 
SLE 
ref 
(1) 
(4-6) 
(7-9) 
(10) 
(H) 
(12) 
(13) 
(14) 
'DIL = drug induced lupus, ¿RA = rheumatoid arthritis, 'PCNA = proliferating cell 
nuclear antigen. 
exacerbations of lupus (17,18), and secondly in renal eluates of patients with lupus 
nephritis an enrichment for anti-dsDNA antibodies has been detected (19,20). About 
10 years ago we postulated that certain anti-dsDNA antibodies are able to cross react 
with heparan sulfate (HS) in the glomerular basement membrane (GBM) and that this 
event leads to nephritis (21). HS is the negatively charged glycosaminoglycan side 
chain of heparan sulfate proteoglycan (HSPG). It is an intrinsic constituent of the 
glomerular basement membrane (GBM) and responsible for the majority of the 
anionic sites in the GBM (22-24). These anionic sites are the major determinants for 
the charge dependent permeability of the GBM. Consequently, loss of these anionic 
sites leads to albuminuria (25-29), while antibodies to HS induce instantly an acute 
selective albuminuria after intravenous injection in rats (30). 
Besides the reactivity of monoclonal anti-DNA antibodies with HS (21), we found 
anti-HS reactivity in sera of lupus patients in association with renal disease (31,32). 
These data are presented in chapter 3. However, in later studies we discovered that 
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this cross reactivity of anti-dsDNA antibodies with HS was a feature of antibodies 
complexed to DNA and histones (nucleosomes) (33). In these immune complexes the 
histone part of the nucleosome, which is strongly positively charged, interacts with 
HS. In a rat kidney perfusion model subsequent perfusion of histones, DNA and anti-
DNA led to binding of antibodies to the GBM, whereas after perfusion of DNA and 
anti-DNA without histones no GBM binding was observed (34). The involvement of 
histones in lupus nephritis is discussed in chapter 2. 
When we studied the cross reactivity of monoclonal anti-dsDNA antibodies with HS, 
we found for some antibodies that not only HS reactivity was due to antibodies 
complexed to nucleosomes, but also anti-dsDNA reactivity. In pure non-complexed 
form these antibodies appeared to be anti-nucleosome antibodies (35). These findings 
are described in chapter 4. In recent years much research has focused on anti-
nucleosome antibodies. These antibodies exclusively react with the intact nucleosome 
and not with its components histones and DNA. Maybe it is better to speak of 
nucleosome-specific antibodies, for anti-DNA and anti-histone antibodies will also 
bind to the nucleosome. 
Antibodies to nucleosomes were in fact the first auto-antibodies described in 
association with SLE. The morphological characteristics of the first serological 
marker for SLE 'the LE cell phenomenon' (36) evolve after opsonization of 'LE cell 
factors' complexed to DNA and histones. Later on, the 'LE cell factors' were 
identified as auto-antibodies and it was shown that nucleosomes were able to inhibit 
the formation of the 'LE cell phenomenon' in contrast to free dsDNA or histones 
(37). Therefore, it appears that the 'LE cell phenomenon' is related to anti-
nucleosome auto-antibodies. 
In recent years monoclonal anti-nucleosome antibodies have been described both in 
human (38) and murine lupus (39,40). Anti-nucleosome antibodies have been found 
to develop early in life in lupus mice, before the occurrence of anti-dsDNA and anti-
histone antibodies (41,42). In humans, the prevalence of anti-nucleosome antibodies 
in SLE is very high (7,43), but until now in only one study anti-dsDNA and anti-
histone antibodies were preadsorbed before measuring anti-nucleosome reactivity. In 
this study the prevalence of these antibodies was 84% (44). Also in drug induced 
lupus anti-nucleosome antibodies have been detected (8). 
There is now generally agreement that the auto-antibody response in lupus is antigen 
driven since somatic mutation and affinity maturation occurs and T-cell help is 
required (41,45). Very interestingly, recently it was found that pathogenic T-helper 
cells in SNF1 lupus mice are specific for nucleosomes and also able to induce anti-
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dsDNA and anti-histone antibodies (46). So, the antigen driving the autoimmune 
response in SLE might very well be the nucleosome. This idea is sustained by the 
recent finding that the antibody response in lupus is directed against antigens 
(nucleosomes and other nuclear antigens) which can be found in blebs, appearing on 
apoptotic cells (47). 
Until now little is known about anti-nucleosome antibodies. For instance it is not 
known what epitopes are recognized on the nucleosomes and in which way the 
interaction with both DNA and histones takes place. Also the pathogenic significance 
of these antibodies has not been studied yet. 
The aim of this study was to evaluate the role of anti-nucleosome antibodies in 
systemic lupus erythematosus. The binding mechanism of antibodies complexed to 
nucleosomes in the GBM was studied in a rat kidney perfusion model (chapter 4). 
Renal biopsies of human lupus nephritis were stained for histones and nucleosomes 
in glomerular deposits. The appearance of histones and nucleosomes was associated 
with histopathological findings and with HS staining in the GBM (chapter 5). When 
hybridomas producing these anti-nucleosome antibodies were inoculated 
intraperitoneally in naive mice, not only glomerular localization was observed but 
also binding to cell nuclei (in vivo ANA). Therefore the possible role of anti-
nucleosome antibodies complexed to nucleosomes and the mechanism of in-vivo 
ANA was analyzed (chapter 6). The specificity of anti-nucleosome antibodies on 
different subnucleosome structures was assessed and binding to linear histone 
epitopes was studied (chapter 7). Based on the observation that nucleosome specific 
T-helper cells could drive the anti-dsDNA response (46), we analyzed whether true 
anti-dsDNA antibodies also recognized nucleosomal proteins (chapter 8). And lastly, 
since apoptosis is in all likelihood the main source for nucleosomes in the circulation 
and derangement of apoptosis has been found in several lupus mouse strains (48,49), 
the role of apoptosis in lupus, both in the induction and the effector phase of the 
disease, is reviewed (chapter 9). 
REFERENCES 
1. Lahita, R.G. 1992. Systemic Lupus Erythematosus. Churchill Livingstone Inc., 
New York. 
14 
2. Nossent, H.C., S. С. Henzen-Logmans, T. M. Vroom, J. H. M. Berden, and 
T. J. G. Swaak. 1990. Contribution of renal biopsy data in predicting outcome 
in lupus nephritis. Arthritis Rheum. 33:970. 
3. McGhee, J.D. and G. Felsenfeld. 1980. Nucleosome structure. Ann. Rev. 
Biochem. 49:1115. 
4. Cohen, MG., Κ. M. Pollard, and J. Webb. 1992. Antibodies to histones in 
systemic lupus erythematosus: prevalence, specificity, and relationship to 
clinical and laboratory features. Ann. Rheum. Dis. 51:61. 
5. Epstein, A. and P. Barland. 1985. The diagnostic value of antihistone 
antibodies in drug-induced lupus erythematosus. Arthritis Rheum. 25:158. 
6. Tuaillon, N., S. Muller, J. L. Pasquali, P. Bordigoni, P. Youinou, and M. H. 
V. van Regenmortel. 1990. Antibodies from patients with rheumatoid arthritis 
and juvenile chronic arthritis analyzed with core histone synthetic peptides. 
Int. Arch. Allergy Appi. Immunol. 91:291. 
7. Burlingame, R.W., M. L. Boey, G. Starkebaum, and R. L. Rubin. 1994. The 
central role of chromatin in autoimmune responses to histones and DNA in 
systemic lupus erythematosus. J. Clin. Invest. 94:184. 
8. Burlingame, R.W. and R. L. Rubin. 1991. Drug-induced anti-histone 
autoantibodies display two patterns of reactivity with substructures of 
chromatin. J. Clin. Invest. 55:680. 
9. Wallace, D.J., H. С Lin, G. Q. Shen, and J. B. Peter. 1994. Antibodies to 
histone (H2A-H2B)-DNA complexes in the absence of antibodies to 
doublestranded DNA or to (H2A-H2B) complexes are more sensitive and 
specific for scleroderma related disorders than for lupus. Arthritis Rheum. 
37:1795. 
10. Reimer, G., К. M. Rose, and U. Scheer. 1987. Autoantibody to RNA 
polymerase I in scleroderma sera. J. Clin. Invest. 79:65. 
11. Hirakata, M., Y. Okano, and A. Suwa. 1992. Novel autoantibodies to RNA 
polymerase II in scleroderma. Arthritis Rheum. 35:S151. 
12. Okano, Y., V. D. Steen, and T. A. Medsger. 1992. Serum autoantibodies 
reactive with RNA polymerase III (RP3) a major autoantigen in systemic 
sclerosis (SSc) with diffuse cutaneous involvement. Arthritis Rheum. 55:S38. 
13. Satoh, M., J. Langdon, and W. H. Reeves. 1993. Clinical applications of an 
anti-Ku antigen capture ELISA. Clin. Immunol. Newsletter 13:23. 
14. Miyachi, K., M. J. Fritzler, and E. M. Tan. 1978. Autoantibody to a nuclear 
antigen in proliferating cells. J. Immunol. 121:222%. 
15 
15. Van Venrooij, W.J., R. Hoet, and B. Hageman. 1990. Anti-(Ul) small nuclear 
RNA antibodies in anti-small nuclear nbonucleoprotein sera from patients with 
connective tissue diseases. J Clin Invest 56:2154 
16. Tan, E.M. 1989. Antinuclear antibodies: diagnostic markers for autoimmune 
diseases and probes for cell biology. Adv Immunol 44:93. 
17. ter Borg, E.J., G. Horst, E. J. Hummel, P. С Limburg, and С. G. M. 
Kallenberg. 1990. Predictive value of rises in anti-double-stranded DNA 
antibody levels for disease exacerbations in systemic lupus erythematosus: a 
long term prospective study. Arthritis Rheum 33:634. 
18. Swaak, A.J.G., J. Groenwold, and W. Bronsveld. 1986. Predictive value of 
complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann 
Rheum Dis 45:359. 
19. Winfield, J.B., I. Faiferman, and D. Koffler. 1977. Avidity of anti-DNA 
antibodies in serum and IgG glomerular eluates from patients with systemic 
lupus erythematosus. J Clin Invest 59:90. 
20. Kalunian, K.C., N. Panosian-Sahakian, F. M. Ebling, A. H. Cohen, J. S. 
Louie, J. Kaine, and B. H. Hahn. 1989. Idiotypic characteristics of 
immunoglobulins associated with systemic lupus erythematosus. Arthritis 
Rheum 32:513. 
21. Faaber, P., G. P. M. Rijke, L. B. A. Van de Putte, P. J. A. Capel, and J. H. 
M. Berden. 1986. Crossreactivity of human and murine anti-DNA antibodies 
with heparan sulphate: the major glycosaminoglycan in glomerular basement 
membrane. J Clin Invest 77:1824. 
22. Kanwar, Y.S., Z. Z. Liu, N. Kashihara, and E. I. Wallner. 1991. Current status 
of the structural and functional basis of glomerular filtration and proteinuria. 
Semin Nephrol 11:390. 
23. Cotran, R.S. and H. G. Rennke. 1983. Anionic sites and the mechanisms of 
proteinuria. N Engl J Med 309:1050. 
24. Farquhar, M.G. 1991. The glomerular basement membrane. A selective 
macromolecular filter. In Cell biology of ectracellular matrix. Hay Ed, ed. 
Plenum Press, New York, p. 395. 
25. Vehaskari, V.M., E. R. Root, F. G. Germuth, and A. M. Robson. 1982. 
Glomerular charge and urinary protein excretion. Effects of systemic and 
intrarenal polycation infusion in the rat. Kidney Int 22:\П. 
16 
26. Hunsicker, L.G., T. P. Shearer, and S. J. Shaffer. 1981. Acute reversible 
proteinuria induced by infusion of the polycation hexadimethrine. Kidney Int. 
20:1. 
27. Kelley, V.E. and T. Cavallo. 1978. Glomerular permeability, transfer of native 
ferritin in glomeruli with decreased anionic sites. Lab. Invest. 39:547. 
28. Assel, E., K-Η. Neumann, Η-J. Schurek, С. Sonnenburg, and H. Stolte. 1984. 
Glomerular albumin leakage and morphology after neutralization of 
polyanions; I. Albumin clearance and sieving coefficient in the isolated 
perfused rat kidney. Renal Physiol. (Basel) 7:357. 
29. Sonnenburg-Hatzopoulos, C , E. Assel, Η-J. Schurek, and H. Stolte. 1984. 
Glomerular albumin leakage and morphology after neutralization of 
polyanions; II. Discrepancy of protamin induced albuminuria and fine structure 
of the glomerular filtration barrier. J. Submicrosc. Cytol. 16:741. 
30. van den Born, J., L. P. W. J. van den Heuvel, Μ. Α. Η. Bakker, J. Η. 
Veerkamp, К. J. M. Assmann, and J. H. M. Berden. 1992. A monoclonal 
antibody against GBM heparan sulfate induces an acute selective proteinuria 
in rats. Kidney Int. 41:\15. 
31. Termaat, R.M., K. Brinkman, J. С Nossent, A. J. G. Swaak, R. J. T. Smeenk, 
and J. H. M. Berden. 1990. Anti-heparan sulphate reactivity in sera from 
patients with systemic lupus erythematosus with renal or non-renal 
manifestations. Clin. Exp. Immunol. 52:268. 
32. Kramers, C , R. M. Termaat, E. J. ter Borg, M. С. J. van Bruggen, С. G. M. 
Kallenberg, and J. H. M. Berden. 1993. Higher anti-heparan sulphate reactivity 
during SLE exacerbations with renal manifestations. A long term prospective 
analysis. Clin. Exp. Immunol. 93:34. 
33. Termaat, R.M., K. Brinkman, F. van Gompel, L. P. W. J. van de Heuvel, J. 
Veerkamp, R. J. T. Smeenk, and J. H. M. Berden. 1990. Cross-reactivity of 
monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound 
DNA/histone complexes. J. Autoimmunity 5:531. 
34. Termaat, R.M., K. J. M. Assmann, H. B. P. M. Dijkman, R. J. T. Smeenk, and 
J. H. M. Berden. 1992. Anti-DNA antibodies can bind to the glomerulus via 
two distinct mechanisms. Kidney Int. 42:1363. 
17 
35. Kramers, С , M. N. Hylkema, M. С. J. van Bruggen, R. van de Lagemaat, H. 
В. P. M. Dijkman, К. J. M. Assmann, R. J. T. Smeenk, and J. H. M. Berden. 
1994. Anti-nucleosome antibodies complexed to nucleosomal antigens show 
anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. 
J. Clin. Invest. 94:568. 
36. Holman, H.R. and H. G. Kunkel. 1957. Affinity between the lupus 
erythematosus serum factor and cell nuclei and nucleoprotein. Science 
126:162. 
37. Rekvig, O.P. and K. Hannestad. 1981. Lupus erythematosus (LE) factors 
recognize both nucleosomes and viable human leukocytes. Scand. J. Immunol. 
13:597. 
38. Ehrenstein, M., С. Longhurst, and D. A. Isenberg. 1993. Production and 
analysis of IgG monoclonal anti-DNA antibodies from systemic lupus 
erythematosus (SLE) patients. Clin. Exp. Immunol. 92:39. 
39. Losman, M.J., T. M. Fasy, K. E. Novick, and M. Monestier. 1992. 
Monoclonal autoantibodies to subnucleosomes from a MRL/Mp-+/+ mouse. 
J. Immunol. 148:1561. 
40. Losman, J.Α., T. M. Fasy, К. E. Novick, M. Massa, and M. Monestier. 1993. 
Nucleosome-specific antibody from an autoimmune MRL/Mp-lpr/lpr mouse. 
Arthritis Rheum. 36:552. 
41. Burlingame, R.W., R. L. Rubin, R. S. Balderas, and A. N. Theofilopoulos. 
1993. Genesis and evolution of anti-chromatin autoantibodies in murine lupus 
implicates T-dependent immunization with self antigen. J. Clin. Invest. 
91Л6І1. 
42. Amoura, Z., H. Chabre, S. Koutouzov, С Lotton, A. Cabrespines, J. F. Bach, 
and L. Jacob. 1994. Nucleosome restricted antibodies are detected before 
anti-dsDNA and/or anti-histone antibodies in serum of MRL-Mp lpr/lpr and 
+/+ mice, and are present in kidney eluates of lupus mice with proteinuria. 
Arthritis Rheum. 57:1684. 
43. Massa, M., F. de Benedetti, P. Pignatti, S. Albani, G. Di Fuccia, M. 
Monestier, and A. Martini. 1994. Anti-double stranded DNA, anti-histone and 
anti-nucleosome IgG reactivities in children with systemic lupus 
erythematosus. Clin. Exp. Rheumatol. 72:219. 
44. Chabre, Η., Ζ. Amoura, J. С. Piette, P. Godeau, J. F. Bach, and S. Koutouzov. 
1995. Presence of nucleosome restricted antibodies in patients with systemic 
lupus erythematosus. Arthritis Rheum. (In Press) 
18 
45. Marion, T.N., A. L. M. Bothwell, D. E. Briles, and Jr Janeway,C.A.. 1989. 
IgG anti-DNA autoantibodies within an individual autoimmune mouse are the 
products of clonal selection. J. Immunol. 142:4269. 
46. Mohan, C , S. Adams, V. Stanik, and S. K. Datta. 1993. Nucleosome: a major 
immunogen for pathogenic autoantibody-inducing Τ cells of lupus. J. Exp. 
Med. 777:1367. 
47. Casciola-Rosen, L.A., G. Anhalt, and A. Rosen. 1994. Autoantigens targeted 
in systemic lupus erythematosus are clustered in two populations of surface 
structures on apoptotic keratinocytes. J. Exp. Med. /79:1317. 
48. Watanabe-Fukunaga, R., С I. Brannan, N. G. Copeland, N. A. Jenkins, and 
S. Nagate. 1992. Lymphoproliferation disorder in mice explained by defects 
in Fas antigen that mediates apoptosis. Nature 556:314. 
49. Takahashi, T., M. Tanaka, С. I. Brannan, N. A. Jenkins, N. G. Copeland, T. 
Suda, and S. Nagata. 1994. Generalized lymphoproliferative diseases in mice, 
caused by a point mutation in the Fas ligand. Cell 76:969. 
19 

CHAPTER 2 
Histones in lupus nephritis. 
C. Kramers', M.N. Hylkema2, R.M. Termaat', K. Brinkman2, 
R.J.T. Smeenk2, J.H.M. Berden'. 
'Division of Nephrology, University Hospital, Nijmegen, and 
2Department of Autoimmune Diseases, Central Laboratory of the 
Dutch Red Cross Blood Transfusion Service, Amsterdam, 
the Netherlands. 
Published in Exp Nephrol 1993, 1 224-228 
(reproduced with permission) 

Kees Kramers' 
Machteid Hylkemab 
Rose-Mane Termaal* 
Kees Вппктапъ 
Ruud Smeenkb 
Jo Berden' 
a
 Division of Nephrology, 
University Hospital. Nijmegen, and 
b
 Department of Autoimmune Diseases, 
Centra] Laboratory of the 
Dutch Red Cross Bloodtransfusion Service, 
Amsterdam, The Netherlands 
Histones in Lupus Nephritis 
Keywords 
Systemic lupus erythematosus 
Histones 
Nephritis 
Anti-DNA cross-reactivity 
Heparan sulphate 
Nucleosome 
Glomerular basement membrane 
Lupus nephritis (LN) is one of the most severe compli­
cations of systemic lupus erythematosus (SLE), ultimately 
affecting 30-50% of patients [1]. In 15-20% of these 
patients it leads to end-stage renal disease [2]. 
Anti-DNA Antibodies and Lupus Nephritis 
The pathogenesis of LN is still unclear, despite three 
decades of extensive research. The presence in LN of 
mesangial, subepithelial and subendothelial deposits of 
immunoglobulins and complement factors suggests an 
immunecomplex mechanism. Renal exacerbations are of­
ten preceded by a rise in titer of high avidity anti-dsDNA 
antibodies [3-5] although this rise is not observed in 
every exacerbation and sometimes serological activity is 
seen in conjunction with a stable clinical course [6]. Renal 
eluates contain predominantly high avidity anti-dsDNA 
antibodies [7, 8]. Therefore, it seems justified to assign a 
pathogenic role to anti-dsDNA antibodies in LN [9, 10]. 
These observations have led to the classical concept that 
anti-dsDNA antibodies and DNA form immune com­
plexes in the circulation, which then become trapped in 
the glomerular basement membrane (GBM), thereby ini­
tiating glomerular inflammation. The last decade how­
ever, new hypotheses have been put forward, since defi­
nite proof for this classical concept failed to appear [ 10]. 
Cross-Reactivity of Anti-DNA 
An alternative explanation for the pathogenicity of 
anti-DNA is based on the observation that anti-DNA may 
crossreact with several other molecules, as first described 
for cardiohpin and other negatively charged phospholip­
ids [ 10-13]. A few years ago, we described the cross-reac­
tion of anti-DNA with an intrinsic constituent of the 
GBM: heparan sulphate (HS) [14]. This HS is the nega­
tively charged side chain of heparan sulphate proteogly­
can (HSPG) and responsible for the majority of the 
anionic sites in the GBM, which are the major determi­
nants for the charge-selective permeability of the GBM. 
Loss of these anionic sites leads to proteinuria. In both 
human and murine SLE sera we found anti-HS reactivity, 
which could be inhibited by DNA, while the anti-DNA 
binding was inhibitable with HS [14]. The potential 
pathogenic significance of this cross-reactivity was under­
lined by the finding that anti-HS reactivity was present in 
renal eluates of SLE patients and lupus mice [ 14]. Clini­
cally, we found a correlation of anti-HS reactivity with 
renal disease, first in a selected cohort of SLE patients 
[15], but later on also in a prospective analysis of 72 con­
secutive SLE patients [ 16]. Also studies in an isolated per­
fused rat kidney model, in which proteinuria developed 
after perfusion with an anti-DNA monoclonal antibody 
(mAb) or purified IgG isolated from sera of patients with 
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lupus nephritis, pointed towards a binding of anti-DNA 
antibodies to intrinsic glomerular constituents [17]. 
Moreover, it was recently reported that cross-reactive 
anti-DNA antibodies predominated in renal eluates from 
lupus patients [18]. 
Histones and Cross-Reactivity 
To study the cross-reactivity with HS in more detail we 
used a panel of anti-DNA mAb from lupus-prone mice. 
Initially, these studies confirmed the binding of anti-
DNA to HS and the parental molecule HSPG, since 40% 
of the mAb bound to HS and this binding could be inhib­
ited by DNA and vice versa [19]. However, when we puri­
fied hybridoma culture supernatants of these cross-reac­
tive mAb under dissociating high salt conditions (3 M 
NaCl) on a protein A-Sepharose column, they completely 
lost their property to bind HS and HSPG. Reconstitution 
of the purified mAb with the protein-Α column effluent 
restored the HS and HSPG binding in ELISA. 
Subsequently, we identified histones and DNA in the 
protein-Α column effluent [20]. Certain unpurified anti-
DNA mAb also bound strongly to isolated GBM loops, 
while after purification the binding disappeared. Appar­
ently, this binding occurred through anionic sites in the 
GBM, since preincubation of the GBM loops with cat-
ionic ferritin prevented binding and pretreatment with 
the HS degrading enzyme heparitinase reduced the bind­
ing considerably [19]. After preincubation of the GBM 
loops with histones and subsequently with DNA the puri­
fied mAb again bound in a fine granular pattern [21]. 
Taken together these experiments show that the pre­
sumed cross-reactivity of anti-DNA with HS is mediated 
via a ligand consisting of histones and DNA, i.e. nucleo-
some particles. Within the nucleosome the histone part is 
responsible for the binding to HS, HSPG and the GBM. 
At the same time Jacob et al. [22] came to the conclusion 
that the cross-reactivity of anti-DNA with a cell mem­
brane protein (which they named lupus-associated mem­
brane protein 'LAMP'), was also due to the same interme­
diate ligand. More recently, it was shown that anti-DNA 
mAb can also bind to endothelial cells via histones and 
DNA [23]. It can therefore be concluded that a number of 
'cross-reactions' of anti-DNA is mediated through his­
tones and DNA [24]. 
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Fig. 1. The nucleosome, consisting of the histone octamere, 
around which 145bpofDNAare wrapped twice. Please note that the 
positively charged N-terminal regions of the histones are located on 
the outside of the nucleosome. Histone HI interacts with the octa-
mere/DNA complex and bridges adjacent nucleosomes. Repro­
duced, with permission from Grunstein M: Histones as regulator 
genes. Scient Am 1992;October issue:40-47. 
Histones as Nephritogenic Antigens 
Histones are a set of DNA-binding proteins, which 
have a function in the packing of DNA molecules. Two of 
each of the four core histones (H2a, H2b, H3 and H4) 
form together an octamere around which 145-bp of DNA 
are wrapped twice. Histone H1 is bound to the core parti­
cle consisting of the histone octamere/DNA complex and 
together they form the nucleosome. The core histones are 
single polypeptide chains, having a molecular weight 
from about 11 to 15 kD. They are positively charged with 
a pi of about 11. The basic residues are clustered in the 
N-terminal part of the molecules and these positively 
charged regions are located on the outside of the octamere 
and interact with DNA (fig. 1). Despite their net positive 
charge histones tend to aggregate, because of hydrophobic 
regions in the central and carboxy-terminal parts of the 
molecule. In general, cationic molecules are potent ne­
phritogenic antigens. They can bind to the GBM through 
charge interactions, penetrate all three layers of the GBM 
and persist in the GBM provided that their size is between 
40 and 500 kD and the pi exceeds 8.5-9.0 [25]. Theoreti­
cally, histone aggregates are therefore excellent candidates 
to act as nephritogenic antigens in vivo, and indeed in 
1989 Schmiedeke et al. [26] showed that histones display 
Fig. 2. Direct immunofluorescence of the 
glomerular binding of an anti-DNA mono-
clonal antibody after subsequent perfusion 
of histones, DNA and anti-DNA. showing a 
granular pattern along the capillary wall (a). 
When the anti-DNA monoclonal antibody is 
injected intravenously 1 h after renal perfu-
sion of histones and DNA a membranous 
pattern is observed (b). Reproduced, with 
permission from Termaat et al. [21]. 
a high affinity for the GBM. To test whether histones and 
DNA could mediate the binding of anti-DNA in vivo, we 
performed renal perfusion studies in the rat. In ex vivo 
perfusion experiments we found that after consecutive per-
fusion of histones, DNA and purified anti-DNA mAb, the 
antibodies localized abundantly in a granular pattern along 
the capillary wall. On immunoelectron microscopy the 
deposits were localized on the endothelial cells and suben-
dothelially in the GBM. After perfusion of DNA alone and 
subsequently anti-DNA, we only found glomerular local-
ization with a high avidity mAb, which was, however, much 
less intense and on electron microscopy exclusively located 
in the mesangium. Control experiments with histones and 
anti-DNA or histones, DNA and a nonrelevant mAb (same 
isotype and concentration), or anti-DNA alone failed to 
give any glomerular localization. If we changed the perfu-
sion procedure to an in vivo perfusion, in which we admin-
istered histones and DNA via the renal artery, restored the 
renal circulation and then injected 1 h later the purified 
anti-DNA mAb intravenously, we found a pure membra-
nous localization, with immunoelectron microscopy de-
posits underneath the visceral epithelial cells and in the slit 
pores of the GBM [21]. So, anti-DNA antibodies can bind 
via histones and DNA to the GBM and depending on the 
perfusion protocol can form subendothelial or subepithe-
lial deposits (fig. 2). Furthermore, only high avidity anti-
DNA antibodies can also bind via DNA alone to the mesan-
gium but hardly to the GBM. It is indeed not very likely that 
DNA, which is negatively charged, binds to the GBM. Izui 
et al. [27], who developed the idea that DNA can serve as a 
planted antigen in LN, could only demonstrate binding to 
the GBM under in vitro conditions. In vivo binding could 
only be achieved in animals pretreated with LPS [27]. Very 
recently, it was demonstrated that the injection of LPS 
leads to the release of nucleosomes in the circulation [28] 
and this may have mediated the binding of DNA to the 
GBM in the classical Izui experiments [27]. However, at 
present it is not known whether nucleosomes themselves 
can act as planted antigens, since they do not have a net 
positive charge, although this is not a prerequisite for 
binding to the GBM. Hybrid molecules without a net pos-
itive charge, but with confined cationic regions can bind 
to the GBM. even despite the presence of anionic charges 
at other sites of the molecule [29]. This is substantiated by 
the recent finding that nucleosomes can bind to the glo-
merulus in vivo [30]. Whether the nucleosome itself, or a 
partly degraded or altered nucleosome is the nephrito-
genic particle remains to be elucidated. 
Involvement of Histones/Nucleosomes in Lupus 
Nephritis 
Histones have never been described as circulating free 
molecules, but circulating nucleosomes have been dem-
onstrated in animals treated with LPS or during infec-
tions [28], and also in the circulation of SLE patients [31]. 
Therefore, nucleosomes bound to antibodies may be 
present in the circulation of SLE patients. As already 
mentioned we analyzed anti-HS reactivity in SLE pa-
tients in relation to clinical disease manifestations. From 
the data presented so far it is clear that with the HS ELISA 
anti-DNA antibodies are detected which are complexed 
to histones and DNA. When we studied anti-HS reactiv-
ity in selected SLE patients either with biopsy-proven dif-
fuse proliferative LN or patients with nonrenal exacerba-
tions, in all 5 cases of LN anti-HS reactivity was present 
before the onset of nephritis, while only 1 of 4 nonrenal 
exacerbations was positive. In patients who remained 
clinically stable no anti-HS reactivity was detectable [16]. 
Subsequently, we analyzed anti-HS reactivity in 72 con-
secutive SLE patients who experienced 40 exacerbations 
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over a period of 3 years. In 20 of these exacerbations one or 
more renal symptoms were present. The patients with evi­
dence of renal involvement had significantly higher anti-
HS titers than those without renal manifestations during 
the flare [17]. When we analyzed the correlation between 
anti-HS and anli-DNA tilers in both studies we found three 
patterns: anti-DNA-negative sera were always anti-HS neg­
ative; certain sera were anti-HS negative despite a high anti-
DNA tiler, and in the remaining sera there was a significant 
correlation between the anti-HS and the anti-DNA titer. 
These findings implicate that anti-HS reactivity is a feature 
of anti-DNA antibodies and that there may be two sub­
groups of anti-DNA antibodies: those which do (HS posi­
tive) and those which do not (HS negative) complex with 
nucleosomes. Besides anti-DNA also antihistone anti­
bodies can bind to nucleosomes. Although this review will 
not analyze in depth the clinical significance of antihistone 
antibodies in SLE, it became clear, once it was possible to 
obtain purified histones, that the majority of SLE patients 
have antihistone antibodies. In some studies a correlation 
between antihistone reactivity and LN or active disease 
was described [32, 33], but in other studies this correlation 
was not found [34-36] and even a negative correlation 
between the occurrence of antihistone antibodies and LN 
has been described [37, 38]. Moreover, in drug-induced 
lupus antihistone antibodies predominate, whereas renal 
involvement is rare [39]. A possible explanation could be 
that antihistone antibodies bind to the histone part of the 
nucleosome in such a way that the interaction between the 
nucleosome and the GBM is prevented. In contrast to this, 
anti-DNA antibodies might cover the negative charge of 
DNA in the nucleosome, thereby enhancing the binding 
capacity of the nucleosome to the negatively charged GBM. 
Histones have been demonstrated in glomerular de­
posits in human and murine SLE (NZB/WFi, graft vs. 
host mice). These deposits could only be identified with 
the use of antisera against N-terminal regions of histones 
and not with antisera against other regions of histones, 
nor with antisera against whole histones [40, 41]. This 
indicates that the N-terminal regions are the only parts of 
histones which are accessible in these depositions. This 
suggests that the nucleosome or the core octamere is 
grossly intact in these depositions, for the N-terminal 
regions are located on the accessible outside of the nucleo­
some. Interestingly, antihistone antibodies in SLE are 
directed almost exclusively against the same epitopes on 
the N-terminal part of histones [42]. This suggests that the 
nephritogenic particle and the immunogen at work in SLE 
might be the same or resemble each other closely. In both 
instances it might be the (altered?) nucleosome. 
Conclusion 
In this review we discussed some recent findings which 
suggest that histones or nucleosomes play a pivotal role in 
the initiation of the glomerular inflammation in SLE. In 
the proposed concept anti-DNA antibodies are com-
plexed to nucleosomes either in the circulation or in situ 
in the GBM. These nucleosomes are, via their histone 
part targetted to the GBM through charge interactions 
with anionic sites. Once these initial deposits are formed, 
their presence might enhance further deposition of anti-
DNA antibodies, via binding to the DNA part of the 
nucleosome. Recently, indications have emerged (which 
are not addressed in this review) that nucleosomes might 
also be involved in the induction of antinuclear anti­
bodies in SLE [43, 44]. It seems therefore that nucleo­
somes are important for the induction as well as for the 
pathogenicity of autoantibodies in SLE. 
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SUMMARY 
Cross-reactive antibodies against heparan sulphate (HS) have been suggested to play a role in 
initiating renal disease in SLE Recently we found that HS-reactiviiv is mediated by anti-DNA 
antibodies complexed with DNA and histoncs To evaluate the clinical significance of anti-HS 
reactivity we studied prospecmeK a cohort οΓ72 consecutive SLE patients of whom 22 experienced 
40 exacerbations In 20 of these exacerbations renal symptoms were present In these 20 
exacerbations significantly higher anli-DNA (median I 160) and anti-HS (median I 10) litres were 
detected compared with exacerbations without renal manifestations (median 1 60 for anli-DN A and 
negative for anti-HS) There were no correlations with other symptoms of SLE Anti-HS litres 
showed a significant correlation with anti-DNA antibody litres (r, = 0 57. Ρ < 0 05) Anti-HS without 
anti-DNA reactivity was never delected Some SLE patients showed a high anti-DNA titre without 
anti-HS reactivity, suggesting that not all anti-DNA antibodies are able to bind lo hislone/DNA 
complexes and thus to exhibit anli-HS reactivity Our findings indicate that anti-HS reactivity is 
correlated with renal disease in SLE 
Keywords prospective study systemic lupus erythematosus nephritis anti-DNA antibodies 
anti-HS reactivity cross-reactivity 
INTRODUCTION 
SLE is an autoimmune disease characterized h\ the occurrence 
of a multitude of autoantibodies primarily directed against 
nuclear antigens [I] Antibodies against double-stranded DNA 
(dsDNA) are regarded as a serologic marker for this disease 
Thc\ can be detected in about 70% of SLE patients and in 
patients with active disease their cumulative incidence is as high 
as 96'!Ί [2] Nephritis is considered to be the most severe 
manifestation of the disease occurring in about 40-50'/,, of SLE 
patients The pathogenesis of SLE-nephnlis .s still controver­
sial Facts arc that renal manifestations of SLE are often 
preceded b> a rise in levels of high avidm anti-dsDNA 
antibodies [2-5] and that these antibodies are detected in 
considerable amounts in immune deposits in the glomerulus [6] 
These observations led to the hypothesis that immune com­
plexes containing high avidity anti-dsDNA antibodies and 
DNA are trapped in the glomerular basement membrane 
(GBM) thus triggering the glomerular inflammation [7] This 
h\pothesis however, has been the subject of much debate First 
Correspondence С Kramers MD Departmenl of Nephrology 
Lnnersil\ Hospital Nijmegen PO Box 9101 6500 HB Nijmegen The 
Netherlands 
the existence ofcirculating DNA/anti-DNA complexes is highlv 
questionable [8] Second, preformed DNA/anti-DNA com­
plexes injected intravenously in experimental animals do not 
locate in the kidney but instead are rapidly cleared by the liver 
[9 10] Because of this alternative explanations have been 
suggested for the initiation of SLE-nephntis [II] which were 
mainly based on the fact that anti-DNA antibodies can cross-
react with several molecules other than DNA [12-14] li was 
suggested by us [15] and others [11 16] that anti-DNA anti­
bodies can bind directly to intrinsic glomerular antigens This 
hypothesis was based on the finding that certain anti-DNA 
antibodies can bind dircctlv to heparan sulphate (HS) an 
intrinsic constituent of the GBM [15] HS is negatively charged 
and responsible for the charge-selective permeability of the 
GBM Later on we found that not anti-DNA antibodies 
themselves but anli-DN A complexed to DNA and histoncs arc 
responsible for this cross-reactivitv with HS Ann-DNA 
MoAbs which had the property of binding lo HS totally losi 
this capability after purification on a protein A-Sepharosc 
column under dissociating conditions After reconstitution wnh 
the column effluent the MoAbs regained their binding to HS In 
the reconstituting effluent DNA and histones could be demon 
strated [ 17] Also in SLE sera we demonstrated a strong decrease 
in anti-HS reactivitv after purification under dissociating condì-
31 
lions [18] We assumed that the histories in the complex were 
responsible for the binding lo HS since histones which are 
highl) positively charged molecules have a high affinilv for the 
GBM [19] In a recent study we showed that if we perfused 
histones DNA and anti-DNA into a rat kidney we could 
demonstrate localization of anti-DNA in the GBM while 
perfusion ofanti DNA alone did nol lead to binding [20) 
The role of histones in SLE-nephnlis is further substantiated 
by the identification ofhistones in glomerular deposits in human 
and murine SLE [21 22] 
In a retrospective study in a small group of selected SLE 
patients we found thai anli-HS reactivity was correlated with 
renal disease [18] In order to substantiate this finding in a 
non-selected consecutive cohort of patients wc performed a 
prospective study in 72 consecutive SLE patients, in whom 
plasma anti-HS reactivity was correlated with clinical manifes­
tations of disease flares 
PATIENTS AND METHODS 
Patients and blood sampling 
Seventy-two consecutive SLE patients were studied (61 women 
and 11 men) Details about these patients have been published 
before [5] They all fulfilled at least Tour criteria of the American 
Rheumatism Association (ARA) revised criteria for SLE [1] 
The mean observation period during this study was 18 5 patient 
months (range 6-39 months) 
A blood sample was obtained at least once a month and 
more often during periods of active disease These samples were 
mostly drawn in lubes containing EDTA although in some 
instances serum was obtained All samples were stored at 
- 2 0 С 
Assessment of disease activity 
During disease flares a disease activity index was calculated as 
described previously [5] This index has been validated by 
comparing its score on a 0-10 point visual analogue scale, as 
assessed by clinicians experienced in the managemenl of lupus 
(r = 067, P<0001)[5] Criteria for major and minor exacerba­
tions were described previously [S] 
Stud\ design 
All samples of patients who experienced an exacerbation were 
analysed in the anli-DNA ELISA and anti-HS ELISA Analysis 
was performed without knowledge of clinical data In addition 
to this all samples (л = 50) of five patients who remained 
clinically quiescent during the whole follow-up period were also 
analysed 
Anti-DNA and anti-HS ELISA 
The anti-DNA antibody titre was assessed in an anti-DNA 
ELISA as described previously [18] Briefly, polystyrene micro-
lilre plates (Costar, Cambridge, MA) were precoated with 150 
/il/well of protamine chloride (0 5 mg/ml) After washing of the 
plates. DNA (Calbiochem, San Diego, CA) was coated over­
night at room temperature (100 ul/well 50 /ig/ml) Plasma 
samples were diluted in PBS containing 1 % w/v gelatin and 
incubated within the plates for 1 h at 37 С Next, plates were 
washed and 100 μ\ of peroxidase-conjugaled rabbit anti-human 
immunoglobulin (ICN Costa Mesa CA) diluted I 500 in PBS/ 
I ' gelatin were added per well Piales were incubated for I h at 
37 С and again washed A freshly prepared substrale solution of 
0 8 mg ml 5 aminosalicylic acid dissolved in 50 IHM phosphate 
buffer pH 6 0 supplemented with 0 8 μ\ ml 30 '/,, ν ν ЬЬСЬ was 
added to each well After 30 min the OD at 450 nm was 
measured 
The anti-HS ELISA was performed in the same way as the 
anti-DNA ELISA Heparan sulphate (HS Seikaguku Kogyo 
Ltd Tokyo Japan) 50 /ig ml was added to wells precoated with 
prolamine chloride 
The ture in the anti-DNA and anti-HS ELISAs was denned 
as the reciprocal of the dilution of the sample giving an 
absorption of 1 Oat450nm Plasma samples of 50 normal blood 
bank donors were tested in both ELISAs Cut-off values were 
denned as the mean + 3 x s d in this group Based on this 
criterion a sample was considered positive if the ture was > 20 
in Ihc anti-HS ELISA and > 10 in the ami-DNA ELISA 
Statistical analysis 
For statistical analysis Wilcoxon s rank correlation test and 
Spearman s correlation test were used 
RESULTS 
Preialence of disease manifestations during exacerbations 
Of the 72 SLE patients who were studied, 22 experienced 40 
exacerbations of which 23 were minor and 17 were major 
Prevalences of disease manifestations during these flares are 
shown in Table I In 20 exacerbations, renal symptoms were 
present Prevalence of renal symptoms during these exacerba­
tions is shown in Table 2 
Anti-HS reactivity in serum versus plasma samples 
In total, 351 blood samples were obtained, of which 302 were 
plasma samples and 49 were serum samples Since it is known 
Table 1 Incidence of SLE disease manifestations in 
40 exacerbations 
Manifestation 
Renal disease 
Vasculitis 
Haematologic disease 
Rash 
Arthritis 
Cerebral 
Serosius 
Number of 
exacerbations 
20 
11 
22 
12 
20 
3 
14 
% 
50 
28 
55 
30 
50 
8 
35 
Table 2 Prevalence of renal symptoms during 
20 exacerbations with renal manifestations 
Renal symptom η 
Proteinuria 14 
Erylhrocyturid 13 
Erythrocyte and'or granular casts 7 
Decrease of creatinine clearance 10 
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Exacerbations 
without renal symptoms 
Exacerbations 
vith renal symptoms 
Fig. 1. Anti-heparan sulphate (HS) titres in exacerbations with and 
without renal symptoms of SLE. 
that DNA and other nuclear antigens can be released during 
clotting [23]. these antigens might bind with anti-DNA anti­
bodies and thus form complexes in vitro which falsely might give 
rise to anti-HS reactivity as an artefact. However, this seems not 
to be a major problem, since we found previously identical anti-
HS reactivity in simultaneously obtained plasma and serum 
samples [18]. 
Anti-HS and anti-DNA titres in relation to disease 
manifestations during exacerbations 
When we analysed the levels of anti-HS reactivity during 
exacerbations, we found higher anti-HS reactivity (P<0 05) in 
exacerbations with renal symptoms compared with exacerba­
tions without renal symptoms, although not all exacerbations 
with renal symptoms were anti-HS-positive (Fig. I ). In contrast, 
this difference in levels of anti-HS reactivity was not observed 
when flares were analysed for the presence or absence of other 
non-renal disease manifestations. 
A similar picture emerged when anti-DNA reactivity was 
compared during disease flares. During exacerbations with renal 
symptoms, higher anti-DNA reactivity was measured, com­
pared with exacerbations without renal symptoms (Fig. 2). For 
other, non-renal, symptoms during flares no difference in anti-
DNA titre was observed. In the 50 samples obtained from five 
patients who remained clinically stable during the observation 
period, we found in only one sample a weak anti-HS reactivity. 
There was no correlation between severity of disease manifes­
tations and anti-HS or anti-DNA titres, since these titres were 
not different between minor and major exacerbations. Because 
the litres were not significantly different between patients with 
mild ( r ^ 3 ) or severe ( r ^ 4 ) renal symptoms, there was also no 
correlation with the severity of the renal symptoms. 
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without renal symptoms 
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. . . 
Exacerbations 
with renal symptoms 
Fig. 2. Anti-DNA titres in exacerbations with and without renal 
symptoms of SLE. 
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Fig. 3. Anti-DNA titre compared with anti-heparan sulphate (HS) titre 
in all samples tested- (One point often represents several different 
measurements.) 
Correlation between anti-HS and anti-DNA reactivity 
In Fig. 3 the anti-HS reactivity of all samples is plotted against 
the anti-DNA titre. There is a significant correlation between 
both titres (r = 0 57, P<005). 
DISCUSSION 
Based on previous studies in which we found that the cross-
reactivity of anti-DNA antibodies with HS [15] was caused by 
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his ionc D N A complexes b o u n d lo a n t i - D N A [17] wc postu­
lated that this binding could bc i m p o r t a n t lor the pathogenes i s 
ol S L E - n c p h n t i s [24] T o e lucidate the clinical significance of 
a n t i - H S reactivity for S L E - n c p h n t i s we have previously cvalu-
alcd this reactivity longiludinal lv in a g r o u p of 10 pat ients 
selected Trom a c o h o r t of 110 pat ients on the basis of their 
clinical history In these pat ients with hrsl onset ol severe diffuse 
proliferative g lomerulonephr i t i s we found a n t i - H S reactivity in 
all five renal exacerbat ions of S LE while only in one out of four 
non-renal exacerbat ions was anl i H S delected Pat ients w h o 
clinically remained quiescent were negative [IK] T o discover 
whether this was also true for a g r o u p of n o n selected S L E 
pat ients we analysed a n t i - H S reactivity in a consecut ive c o h o r t 
of 72 S L E pat ients w h o experienced both m i n o r and major 
disease e x a c e r b a t i o n s In these pat ients it was previously found 
that a rise in a n t i - d s D N A a n t i b o d y levels could predict disease 
e x a c e r b a t i o n s [5] In the c u r r e n t prospect ive study we found 
higher levels of a n t i - H S reactivity d u r i n g S L E exacerbat ions 
with renal s y m p t o m s c o m p a r e d with t h o s e w i t h o u t renal 
s y m p t o m s T h e r e was n o corre la t ion between a m i - H S reactivity 
and any o t h e r disease s y m p t o m d u r i n g the flares T h e s e findings 
are tn line with a recent s tudy in which ant ibodies t o h e p a r a n 
su lphate p r o t e o g l y c a n were frequently found in high Hires in 
S L E pat ients wiih renal involvement [25] In c o n t r a s t t o o u r 
previous s tudy in which we found lhat every exacerbat ion of 
S L E - n e p h n l i s was preceded by a high a n t i - H S reactivity we 
now observed cases with renal s y m p t o m s w i t h o u t de lectable 
anl i H S reactivity a l t h o u g h cons iderable a n t i - D N A binding 
was found W e d o not have a clear e x p l a n a t i o n for this 
d i screpancy h may be related t o differences in selection of 
p a t i e n t s In the first s tudy only pat ients with severe a n d first 
onsei of S L E - n e p h n l i s were analysed In the present s ludy S L E 
pat ients were analysed w h o had a l ready h a d their disease for a 
var iable t ime per iod a n d had experienced prev ious flares with 
renal s y m p t o m s T h i s suggests t h a t there might be a difference in 
the p a t h o g e n i c significance of HS-reacl ive a n t i b o d i e s for the 
initial g l o m e r u l a r d a m a g e a n d subsequent episodes of g lom­
eru lar in f lammat ion HS-reacl ive a n t i - D N A a n t i b o d i e s are d u e 
t o a n t i b o d i e s c o m p l e x e d in the c i rculat ion t o h i s t o n e / D N A 
part icles T h i s is in line with the recent finding that his tones a n d 
D N A are present in the c i rculat ion as o l igonucleosomal part i­
cles [26 27] T h e s e HS-reactive c i rculat ing complexes a re t a r 
geted to the G Β M via their h is tone part inducing g l o m e r u l a r 
depos i t s T h e a n t i - D N A a n t i b o d i e s that d o not react with H S 
may localize in the g lomeru lus via an m situ i m m u n e complex 
m e c h a n i s m o n c e h i s t o n e / D N A part icles have b o u n d previously 
t o the G B M T h i s view is s u p p o r t e d by the recent finding that 
s o m e a n t i - D N A a n t i b o d i e s form circulat ing i m m u n e c o m ­
plexes which c a n localize in the G B M while o t h e r s deposit via 
an m situ i m m u n e complex m e c h a n i s m [28] T h e s e different 
b inding m e c h a n i s m s might explain why in s o m e instances renal 
s y m p t o m s m a y ensue in the absence of HS-reacl ive complexes in 
the c i rculat ion but in the presence of non-HS-react ive ant i-
D N A a n t i b o d i e s 
As previously [18] we also found in this s tudy that a n t i - H S 
reactivity is not a mere reflection of the a n t i - D N A titre We 
never found a n t i - H S reactivity in the absence of a n t i - D N A 
reactivity (Fig 3) which stresses again that a n t i - H S reactivity is 
media ted by a n t i - D N A a n t i b o d i e s a n d t h a t there a re n o 
a u t o a n t i b o d i e s in S L E which specifically a n d directly bind t o 
H S as suggested by o t h e r s [29 30] F r o m Fig 3 it also becomes 
clear that there is a s u b g r o u p of anli D N A a n t i b o d i e s which 
despite a high a n d D N A t u r c docs not bind to H S I n c o n t r a s i lo 
this a n o t h e r g r o u p ol anli D N A a n t i b o d i e s shows H S re 
a c l m l v a n d the litres of ihcse reactivities are corre la ted 
H \ p o t h c l i c a l K these two s u b g r o u p s of a n t i b o d i e s c a n contr i 
bute in a different wav to g l o m e r u l a r d a m a g e as discussed 
bel ore 
In this prospect ive sludv we found a cor re la t ion between 
renal s v m p t o m s d u r i n g S L E disease flares a n d a n t i - H S rcacli 
vily A u t o a n t i b o d i e s complexed to h i s tones a n d D N A display­
ing H S reactivity might c o n t r i b u t e t o the g l o m e r u l a r inf lamma­
tion in lupus nephri t i s F u t u r e research h a s to reveal in m o r e 
detail the in f lammatory potent ia l of these a n t i b o d i e s in the 
g lomeru lus 
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Abstract 
Hlstones can mediate the binding of DNA and anti-DNA 
to the glomerular basement membrane (GBM). In ELISA 
histone/DNA/anti-DNA complexes are able to bind to he­
paran sulfate (HS), an intrinsic constituent of the GBM. 
We questioned whether historie containing immune com­
plexes are able to bind to the GBM, and if so, whether the 
ligand in the GBM is HS. Monoclonal antibodies (mAbs) 
complexed to nucleosomal antigens and noncomplexed 
mAbs were Isolated from culture supernatants of four IgG 
anti-nuclear mAbs. All noncomplexed mAbs showed strong 
anti-nucleosome reactivity in ELISA. One of them showed 
in addition anti-DNA reactivity in noncomplexed form. The 
other three mAbs only showed anti-DNA reactivity when 
they were complexed to nucleosomal antigens. 
After renal perfusion a fine granular binding of com­
plexed mAbs to the glomerular capillary wall and activation 
of complement was observed In immunofluorescence, 
whereas noncomplexed mAbs did not bind. Immuno-elec-
tron microscopy showed binding of complexes to the whole 
width of the GBM. When HS in the GBM was removed by 
renal heparinase perfusion the binding of complexed mAb 
decreased, but did not disappear completely. 
We conclude that anti-nucleosome mAbs, which do 
not bind DNA, become DNA reactive once complexed to 
nucleosomal antigens. These complexed mAbs can bind 
to the GBM. The binding ligand in the GBM is partly, but 
not solely, HS. Binding to the GBM of immune complexes 
containing nucleosomal material might be an important 
event in the pathogenesis of lupus nephritis. (J. Clin. 
Invest. 1994. 94:568-577.) Key words: systemic lupus 
erythematosus · nephritis · anti-nucleosome · hlstones · 
heparan sulfate 
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Introduction 
Systemic lupus erythematosus (SLE)' is an autoimmune dis­
ease characterized by the occurrence of numerous auto-antibod­
ies directed primarily against nuclear antigens Antibodies 
against double-stranded DNA (dsDNA) are regarded as highly 
specific for the disease ( I ) Nephritis is one of the most serious 
manifestations of the disease Since nephritis is associated with 
a rise in titer of especially high avidity IgG anti-dsDNA and a 
depression of serum complement, it is generally assumed that 
these antibodies are involved in the pathogenesis of lupus ne­
phritis and that they cause complement activation ( 2-4 ) More­
over, enrichment of these antibodies in renal and glomerular 
eluates of SLE patients and lupus mice has been found, sus­
taining the nephntogenic properties of these antibodies ( 5 - 7 ) 
How these antibodies bind in the glomerulus, however, is still 
unclear The classical hypothesis that anti-DNA is deposited in 
the glomerular basement membrane (GBM) as DNA/anti-DNA 
immune complexes has been subject of much controversy ( 8 ) 
For instance, when artificially prepared DNA/anti-DNA im­
mune complexes are injected in experimenta] animals, they 
show no affinity for the GBM, but instead are rapidly cleared by 
the liver (9-11) Indeed, it is not very likely that the negatively 
charged DNA in anti-DNA/DNA complexes would easily de­
posit in the negatively charged GBM (12) This controversy 
led Schmiedeke et al ( 13) to the idea that binding of hlstones, 
which are highly positively charged DNA binding proteins 
might mediate the binding of DNA and anti-DNA At the same 
lime, analyzing the cross-reactivity of anti-DNA antibodies with 
heparan sulfate (HS), an intrinsic constituent of the GBM, we 
found that this cross-reactivity was due to histone/DNA con­
taining immune complexes ( 14) The histone part in these com­
plexes was responsible for the binding to HS Furthermore, 
when we perfused subsequent hlstones, DNA and anti-DNA in 
a rat kidney, we observed a strong fine granular binding of 
antibodies to the capillary wall in immunofluorescence (IF), 
whereas after perfusion of DNA and anti-DNA, the binding was 
much less and restricted to the mesangium (15) The concept 
that histones may play a role in the initiation of lupus nephritis 
(reviewed recently in reference 16) was further substantiated 
1 Abbreviations used m this paper dsDNA, double-stranded DNA, 
GBM, glomerular basement membrane, HS, heparan sulfate, GAG, gly-
cosaminoglycan, HSPG, heparan sulfate proteoglycan, IF, immunofluo­
rescence, IEM, immuno-eleclron microscopy, NGS normal goal serum, 
PLP, a mixture of 0 01 M sodium periodale 0 075 M lysine HCl 0 0375 
M Na2HP04 and 2% paraformaldehyde, SLE, systemic lupus erythema 
tosus 
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by the finding of histone deposits in human and murine S L E 
nephritis ( 1 7 , 1 8 ) . 
W e realized however, that subsequent perfusion of purified 
histones, D N A and ant i-DNA is a rather artificial system. It is 
not likely for histones and D N A to exist as separate entities in 
vivo. Indeed, in the circulation D N A is present bound to his­
tones forming ol igonucleosomal complexes ( 1 9 , 2 0 ) . W h e n 
such nucleosomal material is released in the circulation of S L E 
patients, it is very likely that i m m u n e c o m p l e x e s are formed 
with anti-nuclear antibodies with specificity for either histones, 
nucleosomes or D N A . As we described before ( 14, 21 ) a similar 
complex formation occurs in supematants of hybr idomas secre­
ting anti-nuclear ant ibodies . In these s u p e m a t a n t s mAbs can be 
found complexed with nucleosomal antigens released from dy­
ing cells. That is why we chose to isolate i m m u n e complexes 
from such culture supematants , to find out which characterist ics 
of these i m m u n e complexes are associated with binding capac­
ity in the G B M . 
Methods 
Production of monoclonal antibodies 
mAbs were obtained by fusion of spleen cells from mice with spontane­
ous ([NZB X W]F1, MRL/Mp/Ipr/lpr) or experimentally induced (pa-
rental-Fl chronic Graft Versus Host disease) SLE and screened for the 
presence of anti-dsDNA reactivity in ELISA or Farr assay as described 
previously (22) and new culture supematants were prepared from which 
antibodies were purified. For the studies described in this paper. mAbs 
were selected which showed reactivity with HS in crude culture supema­
tants, since this reactivity is due to mAbs complexed to nucleosomal 
material (histones and DNA) as described previously (14) . All selected 
mAbs belong to the IgG2a subclass. 
Preparation of immune-complexed and pure mAbs 
Hybridomas were grown in serum free conditions (IMDM; GIBCO-
BRL, Paisley, UK) supplemented with serum-free medium supplement. 
SF1 (Costar, Cambridge, MA) 2% vol/vol. Three purification proce­
dures were used. 
Procedure I (physiological conditions). Culture supematants were 
applied to a protein-Α Sepharose column (Pharmacia, Uppsala, Swe­
den) equilibrated with phosphate buffered saline (PBS). 
Procedure II (high sat! conditions). NaCl, glycine and NaOH were 
added to culture supematants to a final concentration of 3 M NaCl, 1,5 
M glycine, pH 8.9, before applying to a protein-Α Sepharose column 
which was equilibrated with a 3 M NaCl, 1.5 M glycine, pH 8.9 buffer. 
Procedure III (DNase and high salt conditions). In this procedure 
the purification under high salt conditions was preceded by a DNase 
treatment. The culture supematants were first treated with DNasel 
(Boehringer Mannheim, Mannheim, Germany) with a final concentra­
tion of 40 ¿ig/ml in the presence of 10 mM MgCl2. After 1 h incubation 
at 37°C the reaction was quenched with EDTA (Merck, Darmstadt, 
Germany) with a final concentration of 15 mM. 
After each of these three different purification procedures immuno-
globulins bound to the protein A column were eluted with a solution of 
0.1 M citric acid. pH 2.6. The eluate was immediately brought to pH 
7.4, dialyzed against PBS and stored at -20°C. 
Using the third procedure, noncomplexed mAbs were obtained ex-
cept for niAb No. 34. For this mAb still a fraction of the antibodies was 
complexed to nucleosomal antigens. The complexed and noncomplexed 
antibodies were separated with the use of a DNA-cellulose column ( P-
L Biochemicals, Inc., Milwaukee, WI) , which was equilibrated with 
PBS. Complexed antibodies retained on the column, whereas pure, non-
complexed antibodies were obtained in the column effluent. 
- H 3 
- H 2 b H 2 a 
- H 4 
Figure I. SDS-PAGE of pure 
and complexed mAbs. (Lane A) 
Pure mAb No. 32 obtained via 
procedure ill (only the heavy 
and light chains of lg, but no 
histone bands are present). 
(Lane B) Complexed mAb No. 
32 obtained via procedure 1, 
containing both the Ig heavy and 
light chains and the four core 
histones, but not HI . (Lane C) 
Mixture of"histones (Boehringer 
Mannheim). The HI, H2a, H2b, 
H3, and H4 bands are all pres-
ent, and there is some contami-
nation with other proteins in this 
histone mixture. 
Characterization of bound antigens in immune-complexed 
mAbs 
The presence of histones in complexed mAbs was determined by SDS-
PAGE (8 -25%) analysis followed by double silver staining (Phast gel 
system, Pharmacia). Histones were further identified by immunoblot-
ting. The proteins were transferred to nitrocellulose by means of diffu-
sion at 50°C using the Phast gel system (Pharmacia). Histones were 
identified using a rabbit anti-histone polyclonal antiserum diluted 1:100. 
prepared in our laboratory (15) . The blot was developed with peroxi-
dase-conjugated goat anti-rabbit Ig ( ICN, Costa Mesa, CA) and stained 
with 4-chloro-1 -naphtol. For the identification of DNA in the complexed 
mAbs. DNA was extracted by phenol-chloroform after proteolysis with 
proteinase К (Boehringer Mannheim). Proteolysis was performed by 
adding 100 ¿/g proteinase К in 5 μ\ water to 300 ¿tg Ig. for 1 h at 50°C. 
The DNA extract was 5 ' end-labeled with [12P]dATP. Labeling was 
performed according to standard protocols using T4 polynucleotide ki-
nase. After labeling DNA was analyzed on a 6% Polyacrylamide gel 
(Sequagel-6; National Diagnostics, Atlanta, GA) using a labeled 123 
bp ladder (Pharmacia) as a size marker. 
61 bp 
Figure 2. PAGE of DNA extract 
after labelling with [ , 2P]dATP. 
Three purification procedures 
were used on culture supema-
tants of mAb No. 32. In lane A 
hardly any DNA in the pure 
mAb (procedure III) is present. 
In complexed mAb No. 32, 
(procedure II) small amounts of 
DNA are detectable (lane B). 
Only after purification according 
to procedure I (lane C) large 
quantities of DNA are present in 
the complexed mAb. In lane D 
a purified control mAb (WT1 
mouse anti-human CD7) is 
shown in which no DNA is de-
tectable. 
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Table I Composition, In Vitro Reactivity, and Glomerular Binding of the Different mAb Preparations 
mAb nr procedure 
Composition 
Histones* 
DNA' 
In vitro reactivity 
Fan1 
ELISA ' 
DNA 
Histone 
Nucleosome 
HS 
Glomerular binding1 
I 
+ 
+ 
6 
178 
55 
3500 
11 
+ 
No 2 
11 
+ 
± 
25 
227 
90 
4800 
36 
+ 
III 
-
-
3 
36 
< 1 
3000 
4 
-
1 
+ + 
+ + 
70 
98 
4500 
5000 
9 
+ + 
No 32 
II 
+ + 
± 
75 
100 
187 
7600 
9 
+ + + 
III 
-
-
3 
1 
1 
5400 
1 
-
1 
+ + 
+ 
17 
178 
1777 
7500 
13 
+ + 
No 34 
II 
+ + + 
± 
57 
200 
800 
12000 
20 
+ + + 
III 
-
-
3 
16 
494 
12000 
1 
-
No 42 
II 
-
-
92 
25600 
< 1 
10000 
< 1 
-
Composition of bound complexes (Composition), reactivity in Farr assay and vanous ELlSAs (In vitro reactmtv) and glomerular binding (Glomular 
binding) of the different mAb preparations obtained after purification under physiological conditions (I) high salt conditions (II), or DNase treatment 
followed by high salt conditions (and in the case of mAb No 34 additional separation of hi stone bound mAb on a DNA-cellulose column, see 
text) (III) * Histone content as assessed on SDS-PAGE, the intensity of the histone staining was scored semiquantitatively by companng the 
intensity of the staining with that of the heavy and light chain * Presence of DNA fragments (of predominately 120 bp) as assessed after labeling 
with 32P s Percent precipitation of labeled DNA per 12 ^g of IgG, values ^ 3% are regarded as negative ' Tiler/mg IgG 1 Glomerular binding 
was assessed with indirect IF 
The immunoglobulin (Ig) concentration was determined in an 
ELISA, for which Nunc-immuno plates (Maxisorp F96, GIBCO BRL) 
were coated overnight at 4°C with goat anti -mouse lg (Sigma Chemical 
Co, St Louis, MO) diluted 1 80 in PBS, 100 μΐ per well Plates were 
washed five times with PBS containing 0 05% (vol/vol) Tween 20 and 
blocked with PBS containing 1% wt/vol gelatin for 2 h at 37°C Samples 
were sen all y diluted in PBS/1% gelatin and incubated for I h at 37°C 
Next, plates were washed again and 100 μΐ of peroxidase-conjugated 
goat anti-mouse IgG2a diluted I 750 (Southern Biotechnology Assoc 
Ine , Birmingham, AL) in PBS/1% gelatin were added per well After 
1 h of incubation at 37°C, the plates were washed A freshly prepared 
substrate solution of 0 8 mg/ml 5' aminosalicylic acid dissolved in 50 
mM phosphate buffer, pH 6 0, supplemented with 0 8 ді/ml 30% vol/ 
vol Н
г
О
г
 was added to each well After 30 mm the OD at 450 nm 
was measured An IgG2a myeloma protein (RPC 5, Cappel, Organon 
Technika NV, Turnhout, Belgium) was used as standard 
Tests for antigen reactivity of purified and complexed 
anti-nuclear mAbs 
Ann-dsDNA assays Anti-dsDNA activity was determined in the Farr 
assay and in an anti-dsDNA ELISA The Farr assay was performed 
as described previously ( 23 ) In the anti-dsDNA ELISA photobiotin-
ylated PUC9 plasmid DNA was used (24, 25) Briefly, plates (Max-
isorb F96, GIBCO-BRL) used for the ELISA were coated overnight 
with streptavidin (Sigma Chemical Co ) diluted in distilled water 
( 150 μ% in 150 μΐ/well) at 4°C The plates were washed three times 
in PBS, containing 0 05% Tween 20 and three times with distilled 
water Next, the plates were coated overnight with photobiotinylated 
DNA ( 1 μg/ml in PBS, 4°C. 150 μΙ/well) The plates were washed 
again and blocked for 2 h at room temperature with PBS containing 
10% (vol/vol) normal goat serum (NGS) The use of this blocking 
agent did not influence the binding of the different mAb preparations 
when compared to gelatin or BSA, excluding interference by puta-
tively present nucleosomes or nucleohistone This was further sub­
stantiated by the fact that mAbs with a specificity restricted to nucleo­
somes did not bind to plates coated with the batch of NGS used for 
blocking Samples were serially diluted in PBS, 0 05% Tween 20, 
containing 10% NGS and incubated for 2 h at room temperature 
Next, the plates were washed again and 100 μ\ of peroxidase labeled 
rat mAb anti-mouse Ig (CLB-RM-19, CLB, Amsterdam, the Nether­
lands) diluted 1 1,000 in PBS were added per well The plates were 
washed again and developed with 3,5.3',5 '-tetramethylbenzidine 
(Merck), 100 ¿Jg/ml in 0 11 M sodium acetate, pH 5 5, containing 
0 003%H2O, Byadding2MH2S04. 100/xl/well, color development 
was stopped after 15 mm and OD at 450 nm was measured 
Anti-HS ELISA HS, purified from bovine kidney, was purchased 
from Seikagugu Kogyo Ltd (Tokyo, Japan) Pholobiotinylalion of 
HS was performed in the same way as described for DNA (25) The 
concentration of HS was determined by the Farndale assay ( 26 ) The 
ELISA was performed identically as described for DNA A mAb 
against HS ( JM 403. described in reference 27 ) was used as a positive 
control 
Anti-histone ELISA A mixture of the five histones (HI, H2a, H2b, 
H3, and H4, 2 5 ^ g/ml Boehnnger Mannheim) in 0 1 M Glycme/NaOH, 
pH 9, 0 1 M NaCI was coated overnight at 4*C to Nunc-immuno plaies 
The plates were washed five times with PBS/0 05% Tween 20 and 
blocked with 5% (vol/vol) fetal calf serum (FCS) in PBS 150 μ\Ι 
well, for 1 h at room temperature Using the same methods as described 
for NGS we could exclude that the use of FCS influenced the results 
The plates were washed again and samples serially diluted in PBS/ 
0 05% Tween 20, containing 5% FCS, were incubated ( 100 μΐ/well) 
for 2 h at 37°C After washing the plates again, the procedure was 
identical to that for the anli-DNA ELISA 
Ann nucleosome ELISA Nucleosomes were a kind gift of Dr L 
Cebecauer (Research Institute of Rheumatic Diseases, Piestany, Slo­
vakia) They were punned from calf thymus according to standard 
protocols (28) and contained all five histones and no other proteins (as 
assessed by SDS-PAGE analysis) and DNA (as assessed on an agarose 
gel, data not shown) Nunc-immuno plates were coaled with nucleo 
somes 2 5 ¿/g/ml, in 0 15 M NaCI, 0 15 M In sod ι um citrate, pH 7 0, 
for 1 h at room temperature (100 μΐ/well) Plates were washed five 
times with distilled water and samples, senally diluted in PBS/0 05% 
Tween 20, containing 0 1% highly punfied human serum albumin were 
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nucleosome histone DNA HS 
mAb #2 
mAb #32 
mAb #34 
mAb #42 
OOI 0 1 1 10 0 01 0 1 1 10 0 01 0 1 1 10 100 ι 10 '00 
concentration lgG2a (μ-g/ml) 
Figure 3 Reactivity of all desenbed antibody preparations in the different ELISAs displayed over a wide range of antibody concentrations The 
open triangles represent pure noncomplexed antibodies open rectangles represent immune complexes containing both hislones and DNA and closed 
rectangles represent immune complexes containing hislones and only a small amount of DNA (see Table I Composition) For mAbs No 2, 32, 
and 34 pure noncomplexes antibodies only react with the intact nucleosome and pure noncomplexed mAb No 42 reacts with both nucleosomes 
and DNA The other three mAbs show only DNA reactivity once complexed to nucleosomal matenal 
incubated 100 μΙ/well, for 1 h al room temperature After washing 
the plates five times with PBS/0 05% Tween, further procedures were 
identical to the anti-DNA ELISA 
All ELISAs were titrated and the reciprocal of the dilution leading 
lo an absorption of 1 0 at 450 nm was used as titer All titers were 
expressed per mg of lgG2a 
Preparation of reconstituted immune complexes 
Punfied nucleosomes (30 /ig in 250 μΙ PBS/0 1 mM EDTA-1% BS A) 
were mixed with non-complexed mAb No 32 (250 /ig in 250 μΙ PBS-
1% BSA) obtained after purification procedure HI This mixture was 
incubated for 1 h at room temperature and used for renal perfusion 
studies in rats 
Renal perfusion studies 
Male Wistar rais ( 150 g) were anesthetized by intraperitoneal adminis­
tration of 0 15 ml (9 mg) sodium penlobarbital (Narcovet Apharmo, 
Arnhem, The Netherlands) 
The renal perfusion was performed as described before (15) After 
perfusion the perfused kidney was taken out and immediately snap 
frozen in liquid N2 for immunofluorescence (IF) 
In some experiments only a small part of the kidney was taken for 
IF The remaining part was perfused with PLP for 10 mm and prepared 
for immune electron microscopy (IEM) (for details, see below) 
In additional experiments, after placing a ligature around the aorta 
between the origins of the left and the right renal artery, a 24 gauge 
catheter was placed in the aorta and the vena cava was not incised The 
left kidney was flushed with 0 3 ml 1% ( wi/vol) BSA in PBS, followed 
by perfusion of pure mAb or immune complexes ( 150-500 μg in 500 
μ] ), which were allowed to bind for 3 min After flushing the left kidney 
again with 0 3 ml PBS 1% BSA, the ligature and catheter were removed 
to re-establish normal blood flow 
After 15 mm the ligature was placed again and an 18 gauge catheter 
was placed in the aorta and the left kidney was flushed for 3 min with 
PBS-1% BSA, before it was taken out and snap frozen in liquid N2 or 
prepared for IEM by PLP perfusion 
Hepartnase perfusion 
After placing the ligature and insertion of an 18 gauge catheter, the left 
kidney was flushed with saline for 2 min Next hepannase III (Sigma 
Chemical Co ) 60 U in saline containing 1% BSA and 5 mM CaCl2 
was perfused al a flow rate of 1 ml/min The enzyme was allowed to 
act for 4 mm Next the kidney was flushed with PBS-1% BSA for 3 
mm This hepannase perfusion was followed by perfusion of complexed 
mAbs The kidney was further processed as described above To control 
for nonspecific changes perfusion was performed with buffer without 
hepannase and subsequent with complexed mAbs Experiments were 
repealed three times with different amounts of perfused complexed 
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Figure 4. Direct immunofluorescence of the glomerular binding after 
perfusion with mAb No. 32 complexée! to histones. Binding of com-
plexed mAb in the capillary wall of the glomerulus can be observed 
(X600) . 
mAbs ( ranging from 200-600 μ$ IgG2a ). The expression of glomerular 
HS was assessed with IF by the anti-HS mAb JM 403 (described in 
reference 27). 
¡mm unoh istaiogy 
immunofluorescence. Direct IF was performed on 2-μιη cryostat sec­
tions from perfused rat kidneys using a F( ab )2 FITC-labeled sheep ant i-
mouse IgG (Cappel, Organon Technika NV) diluted 1:750 in order to 
detect deposition of perfused mouse Ig. Sections were also stained with 
a rabbit anti histone polyclonal antiserum diluted 1:600. This antiserum 
was prepared as described before ( 15). After rinsing with PBS bound 
rabbit antibodies were visualized using a FITC-labeled mouse anti-
rabbit IgG(H + L) diluted 1:40 (Jackson Laboratories Inc., West 
Groove, PA ). In experiments in which the blood flow was restored after 
perfusion, sections were also stained with FITC-labeled goat anti-rat 
C3 diluted 1:40 (Nordic, Tilburg, the Netherlands). 
In the experiments in which heparinase was perfused before perfu­
sion of complexed mAbs, sections were stained with a mouse IgM anti-
HS-glycosaminoglycan ( HS-GAG) side chain mAb (J M 403, described 
in reference 27 ) and with a goat anti-human HS-core protein antiserum 
cross reacting with rat HS-proteoglycan (HSPG, described in reference 
29). As secondary antibodies FITC labeled goat anti-mouse IgM (Fc) 
(Nordic) diluted 1:100 or FITC-labeled rabbit anti-goat Ig (De Beer 
Med. BV, Hilvarenbeek. the Netherlands) diluted 1:500 were used. The 
sections were also stained with a rabbit anti-rat ( L2 ) laminin polyclonal 
antiserum diluted 1:400 and with a goat anti-human collagen IV poly­
clonal antiserum cross-reacting with rat diluted 1:200. which were both 
prepared in our laboratory, followed by FITC-labeled mouse anti-rabbit 
Ig (Jackson Laboratories Inc.) diluted 1:40 and by FITC labeled rabbit 
anti-goat Ig (de Beer Med BV) diluted 1:500, respectively, as second 
antibodies. Deposition of mouse Ig was evaluated using a F(ab)> FITC-
labeled sheep anti-mouse IgG as described. The Ig depositions were 
semiquantitatively scored on blinded sections in 30 glomeruli per kidney 
on a scale from 0 - 4 + by two independent observers. 
After all staining procedures, sections were embedded in Aquamount 
(BDH Ltd, Poole, England) and examined with a Zeiss fluorescence 
microscope. 
Immuno-electron microscopy. Tissue was prepared for IEM by per­
fusion of the kidneys during 10 min with a mixture of 0.01 M sodium 
periodate. 0.075 M lysine HCl, 0.0375 M N a ; H P 0 4 and 27c paraformal­
dehyde (PLP). Thereafter the kidney was cut into small pieces ( 5 x 5 
x 1 mm) and immersed in PLP for another 3 h. Next, the tissue was 
washed in PBS for 30 min and cryoprotected by immersion in 80% wt/ 
vol sucrose in PBS for I h. before they were snap fro/en in liquid N 2 . 
20-дт sections were incubated with a peroxidase labeled ant i-
mouse Ig diluted 1:20 (Dakopatt. Copenhagen. Denmark). After three 
washes in PBS, the sections were preincubated in diaminoben/idine 
medium containing 0.6 wt/vol TRIS for 10-15 min, followed by diami-
Figure 5. Indirect immunofluorescence of histones in a kidney perfused with mAb No. 32 complexed to histones (A). A positive staining is seen 
in the nuclei and along the glomerular capillary wall. After perfusion with pure mAb No. 32 only nuclear staining is observed (B) (X500). 
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Figure 6. Immuno-electron microscopy after perfusion with mAb No. 
32 complexed to histories. There is binding of complexed mAb through­
out the width of the GBM and only limited deposition on mesangial or 
endothelial cells (A). In a detail (B) the GBM binding of these com­
plexes is visualized more clearly {A, X5,000; ß, x20,000). 
nobenzidine with addition of H202 to a final concentration of 0.001% 
vol/vol. The sections were washed in distilled water, postfixed in 0.1 
M phosphate buffered 2% wt/vol Os04 for 30 min at room temperature, 
dehydrated, and embedded in Epon 812. Thin sections were prepared 
on a LKB ultratome, and examined unstained in an electron microscope 
(Jeol 1200 EX2, Jeol Europe BV). 
Results 
Identification of historie and DNA in complexed and purified 
mAbs. From a panel of mAbs originally identified as anti-DNA 
mAbs (described in reference 22) mAbs No. 2, 32, 34, and 42 
were used in this study. Purified noncomplexed mAbs were 
obtained after procedure III for mAbs No. 2 and 32 while for 
mAb No. 34 this procedure had to be supplemented by purifica-
tion on a DNA-cellulose column. For mAb No. 42 non-
complexed antibodies were obtained after procedure II. Immune 
complexes containing the core histones (H2a, H2b, H3, and 
H4) and DNA were obtained after procedure I, except for mAb 
No. 42 which did not bind protein A under physiological condi-
tions. The presence of histones was visualized by SDS-PAGE 
(Fig. 1, showing the results for mAb No. 32) and immunoblot-
ting (data not shown). DNA fragments were demonstrated in 
the complexed mAb after labeling with 32P. The greater part of 
this DNA had a size of — 120 bp but also some larger (240 bp) 
and smaller fragments were seen (Fig. 2) . Immune complexes 
containing histones and only a small amount of DNA were 
obtained after procedure II for mAbs No. 2, 32, and 34. A 
summary of the composition of the complexed material bound 
to the mAbs is given in Table I ( Composition ) . 
Reactivity of complexed and pure mAbs in ELISA and Farr 
assay. The reactivities of the different preparations of these 
mAbs in the Farr assay and in the different ELISAs are given 
in Table I (In vitro reactivity). In Fig. 3 the results of the 
different ELISAs are displayed in a dose effect manner over a 
wide range of antibody concentrations. Anti-DNA reactivity in 
the Farr assay and in the ELISA was found after purification 
under physiological conditions (procedure I) and comparable 
with that observed in crude culture supernatants (data not 
shown). DNA binding became even greater after reduction of 
the amount of DNA in the complex (procedure II). After com-
plete removal of bound nuclear material from these mAbs, 
mAbs No. 2, 32, and 34 lost their anti-DNA reactivity almost 
completely, whereas No. 42 remained strongly positive. A more 
or less similar picture emerged when the different preparations 
were tested on histones, i.e., positive in complexed form and 
negative in purified form, except for mAb No. 34. Completely 
different was the reactivity towards nucleosomes, the reactivity 
remained unaltered after purification. From these data it can be 
concluded that mAb Nos. 2 and 32 recognize an epitope ex-
pressed only on the intact nucleosome, mAb No. 34 reacts with 
an epitope on the intact nucleosome although in pure form it 
also reacts with histones, suggesting that for the recognition of 
the epitope on nucleosomes histone related antigens are in-
volved. Finally, mAb No. 42 primarily reacts with dsDNA, 
which also explains the reactivity with the intact nucleosome. 
Glomerular binding after perfusion of complexed and pure 
mAbs. The glomerular binding that occurred after renal perfu-
sion of the different mAb preparations is summarized in Table 
I (Glomerular binding). From these perfusion experiments it 
becomes clear that binding only occurs if the mAbs are com-
plexed. A representative example of the observed binding is 
given in Fig. 4. In purified form none of the mAb showed 
any binding. The major determinant for GBM binding was the 
presence of histones in the complex, irrespective of the amount 
of DNA present. In fact for mAbs No. 32 and 34 the magnitude 
of the binding was even larger for preparations obtained after 
purification under high salt conditions (procedure II, reducing 
the amount of bound DNA considerably ), compared with prepa-
rations obtained after purification under physiological condi-
tions (procedure I; not removing the DNA from the nucleosomal 
particle). This suggests that reduction of the DNA content 
within the nucleosome enhances the glomerular binding. The 
involvement of histones in this GBM binding is further substan-
tiated by indirect IF using an anti-histone antiserum showing 
besides nuclear staining, a fine granular deposition of histones 
along the capillary wall after perfusion of complexed mAb (Fig. 
5 A), but no capillary wall staining after perfusion of pure 
noncomplexed mAb (Fig. 5 B). At the ultrastructural level the 
Ig binding occurred through the whole width of the GBM, with 
only very limited binding to the endothelium or the mesangium 
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Figure 7. Direct immunofluorescence for rat C3 after perfusion with mAb No. 32 complexed to histories, followed by restoration of the blood flow 
for 15 min. Note deposition of rat C3 in the capillary wall of the glomerulus (A) When pure mAb No. 32 was perfused followed by restoration 
of the blood flow, there was no deposition of rat complement in the glomerulus (B). only staining of the basal part of the proximal tubular cells, 
which is normal in rat kidneys (X480). 
reconstitution of these immune complexes, was perfused, no 
binding was observed, indicating that it was the nucleosome in 
the complex, which mediated the glomerular binding of the 
antibodies. In addition perfusion of nucleosomes with a nonrele-
vant mAb WT1 directed against human CD7 did not lead to 
glomerular antibody binding. 
Binding of complexed mAbs after heparinase perfusion. To 
investigate the significance of GBM-HS in the glomerular bind-
ing of complexed mAb. heparinase was perfused before mAb 
perfusion. After heparinase. staining of the HS-GAG side chain 
within the GBM had almost disappeared completely, whereas 
staining of the HSPG-core protein was intact, indicating that 
the HS-GAG side chain was effectively removed from the core 
protein by this procedure (Fig. 9) . Staining of other GBM 
components, like laminin or collagen IV also remained intact 
(data not shown). If histone-containing immune complexes 
were perfused after heparinase perfusion, binding of the mAb 
decreased, but did not disappear totally (Table II. Fig. 9 ) . sug-
gesting that HS is not the only ligand through which these 
immune complexes can bind to the GBM as we have already 
suggested before (15). 
Discussion 
In previously reported experiments from others (13) and from 
our laboratories (14. 15. 30). it was shown that anti-dsDNA 
antibodies can bind to the GBM via an intermediate bridge of 
histones and DNA. in which the histone part is responsible for 
the binding to anionic sites in the GBM (for review see refer-
ence 16). Since our previous studies were performed with sub-
sequent separate perfusion of histones. DNA. and purified anti-
DNA. we now extend these observations in the present study 
by using mAb to nucleosomal antigens. These mAbs were se-
(Fig. 6. A and B). That this glomerular binding may have 
pathogenic potential can be derived from the observation that 
restoration of the renal circulation after perfusion of complexed 
mAbs leads to C3 deposition along the capillary wall in a pattern 
identical to that of the Ig deposits (Fig. 7) . 
Glomerular binding after perfusion of nucleosome reconsti-
tuted complexes. When purified mAbs were reconstituted with 
purified nucleosomes. glomerular binding was observed in IF 
after perfusion, which was comparable with the binding seen 
after perfusion of complexed antibodies obtained from culture 
supernatants. A representative example of the observed binding 
is given in Fig. 8. When the noncomplexed mAb. used for the 
Figure 8. Direct immunofluorescence of the glomerular binding after 
perfusion of a reconstituted immune complex of pure noncomplexed 
mAb No. 32 (obtained after procedure III) and highly purified nucleo-
somes. Binding of complexed mAb in the capillary wall of the glomeru 
lus can be observed (x300). 
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Figure ü. Indirect immunofluorescence of a kidney perfused wilh hepannase compared with a control perfusion. After control perfusion the staining 
of HSPG-core protein (A ) and HS-GAG side chain ( C) is intact. In the kidney perfused with heparinase the staining of the HSPG-core protein is 
still intact (B), whereas the staining of the HS-GAG side chain has disappeared (D). When mAh No. 32 complexed to histones is perfused after 
heparinase or a control perfusion, the binding of complexed niAb is decreased in the heparinase perfused kidney (F) as compared with the control 
perfusion (£) (A-D, X350; E, X400; F, X480). 
lected from a panel of mAbs on the basis of their binding to 
HS. This reactivity was found using crude hybridoma culture 
supernatants, since we have shown in previous experiments that 
HS reactivity is due to antibodies complexed to nuclear antigens 
( 14). To evaluate whether these complexed mAbs could bind 
to the GBM, we performed perfusion studies with complexed 
and noncomplexed antibody preparations and with reconstituted 
complexes composed of purified mAb and nucleosomes. The 
GBM binding was related to the composition of the antibody 
bound material and the reactivity of the mAb in vitro. 
The purification procedures confirm our previous observa-
tions that during hybridoma culture nuclear antigens become 
bound to the mAbs, since we could identify core histones and 
DNA in the complex bound to the mAb after isolation under 
physiological conditions. Purification under high salt conditions 
led to a significant removal of DNA from the bound complex 
for mAbs No. 2, 32, and 34, whereas after this procedure mAb 
No. 42 did not contain any nucleosomal material at all. Why, 
after purification under high salt conditions the DNA content 
in the complex with mAbs No. 2, 32, and 34 is significantly 
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Table II Influence of Hepannase Perfusion (Removing HS from 
the GBM) on the Subsequent Binding of Perfused Complexed 
mABNo П 
GBM staining 
Amount of complexed Decrease of 
mAb perfused (^g lgG2a) HS GAG HSPG core GBM binding 
200 - + 81 
100 - + 76 
600 - + 31 
reduced, but the histone content not, is not completely clear It 
may be related to antigen binding properties of these mAbs, 
since mAb No 42 is directed against DNA and the other three 
are directed against nucleosomal epitopes In the case of two 
of these three mAbs (No 2 and 32) pure antibody was obtained 
after DNase pretreatment, suggesting that the residual DNA in 
the complex observed after high salt purification only, plays a 
role in the binding of the antibody In any case the combined 
use of DNase pretreatment and high salt conditions yielded 
noncomplexed mAbs No 2 and 32 In contrast to this, a subfrac -
tion of mAb 34 was still bound to histones after this procedure 
This mAb was further punned using a DNA-cellulose column 
Complexed antibodies, containing histones, retained on the col­
umn and the fraction of noncomplexed mAb No 34 was ob­
tained in the effluent and used for further studies 
The in vitro analysis of the antigen reactivity of complexed 
and noncomplexed mAb indicates that binding of nucleosomal 
material can strongly influence the displayed specificity In gen­
eral the Farr assay is regarded as the most appropriate test to 
detect high avidity anti-dsDNA antibodies (22) However, our 
results show that Farr positivity can be the result of binding of 
complexes composed of nucleosomal matenal and ami-nucleo-
some antibodies, since effective removal of these nuclear anti­
gens leads to disappearance of the binding in the Farr assay 
This Farr reactivity seems to be the result of the presence of 
histones within the nucleosomal particle, which is conceivable 
because of the DNA binding properties of these proteins One 
could argue that this phenomenon is a peculiar characteristic of 
these mAbs However, preliminary data (unpublished observa­
tions ) indicate that this is also true for polyclonal auto-antibod-
les from SLE patients These observations however, do not 
reduce the usefulness of the Farr assay in the follow-up of SLE 
patients, since Farr positivity might be due to the presence in 
the circulation of auto-antibodies complexed to nucleosomes 
which we regard as potentially nephntogenic Furthermore, 
these observations might explain why Farr positivity is associ­
ated with onset and/or exacerbation of lupus nephritis (4) and 
with anti-HS reactivity in SLE patients (31, 32) 
The in vitro analysis shows in addition that anti-DNA reactivity 
both in the Farr assay and in the ELISA and anti-histone reacüvity 
can be a feature of antibodies primarily directed against (neo-) 
epitopes expressed on nucleosomes The presence of ann-nucleoso-
mal antibodies in SLE has been described before ( 33-35 ) In addi-
tion, mAbs derived from lupus mice have been described which 
showed a much higher reactivity towards histone-DNA complexes, 
than to histones or DNA alone (36, 37), and recently Losman et 
al desenbed a mAb which only reacted with the intact nucleosome 
and not with any of the subnucleosomal panicles ( 38 ) This reacüv-
ity is similar to what we observed with punfìed mAbs No 2 and 
32 which also react with a neo-epitope on the intact nucleosome 
The reactivity of punned mAb No 34 is somewhat different, since 
it süll reacted in non-complexed form with histones From these 
data it is tempting to speculate that the epitope This mAb recognizes 
within the nucleosomes is different from that recognized by mAbs 
No 2 and 32, since these became negauve in the histone ELISA 
once punfìed Our observations support the possibility that ann-
nucleosomal autoantibodies might be present much more frequent 
in SLE than we appreciate today This is further underlined by the 
recent report that nucleosomes are a major immunogen for patho-
genic auto-antibody inducing T-helper cells (39) 
When we tested the vanous mAb preparation for their ca-
pacity to bind to the GBM, we found that the mAbs complexed 
to nucleosomal antigens (mAbs No 2, 32 and 34) did bind to 
the GBM, while the noncomplexed, pure mAbs did not bind at 
all To exclude that additional components from the culture 
supematants copunfied with the nucleosomal matenal are re-
sponsible for this binding, we prepared nucleosome-antibody 
complexes by reconstituting pure noncomplexed mAb (proce-
dure HI) with highly punfìed nucleosomes and again saw bind-
ing to the GBM The observation that non-complexed mAb did 
not bind to the GBM does not support a direct binding to lntnn-
sic constituents as has been suggested before ( 8,40, 41 ) When 
we analyzed the composition of the nucleosomal matenal which 
could mediate the binding of mAb to the GBM, we found that 
the presence of histones was cntical Furthermore, a reduction 
of the amount of DNA within the nucleosome enhanced this 
binding This observation raises the possibility that partial diges-
tion of the nucleosome by DNase enhances the nephntogenic 
potential of anti-nuclear antibodies complexed to nucleosomes 
The involvement of histones in lupus nephritis is substantiated 
by the recent demonstration of histone deposits in both human 
and munne lupus nephntis (17, 18, 42) The GBM binding 
of the complexes containing nucleosomal matenal used in the 
present study was different from the binding that we observed 
previously after subsequent perfusion of histones, DNA and 
anti DNA In our present study we found a localization through-
out the whole width of the GBM and hardly any binding to 
endothelial or mesangial cells, whereas in our previous expen-
ments ( 15) the majonty of the binding occurred to endothelial 
cells and the lamina rara interna of the GBM The fact that C3 
deposition is induced suggests the nephntogenic potential of 
this binding Our hepannase perfusion expenments show that 
HS is an important target for this nucleosome mediated antibody 
binding, but also that it is not the only anionic ligand within 
the GBM Additional studies are needed to delineate funher 
these other binding moieties It is tempting to speculate that 
this nucleosome binding to HS is the explanation for our recent 
observation that in human (43) as well as in munne lupus 
nephntis (44) the HS staining in the GBM, as assessed by an 
anti-HS mAb, has almost completely disappeared, moreover 
since nucleosomes were able to inhibit the binding of this anti-
HS mAb to HS in vitro 
In summary, we found that nucleosomal matenal can medi-
ate the binding of antibodies to the GBM and that complexes 
composed of nucleosomal antigens and anti-nucleosome anti-
bodies may show anti-DNA reactivity, even in a Fan-type assay 
which previously was thought to specifically detect high avidity 
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antibodies to DNA only Binding of these nucleosome con­
taining complexes to the GBM, might be a first step, leading 
to lupus nephntis 
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ABSTRACT 
Recently, we showed that anti-nuclear auto-antibodies complexed to nucleosomes can 
bind to heparan sulfate (HS) in the glomerular basement membrane (GBM) via 
interaction of the histone part of the nucleosome (J.Clin.Invest. 1994;94:568). 
Histones have been identified in glomerular deposits in human and murine lupus 
nephritis, and a decreased HS staining was found in glomeruli of albuminuric MRL/1 
lupus mice, most likely due to masking by deposition of antibodies complexed to 
nucleosomes (Am.J.Pathol. 1995; 146:753). In this study we questioned firstly 
whether nucleosomes could be identified in glomerular deposits in human lupus 
nephritis and secondly whether the presence of histones or nucleosomes was 
correlated with absence of HS staining. Eleven SLE patients with diffuse proliferative 
glomerulonephritis (DPGN, WHO class IV), six SLE patients with membranous 
glomerulonephritis (MGN, WHO class V) and nine non-SLE controls (4 with 
mesangiocapillary glomerulonephritis (MCGN) and 5 with idiopathic membranous 
glomerulonephritis) were selected. All sections were stained for histones (using a 
polyclonal rabbit antiserum against peptide 1-21 of histone H3), and with monoclonal 
antibodies (mAbs) for DNA (mAb #42), histones (mAbs KM2 and #34), nucleosomes 
(mAbs LG8-1 and LG10-1), IgG, HS (JM 403) and heparan sulfate proteoglycan 
(HSPG) core protein (JM 72). Using the polyclonal anti-H3 1 -21 antiserum, histones 
were detected in all patients with DPGN and in 2 out of 6 patients with SLE-MGN. 
Using the anti-histone mAbs, histones were stained in 6 patients with DPGN and in 
2 patients with MGN. Nucleosomes were detected in 5 patients with DPGN and in 
none of the MGN patients. The high avidity anti-dsDNA mAb did not stain any 
glomerular deposits. HS staining was nearly absent in DPGN, whereas staining was 
only moderately reduced in patients with MGN (p=0.001, Mann Whitney U). 
Staining of HSPG core protein was normal in all patients. 
In conclusion, using the polyclonal anti-H3 antiserum, histones were identified in all 
patients with DPGN and their presence was associated with a decrease of HS 
staining. Nucleosomes were identified in 5 out of 11 patients with DPGN. In all other 
patients nucleosomes were not detected. This is the first demonstration of 
nucleosomes in glomerular deposits in SLE nephritis. It remains to be elucidated 
whether the nucleosomal particle deposited in these lesions consists mainly of 
histones or that nucleosome specific epitopes are masked by anti-nucleosome and/or 
anti-dsDNA auto-antibodies already bound in vivo to these epitopes. 
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INTRODUCTION 
In systemic lupus erythematosus (SLE) about 50% of patients develop renal disease 
(1). Anti-nuclear antibodies and more specifically anti-dsDNA antibodies are a 
hallmark for the disease (2). Since often a rise in titer of anti-dsDNA antibodies is 
found preceding a renal exacerbation (3,4) and renal eluates of patients with lupus 
nephritis are enriched for anti-dsDNA antibodies (3,5), these antibodies are thought 
to play a pathogenic role in the initiation of the glomerular disease. Some years ago 
we showed that certain anti-dsDNA antibodies are able to bind to heparan sulfate 
(HS), an intrinsic constituent of the glomerular basement membrane (GBM). (6). In 
subsequent experiments we showed that this HS cross-reactivity was a property of 
antibodies complexed to nucleosomal antigens (i.e. DNA and histones) (7) and that 
anti-nucleosome antibodies complexed to nucleosomal antigens were able to bind to 
HS in the GBM, whereas pure antibodies did not bind (8). 
In the meantime it was shown that histones are present in immune deposits of both 
human (9) and murine (10) lupus nephritis, whereas in murine lupus an association 
between histone deposits and albuminuria was found (10). 
Recently, we found that in human lupus nephritis in the majority of patients HS 
staining was absent, whereas staining for the heparan sulfate proteoglycan (HSPG) 
core protein was intact (11). In subsequent studies in MRL/1 mice we found that HS 
staining disappeared in albuminuric mice, and that there was a correlation between 
HS staining and albuminuria as well as between HS staining and GBM Ig deposits. 
Since glomerular HS content was not decreased in mice in which HS staining was 
absent, we concluded that HS might have been masked by nucleosome containing 
immune deposits (12). Although other investigators showed histones (9,10) or DNA 
(13) in the deposits, nucleosomes were never identified in glomerular immune 
deposits. 
In the present study we questioned firstly whether nucleosomes were present in the 
glomerular immune deposits in human lupus nephritis and secondly whether presence 
of histones or nucleosomes correlated with loss of HS staining. Since we were 
interested in the interaction between immune deposits and HS in the GBM, patients 
with diffuse proliferative glomerulonephritis (DGPN) and with membranous 
glomerulonephritis (MGN) were selected. 
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MATERIAL AND METHODS 
Renal biopsies of SLE patients 
Eleven renal biopsies of SLE patients with DPGN and six of SLE patients with MGN 
were selected. All patients fulfilled at least 4 ARA criteria for SLE. From all renal 
biopsies 2 μιη cryostat sections were cut. In control experiments renal biopsies of 4 
patients with non-SLE mesangiocapillary glomerulonephritis and 5 patients with non-
SLE MGN were stained. 
Immunohistology 
All sections were stained in direct IF for IgG deposits and in indirect IF for heparan 
sulfate (HS), heparan sulfate proteoglycan (HSPG) core protein, histones, DNA and 
nucleosomes. 
Human IgG: Depositions of human IgG were studied in direct IF by incubating 
sections with FITC labeled F(ab)2 rabbit anti-human IgG (CLB, Amsterdam, the 
Netherlands) 5 mg/ml diluted 1:400 in PBS containing 1% (wt/vol) BSA (PBS/BSA) 
for 30 minutes at room temperature. After the staining procedure, the sections were 
embedded in Aquamount (BDH Ltd. Poole, UK) and examined with a Zeiss 
fluorescence microscope. 
HS and HSPG core protein: HS was stained by incubating the sections with a mouse 
anti-rat HS monoclonal antibody (mAb, JM 403) that only recognizes HS in 
basement membranes and cross-reacts with human HS (14). HSPG core protein was 
stained by incubating with a mouse monoclonal anti-human HSPG-core protein (JM-
72, (14)). HS and HSPG-core protein were stained simultaneously on the same slide 
using double-staining as was described before (14). 
Histones: Histones were stained by incubating the sections with a polyclonal rabbit 
antiserum raised against the N-terminal 1-21 peptide of histone H3 (15) and by 
incubating with two mAbs against histones derived from lupus prone mice (mAbs 
KM2 and #34). MAb KM2 is directed against H2A and H4. It is equally reactive 
with the nucleosome as with a mixture of the five histones (data not shown). MAb 
#34 shows stronger reactivity with the nucleosome than with a mixture of histones 
(8). It binds to histone H3 (data not shown). The IF using the polyclonal rabbit 
antiserum was performed as was described before (9,10). The IF using the mAbs was 
performed by incubating the sections with mAb KM2 and mAb #34 (10 μg/ml) in 
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PBS/BSA for 30 minutes at room temperature. Next, sections were incubated with 
FITC labeled F(ab)2 sheep anti-mouse Ig (Cappel, Organon Teknika, Turnhout, 
Belgium) 10 mg/ml, diluted 1:750 in PBS/BSA for 30 minutes at room temperature. 
After the staining procedure, the sections were embedded in aquamount (BDH Ltd. 
Poole, UK) and examined with a Zeiss fluorescence microscope. 
DNA and nucleosomes: DNA and nucleosomes were stained by incubating the 
sections with mAbs derived from lupus prone mice. The anti-dsDNA mAb (#42) was 
derived from a panel of anti-dsDNA mAbs described previously (16). The anti-
nucleosome mAbs (LG8-1 and LG 10-1) only recognize the intact nucleosome and 
not DNA or histones separately as was described before (17). For IF the sections 
were incubated with mAb #42, mAb LG8-1 and mAb LG 10-1 (10 μg/ml) in 
PBS/BSA for 30 minutes at room temperature. Further procedures were identical to 
the IF using the mAbs KM2 and mAb #34. 
We also performed a double staining for IgG and nucleosomes using FITC-labeled 
F(ab)2 rabbit anti-human IgG followed by anti-nucleosome mAb LG 10-1 with 
TRITC-labeled anti-mouse IgG2b as secundary antibody to compare the localization 
of the IgG and nucleosome deposits. 
Staining of histones using the polyclonal rabbit antiserum and HS-staining was scored 
semiquantitatively on a 0-8 scale on coded sections by three independent 
investigators. 
Statistical analysis 
Presence of histones was compared between kidney biopsies of patients with DPGN 
and MGN using the Fisher exact test. 
HS staining (scored semiquantitatively on a 0-8 scale) was compared between kidney 
biopsies of patients with DPGN and MGN using the Mann Whitney U test. The 
correlation between HS staining and staining of histones with the polyclonal rabbit 
antiserum was tested in Spearman's correlation test. 
RESULTS 
Staining of IgG, histones, nucleosomes and DNA in glomerular deposits 
Using the anti-H3 (1-21) peptide antiserum, in all kidney biopsies of patients with 
DPGN (Fig 1 ) and in 2 out of 6 patients with SLE-MGN histones were detected 
(p<0.01)(Table 1). Histone deposits were abundantly present in the walls of the 
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Table 1. Immunofluorescence findings in renal biopsies of SLE patients with either 
diffuse proliferative glomerulonephritis (DPGN; WHO class IV) or membranous 
glomerulonephritis (MGN; WHO class V) and non-SLE controls with either 
mesangiocapillary glomerulonephritis (MCGN) or idiopathic MGN. 
Antibodies 
mAbs' 
anti-nucleosome 
anti-dsDNA 
anti-histone 
polyclonal2 
anti-H3(l-21) 
SLE 
DPGN 
class IV 
5/113 
0/11 
6/11 
11/114 
nephritis 
MGN 
class V 
0/6 
0/6 
2/6 
2/6 
non-SLE 
MCGN 
0/4 
0/4 
0/4 
1/4 
nephritis 
MGN 
0/5 
0/5 
0/5 
0/5 
' staining of nucleosomes in glomerular deposits using mAbs LG8-1 or LG 10-1; 
staining ofhistones using mAbs KM2 or #34; staining of DNA using mAb #42. 
2
 staining ofhistones using a polyclonal rabbit anti-H3 1-21 serum. 
3
 number of positive biopsies / number of biopsies tested. 
4
 P<0.01 (Fisher exact test) for SLE-MGN compared to DPGN. 
capillary loops and grossly followed the pattern of IgG deposition (data not shown). 
Using the anti-histone mAbs in 6 kidney biopsies of DPGN patients and in 2 of the 
MGN patients histones were identified in the immune deposits (Table 1). MAb #34 
stained histones in 5 renal biopsies of DPGN and in 2 biopsies of MGN patients (the 
same two biopsies which were positive when stained with anti (1-21) H3 serum), and 
mAb KM2 stained deposits in 3 biopsies of DPGN patients. Nucleosomes were 
identified in immune deposits of 5 renal biopsies of patients with DPGN (Fig 2) and 
in none of the biopsies of SLE-MGN (Table 1). MAb LG8-1 stained deposits in 2 
renal biopsies of DPGN patients and mAb LG 10-1 stained deposits in 4 biopsies of 
DPGN patients. In the IF analysis with the anti-histone or anti-nucleosome mAbs 
only limited regions of staining were found in the walls of capillary loops, where the 
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staining was both focal and segmental. In all biopsies with positive staining, this 
staining was weak compared to the histone staining using the polyclonal rabbit 
antiserum in the same biopsies. Anti-dsDNA antibodies did not stain deposits in any 
of the biopsies (Fig 3). As assessed by double staining, Ig deposits were often 
observed without staining of nucleosomes but when present the localization of the 
nucleosome deposits was the same as the IgG deposition. Nucleosome deposits were 
never found where IgG deposits were absent (data not shown). 
In the control experiments (non-SLE biopsies) not one of the mAbs stained 
glomerular deposits, whereas the polyclonal rabbit anti-H3 (1-21) serum stained 
glomerular immune deposits in one patient with non-SLE mesangiocapillary 
glomerulonephritis (Table 1). 
Staining of glomerular HS and HSPG core protein 
Staining of HSPG core protein was normal in all kidney biopsies studied (Fig 4A, 
С and E). GBM-HS staining was normal (Fig 4B) or only moderately reduced (Fig 
4D) in renal biopsies of patients with SLE-MGN, whereas staining was nearly absent 
in all patients with DPGN (p=0.001), (Fig 4F, Table 1). There was a significant 
inverse correlation between HS staining and histone deposition as found by the 
polyclonal rabbit anti-H3 1-21 antiserum (r=-0.77, pO.0001, Fig 5). 
DISCUSSION 
In recent years evidence has emerged that nucleosomes may play an important role 
in the initiation of lupus nephritis (18). Histones have a high affinity for the GBM 
(19). They are positively charged (pl=10) and probably interact with the negatively 
charged HS in the GBM. We showed that after subsequent renal perfusion in the rat 
of histones, DNA and anti-dsDNA mAbs, these antibodies bind to the GBM, whereas 
subsequent perfusion of DNA and anti-dsDNA leads to limited mesangial binding of 
antibody, while anti-dsDNA antibodies perfused alone do not bind at all (20). An 
interaction with HS in the GBM was confirmed by the finding that anti-dsDNA 
antibodies complexed to DNA and histones were able to bind HS in ELISA (7,8). 
Subsequently, we showed in the same rat kidney perfusion model that anti-
nucleosome antibodies complexed to nucleosomes are able to bind to the GBM. 
When HS was removed from the GBM by prior perfusion with the HS degrading 
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Figure 1: Representative 
example of a kidney biopsy of 
a SLE patient with DPGN 
stained with a polyclonal 
rabbit anti-H3 1-21 serum, 
showing abundant histone 
deposits in the walls of the 
glomerular capillary loops (x 
240). 
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Figure 2: Representative 
example of a kidney biopsy of 
a SLE patient with DPGN, 
stained with a mouse anti-
nucleosome mAb (LG10-1). 
Besides prominent nuclear 
staining, also segmental 
staining of the capillary loops 
can be seen (x 160). 
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Figure 3: Representative 
example of a kidney biopsy of 
a SLE patient with MGN, 
stained with a mouse anti-
dsDNA mAb (#42). Only nuclei 
stain and no staining in the 
walls of the capillary loops 
nor the mesangium is observed 
(x 240). 
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Figure 4 (opposite page): Representative examples of double staining of a kidney 
biopsy of two patients with MGN (Fig 4A and 4B, and Fig 4C and 4D) and of a 
patient with DPGN (Fig 4E and 4F), with the mouse anti-HS mAb JM-403 and with 
the mouse anti-HSPG core protein mAb JM-72. In Fig 4A, 4C and 4E the biopsies 
are stained with JM-72, showing intact staining of the HSPG-core protein. In Fig 4B, 
4D and 4F the same biopsies are stained with JM-403, showing normal (4B) and 
moderately reduced (4D) GBM-HS staining in the MGN patients and almost absent 
GBM-HS staining in the patient with DPGN (4F). (4A and 4B χ 200, 4C, D, E and 
F χ 280). 
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Figure 5: Correlation between US-staining and staining ofhistones (as assessed with 
the anti-H3(l-21) serum) in the walls of the capillary loops. Staining was scored on 
a 0-8 scale. DPGN (·). SLE-MGN (A). 
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enzyme heparinase, the binding of subsequently perfused complexed anti-nucleosome 
antibodies was greatly reduced (8). Taken together, these experiments show that HS 
in the GBM is an important ligand for the binding of these nucleosome complexed 
antibodies and that histones in these complex interact with HS presumably based on 
charge. 
Although histones have been found in the serum of humans (21), it is not very likely 
that they exist as separate molecules devoid of DNA. In the nucleus, histones are 
bound to DNA, within the nucleosome. These nucleosomes have been found in the 
circulation of lupus patients (22). It is assumed that they are released by dying cells. 
Apoptosis of cells leads to release of oligonucleosomes (23,24), whereas necrosis 
yields less well defined histone/DNA complexes. It is presently unknown what 
happens with nuclear material after release in the circulation. DNase and proteinases 
are present in the plasma so remodelling of the particle is very well possible. 
In the present study we analyzed whether nuclear material was present in glomerular 
deposits in human lupus in more detail by staining for histones, DNA and 
nucleosomes. Using the polyclonal anti-H3 1-21 antiserum deposits were found in all 
kidney biopsies of patients with DPGN and in 2 out of 6 patients with MGN. Using 
the anti-histone mAbs in 6 renal biopsies of patients with DPGN and in 2 MGN 
patients histone deposits were found, and this staining was considerably weaker than 
the staining seen with the polyclonal anti-histone antiserum. Because of the broader 
anti-histone specificity, the polyclonal antiserum has a greater sensitivity for the 
detection of these histone deposits. Nucleosomes were found in 5 out of 11 kidney 
biopsies of DPGN patients and in none of the MGN patients. The anti-dsDNA 
antibodies did not stain any deposits. 
These findings suggest that the nuclear particle which is deposited, contains at least 
histones. Localization of auto-antibodies in the GBM can arise along two different 
mechanisms. First, they can deposit from the circulation as complexes. Localization 
via this mechanism leads mainly to subendothelial deposits, as is found mainly in 
DPGN. The other possibility is an in situ immune complex formation in which the 
antibody reacts with an intrinsic GBM antigen or an exogenous planted antigen. This 
mechanism mainly leads to subepithelial deposits as seen mainly in MGN. It is 
unlikely that the nucleosome binds to the GBM in free non-complexed form and acts 
as a planted antigen, since renal perfusion of intact nucleosomes mainly leads to 
mesangial and not to GBM localization (25). This is due to the pi of the native 
nucleosome which is about 7. Furthermore, the negatively charged DNA is located 
on the outside of the nucleosomes which reduces the possibility that native 
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nucleosomes interact with the negatively charged GBM. Such a direct binding can 
only be envisaged if nuclear material is remodelled by plasma DNase and proteinases 
which creates a nuclear particle with less DNA and relatively more histones. Such 
a particle is theoretically able to bind to the GBM leading to in situ-immune complex 
formation. This mechanism could explain the higher frequency of histone deposits 
as we found. However, an argument against this possibility is that these histone 
deposits should have preferentially be present in SLE-MGN, which was not the case. 
Another, more likely, possibility is that DNA or nucleosome specific epitopes of the 
nucleosome are covered by anti-dsDNA or nucleosome specific antibodies. When 
nucleosomes are released in the circulation in lupus patients they will bind to these 
antibodies and form nucleosome-antibody complexes. Only when these antibodies 
cover the negatively charged DNA in the nucleosome, the complex is able to bind 
to the GBM. In this view the overall pi and thus the nephritogenicity of the complex 
is determined by the antigen specificity of the bound antibody. This view is 
confirmed by the fact that glomerular eluates are greatly enriched for anti-dsDNA 
(5,26) and anti-nucleosome antibodies (unpublished observations). In contrast, anti-
histone antibodies would cover the histone part of the nucleosome, thereby reducing 
the positive charge which prevents it from binding to the GBM. Very interestingly, 
in drug induced lupus, in which anti-histone antibodies are abundantly present and 
anti-dsDNA antibodies are absent, nephritis is seldom seen (27). 
Furthermore, in our experience, glomerular eluates of lupus mice contain only small 
quantities of anti-histone antibodies which show no correlation with albuminuria 
(unpublished observations). This mechanism of in vivo covering of nucleosome and 
DNA specific epitopes with a relative sparing of histone specific epitopes could 
explain the low frequency of nucleosome specific staining and the high incidence of 
histone specific staining that we observed. Formal proof for this assumption could 
have come from elution studies on kidney sections, which could lead to uncovering 
of these nucleosome specific epitopes. However, attempts to achieve this were for 
technical reasons unsuccesful as we have described previously (12). 
The second aim of our study was to find out whether loss of GBM-HS staining in 
lupus nephritis was associated with histone or nucleosome deposition. In a recent 
study we found a decrease of glomerular HS staining without loss of HS content. In-
vitro experiments showed that histones, nucleosomes and anti-nucleosome antibodies 
complexed to nucleosomes were all able to mask HS in ELISA (12). In the present 
study this in vitro finding was extended since the loss of HS staining correlated with 
histone deposition. Very interestingly, histone deposition was only found in 2 out of 
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6 kidney biopsies of SLE-MGN patients, and in these patients HS staining was not 
or only moderately reduced. This may be due to quantitative differences in 
glomerular IgG deposition between DPGN and MGN patients, since in DPGN 
heavier IgG deposits are present. This is in line with our observation in murine lupus 
nephritis, where an inverse correlation between IgG deposition and GBM-HS staining 
was found (12). On the other hand it is very well possible that other antibody 
specificities like anti-laminin or anti-DPPIV (28) play a role in the membranous form 
of lupus nephritis and that the histopathological differences between DPGN and 
MGN are based on differences in nephritogenic antibody populations. However, this 
hypothesis is largely speculative and should be tested by further experiments. 
In conclusion, we show for the first time that nucleosomes can be identified in 
immune deposits of some lupus patients with DPGN. Histones are mainly found in 
lupus patients with DPGN and their presence correlates with a loss of GBM-HS 
staining, which is probably due to masking of HS. 
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CHAPTER 6 
Anti-nucleosome antibodies complexed to 
nucleosomal antigens bind to cell surfaces and are 
internalized. Fixation related migration of 
antibodies leads to in-vivo ANA. 
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ABSTRACT 
It has been suggested that binding of anti-dsDNA antibodies to cell surfaces, 
followed by internalization and nuclear binding (so called in-vivo ANA) is of 
pathophysiological significance for tissue damage in systemic lupus erythematosus 
(SLE). We have shown before that pathogenic anti-nuclear antibodies complexed to 
nucleosomal antigens can bind to heparan sulfate in the glomerular basement 
membrane in-vivo. Since nucleosomes are also reported to bind to the cell surface, 
we hypothesized that in-vivo ANA is a property of anti-nuclear antibodies bound to 
nucleosomal antigens. Therefore, we studied three monoclonal anti-nucleosome 
antibodies (mAbs) that exhibit in-vivo ANA as seen by immunofluorescence (IF) in 
mice inoculated intraperitoneally (ip) with the hybridoma producing the mAb. The 
same mAbs complexed to nucleosomal antigens after intravenous injection into mice 
induced in-vivo ANA, in contrast to purified non-complexed mAbs. To study this in 
more detail, we incubated complexed mAbs with various cell lines and found binding 
to the cell surface and subsequent internalization into cytoplasmic vesicles. However, 
no binding to the nucleus was observed by immuno electron microscopy (IEM) and 
by confocal laser microscopy. Non-complexed mAbs did not bind to the cell surface. 
Next, from mice bearing the hybridomas producing the mAbs ip, a small part of the 
kidney was snap frozen in liquid N2, fixed with acetone and studied in IF, whereas 
the remaining part of the kidney was in-vivo fixed by renal perfusion with a mixture 
of 0.01 M sodium periodate, 0.075 M lysine HCl, 0.0375 M Na2HP04 and 2% 
paraformaldehyde (PLP) and studied in both IF and IEM. In the acetone fixed kidney 
sections obtained without in-vivo fixation we again observed in-vivo ANA. However, 
after in-vivo PLP perfusion fixation, no nuclear binding was found. In IEM, 
localization in cytoplasmic vesicles was seen. In conclusion, anti-nucleosome 
antibodies complexed to nucleosomal antigens can bind to the cell surface and are 
transported into the cytoplasm, but do not bind to the nucleus. The reported nuclear 
localization of anti-nuclear antibodies is due to the type of fixation procedure. 
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INTRODUCTION 
Systemic lupus erythematosus is an auto-immune disease, which affects many organs 
in the body. Anti-nuclear autoantibodies are the hallmark of the disease, especially 
anti-double stranded DNA (dsDNA) antibodies (1). These anti-dsDNA antibodies are 
thought to be responsible for most of the tissue damage in this disease, although the 
mechanisms by which these lesions are produced in the various organs is still a 
matter of debate. It has been proposed that anti-dsDNA antibodies are able to bind 
to cell surface bound DNA (2) or, alternatively, directly via cross reactivity with cell 
surface proteins (3). This binding may lead to cell damage, for instance it was 
recently described that it leads to enhancement of apoptosis of rat mesangial cells (4). 
Other reports mentioned that cell surface bound anti-dsDNA antibodies were 
internalized and that these antibodies are subsequently transferred to the nucleus 
leading to derangement of cell functions (5,6). However, one of the first authors who 
described the binding of anti-dsDNA antibodies to cell surface proteins (7), later 
discovered that this binding was caused via the intermediary action of nucleosomes 
or DNA/histone complexes bound to the antibodies (8). Others found that 
nucleosomes or DNA/histone complexes could bind to cell surfaces, probably via a 
DNA receptor inducing cytokine production (9). At this moment, it is still unclear 
whether the binding of nuclear material to cell surfaces, alone or complexed to 
antibodies, is a charge related phenomenon or mediated via a specific receptor. In 
favor of a charge dependent interaction is our finding that anti-nucleosome antibodies 
complexed to nucleosomal antigens are able to bind to the glomerular basement 
membrane (GBM) in-vivo, through an interaction with the negatively charged heparan 
sulfate in the GBM (10). 
When we inoculated in naive mice the hybridomas producing the mAbs that showed 
this GBM binding, we invariably observed in-vivo ANA in kidney sections by 
immunofluorescence (IF). This nuclear staining can be frequently observed in 
sections of kidneys from SLE patients or lupus prone mice, and is sometimes 
explained as a smearing artefact occurring during sectioning of the tissue. Others 
state that this nuclear staining is the result of an active process in-vivo (5,6). In the 
present study we tested the hypothesis that in-vivo ANA is produced by antibodies 
complexed to nucleosomal antigens. In this perspective the complexed auto-antibody 
binds to the cell surface via nucleosomal material and, after binding, the complex is 
internalized. We also analyzed whether this internalization ultimately leads to nuclear 
binding. 
72 
MATERIALS AND METHODS 
Preparation and characterization of pure non-complexed antibodies and 
antibodies complexed to nucleosomal material 
Three monoclonal anti-nucleosome antibodies (clones #2, #32 and #34) derived from 
lupus mice were used. By purification on a protein A sepharose column under 
physiological conditions (procedure I), high salt conditions (procedure II) or DNase 
treatment followed by high salt conditions (and in the case of mAb #34 additional 
separation of histone bound mAb on a DNA-cellulose column) (procedure III), 
antibodies complexed to nucleosomal material (procedure I and II) or pure non-
complexed antibodies (procedure HI) were obtained as described before (10). 
Purified and complexed antibodies were tested in the Fair assay and in ELISAs (anti-
dsDNA, anti-histone and anti-nucleosome) as described before ( 10). Composition and 
antigen reactivities of the antibody preparations used have been published before (10) 
and are summarized in Table 1. 
MAbs #2 and #32 are anti-nucleosome mAbs, which in purified form (purification 
procedure III) only recognize the intact nucleosome and not its components histones 
or DNA. In pure form (procedure III) mAb #34 also recognizes histones, but its 
reactivity with the intact nucleosome is stronger. All three mAbs only show DNA 
reactivity when they are complexed to nucleosomal antigens (purification procedures 
I and II). 
In-vivo studies 
Hybridoma inoculation. Hybridoma cells producing the mAbs (5 χ IO6 cells per 
mouse) were inoculated intraperitoneally (ip) in 8 week old BALB/c mice (n=3 per 
mAb), which were primed 8 days before with pristane. Two days after development 
of ascites the animals were sacrificed, the kidneys were flushed with PBS and snap 
frozen in liquid N2. 
In an additional experiment only a small part of the kidney was snap frozen in liquid 
N 2 after flushing with PBS, and the remainder of the kidney was perfused during 10 
min with a mixture of 0.01 M sodium periodate, 0.075 M lysine HCl, 0.0375 M 
NajHPO,, and 2% paraformaldehyde (PLP). This was done in order to obtain in-vivo 
fixation. Thereafter, the kidney was cut into small pieces (5x5x1 mm) and immersed 
in PLP for another 3 h. A small part of tissue was used for IF, while the remaining 
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Table 1- Composition of bound complexes (panel A), reactivity in Farr assay and various ELISAs (panel B) of the different mAb 
preparations obtained after purification under physiological conditions (I), high salt conditions (II) or DNase treatment followed 
by high salt conditions (and in the case of mAb #34 additional separation of histone bound mAb on a DNA-cellulose column) (III). 
mAb 
procedure 
A: COMPOSITION 
histones* 
DNA1 
В: In-vitro REACTIVITY 
Farr§ 
ELISA1 
DNA 
histone 
nucleosome 
I 
+ 
+ 
6 
178 
55 
3500 
#2 
II 
+ 
+ 
25 
227 
90 
4800 
III 
— 
3 
36 
<1 
3000 
I 
++ 
++ 
70 
98 
4500 
5000 
#32 
II 
++ 
+ 
75 
100 
187 
7600 
III 
— 
3 
1 
1 
5400 
I 
++ 
+ 
17 
178 
1777 
7500 
#34 
II 
+++ 
± 
57 
200 
800 
12000 
III 
-
3 
16 
494 
12000 
= 
* = histone content as assessed on SDS-PAGE; the intensity of the histone staining was scored semiquantitatively by comparing 
the intensity of the staining with that of the heavy and light chain, f = presence of DNA fragments (of predominately 120 bp) as 
assessed after labelling with 32P. § = % precipitation of labelled DNA per 12 μ8 oflgG; values < 3% are regarded as negative. 
I = titer/mg IgG. (Reproduced with permission from J Clin Invest 1994;94:568-577). 
pieces were used for immuno electron microscopy (IEM). To this end they were 
washed in PBS for 30 min, cryoprotected by immersion in 80% wt/vol sucrose in 
PBS for 1 h and snap frozen in liquid N2. 
Intravenous injection. Complexed and non-complexed mAbs (1 mg Ig in 500 μΐ 
phosphate buffered saline (PBS)) were injected intravenously (iv) in 6-8 week old 
BALB/c mice. After 5 or 45 min kidneys were flushed with PBS, taken out and snap 
frozen in liquid N2. 
Immunohistology of kidney tissue 
Direct IF was performed on 2 μτη cryostat sections. Sections were fixed for 5 min 
in cold acetone and air dried. Next, sections were incubated for 1 h at room 
temperature with F(ab)2 FITC-labeled sheep anti-mouse IgG (Cappel, Organon 
Teknika NV, Turnhout, Belgium) diluted 1:750 in PBS/1% wt/vol bovine serum 
albumin (BSA), and 4% normal rat serum. After washing, the sections were 
embedded in Aquamount (BDH Ltd, Poole, England) and examined with a Zeiss 
fluorescence microscope. 
Double labeling with 4,6-Diamidino-2-phenylindole (DAPI, Sigma, St Louis, MO, 
USA) was performed by diluting DAPI (1 μg/ml) in Aquamount. 
For immuno electron microscopy (IEM), twenty μιτι sections were incubated with a 
peroxidase labeled rabbit anti-mouse Ig diluted 1:20 (Dakopatt, Copenhagen, 
Denmark) and washed three times with PBS. Subsequently, the sections were 
preincubated in diaminobenzidine medium (0.05% diaminobenzidine wt/vol in TRIS) 
for 10-15 min, followed by diaminobenzidine medium with addition of H202 to a final 
concentration of 0.03% vol/vol. The sections were washed in distilled water, 
postfixed in 0.1 M phosphate buffered 1% wt/vol Os0 4 for 30 min at room 
temperature, dehydrated, and embedded in Epon 812. Thin sections were prepared 
on a LK.B ultratome, and examined unstained in an electron microscope (Jeol 1200 
EX2, Jeol Europe BV). 
Binding of complexed and non-complexed mAb to surfaces of cells in culture 
For these experiments 3 cell lines were used. СЕМ and PEER are human Τ cell lines, 
that are Fc receptor negative. HL60 is a human myeloid cell line, which bears Fc 
receptors I and II. Cells were cultured in RPMI 1640, dutch modification (ICN, Costa 
Mesa, CA), supplemented with 2 т М glutamine and ImM pyruvate containing 
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gentamycin (40 μ§/πι1) and 5% (vol/vol) fetal calf serum (Life Technologies, 
Gaithersburg, MD). Only cultures less than 3 week old with a viability of >95% as 
assessed with trypan blue, were used. Cells in suspension (100 μΐ, 5xl0 6 cells/ml in 
PBS/1%BSA) were incubated with complexed mAb, non-complexed mAb or an 
irrelevant mouse IgG2a mAb (100 μΐ, 200 μg/ml in PBS) for 30 min at 4°C. After 
washing twice with PBS/1%BSA they were incubated with FITC conjugated F(ab)2 
sheep anti-mouse IgG (100 μΐ, diluted 1:300 in PBS/1%BSA) (Cappel, Organon 
Teknika) for 30 min at 4°C. After washing the cells again twice with PBS/1%BSA 
the fluorescence intensity was determined with a Fluorescence Activated Cell Sorter 
(Coulter Electronics Ltd, Luton, UK). 
Internalization and ultrastructural intracellular localization of bound mAb 
PEER Cells in suspension (1300 μΐ; 5 χ IO6 cells/ml) were incubated with pure non-
complexed or complexed mAbs for 30 min, 2, 5 or 18 h in RPMI containing 5% fetal 
calf serum at 37°C. After incubation the cells were fixed in 2% paraformaldehyde 
(PF)/0.1 M phosphate buffer (PB) pH 7.4 for 1 h at room temperature. The cell 
suspension was divided in two parts. One part was used for IF and the other part of 
the suspension for IEM. 
In addition a pulse chase experiment was performed. Complexed mAb was incubated 
at 4°C with cells (1300 μΐ; 5 χ IO6 cells/ml) in RPMI containing 10% FCS. Cells 
were washed three times in PBS containing 1% BSA in order to remove unbound 
mAb. Next cells were incubated in RPMI containing 10% FCS at 37°C and studied 
by confocal laser microscopy at different time points (5 min, 30 min, 2, 5 and 18 h). 
Immunofluorescence. The cells were spun down in O.C.T. Tissue-Тек compound 
(Miles, Elkhart, IN, USA) and snap frozen in liquid N2. 6 μπι sections were cut in 
a cryostat (-Micron) at -20°C, picked up on silan coated slides at -20°C and air dried. 
After a brief rinse in PBS/0.05% Tween (PBST), the sections were incubated with 
1% normal goat serum/PBST for 30 min to block non-specific protein binding. After 
removal of the latter solution, the sections were incubated for 1 h in a moist chamber 
at room temperature with goat anti-mouse FITC (Cappel, Organon Teknika) diluted 
1:80 in PBST. Then the slides were rinsed with three changes of PBST for 10 min 
each and mounted with Mowiol (Hoechst, Frankfurt am Main, Germany) /2.5% 
NaN3. The sections were viewed with a Zeiss fluorescence microscope. 
Immuno electron microscopy. The cells were spun down in 10% gelatin/0.1 M 
phosphate buffer pH 7.4 (PB), and postfixed in 2% paraformaldehyde (PF)/0.1 M PB 
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overnight at 4°C. The next day they were cut in small blocks, infiltrated with 2.3 M 
sucrose, placed on copper stubs and snap frozen in liquid N2. Ultrathin cryosections 
(eighty nm) were cut with a cryo-ultramicrotome (Leitz ultracut-FCS), picked up with 
2.3 M sucrose and placed on formvar coated copper grids. After blocking the non­
specific protein binding with PBS/0.15% glycine/0.1% BSA/0.1% gelatin pH 7.4 
(PBSG) for 30 min the sections were incubated overnight at 4°C in a moist chamber 
with rabbit-anti-mouse IgG (Cappel) 1:500/PBSG. The next day the grids were rinsed 
three times with PBSG and incubated with protein-Α gold 10 nm/1% BSA/PBS for 
1 h at room temperature. After rinsing again three times in 0.1 M PBS and 3 times 
in milli-H20 the grids were placed on drops of a methylcellulose/uranylacetate (9:1) 
solution for 10 min on ice and picked up with stainless steel loops. Excess 
methylcellulose was removed by filter paper and the grids were air dried. The 
sections were viewed with a JEOL 1010 electron microscope. 
Confocal laser microscopy. After fixing with 1% PF/0.1 M PB the cells were spread 
on silan coated slides and air dried. The cells were permeabilized with 0.5% 
saponine/0.1 M PB for 30 min and incubated as described for the 
immunofluorescence technique. After mounting with Mowiol/2.5% NaN3 the cells 
were viewed with the confocal laser microscope (MRC 600, Biorad, Hemel 
Hempstead Herts, UK). 
RESULTS 
In-vivo ANA after ip hybridoma inoculation in mice 
BALB/c mice (n=3 per clone) were injected ip with 5 χ IO6 hybridoma cells. In 
kidney sections of mice bearing either of the three hybridomas ip a consistent in-vivo 
ANA was observed in IF (Fig 1). DAPI double labeling revealed that all nuclei were 
ANA positive (data not shown). As we have shown previously with in-vivo renal 
perfusion of nucleosome complexed anti-nucleosomal mAbs (10) we observed also 
in this experimental set-up glomerular binding (Fig 1). 
In-vivo ANA of complexed and non-complexed antibodies after iv injection 
To evaluate whether this nuclear binding was, as we hypothesized, due to antibodies 
complexed to nucleosomes, we injected complexed antibodies iv in mice. At 5 min 
again binding to glomerular capillary loops and some in-vivo ANA was found by IF 
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Figure 1: Direct immunofluorescence of kidneys of mice inoculated ip with the 
hybridoma producing mAb #32 showing in-vivo ANA. Also glomerular deposits are 
observed (x 240). 
(Fig 2A) while after iv injection of pure non-complexed mAb, no glomerular binding 
and a very faint in-vivo ANA was observed (Fig 2B). When kidneys were studied 45 
min after iv injection of complexed anti-nucleosomal mAbs the antibodies were 
found in the cell nuclei by IF (Fig 2C). Double labeling with DAPI revealed that the 
nuclei of all cells were positive (data not shown). When purified non-complexed 
mAbs were injected, only a very faint staining of nuclei, similar as shown in Fig 2B, 
was observed after 45 min. So, nuclear binding was a property of nucleosome 
complexed antibodies. 
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Figure 2: Direct immunofluorescence of mouse kidneys after iv injection of pure 
antibodies (тАЪ #32) or antibodies complexed to nucleosomal antigens. When 
complexed antibodies are injected GBM binding and some in-vivo ANA is observed 
after 5 min (2A χ 240) and after 45 min only marked nuclear binding (in-vivo ANA) 
is found (2С χ 320). When purified mAbs are injected at 5 (Fig 2Β χ 320) and 45 
min no glomerular binding and very faint in-vivo ANA is observed. 
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Binding of complexed and non-complexed mAb to surfaces of cultured cells 
To analyze the course of events leading to in-vivo ANA, we turned to binding studies 
using well defined cell lines. Non-complexed anti-nucleosome mAbs showed hardly 
any binding to the cell surface of СЕМ, PEER or HL60 cells (Table 2). However, 
when the antibodies were complexed to histones and DNA a marked binding was 
observed. In most cases binding of complexed antibodies containing less DNA 
(obtained by procedure II) was higher, than that of complexes of the same mAb, 
obtained by procedure I, which contained considerably more DNA. Cell surface 
binding was seen with all three cell lines studied, irrespective of the presence of Fc 
receptors, since СЕМ and PEER are Fc receptor negative. Fluorescence intensity 
observed after incubation of control IgG2a mAbs in the same concentration did not 
exceed background levels (Table 2) except for mAb WT1, which was positive on 
СЕМ and PEER cells, since these cells express the CD7 antigen recognized by WT1. 
Internalization after binding of complexed anti-nucleosome mAbs to cultured 
cells 
To study whether cell surface binding of antibodies complexed to nucleosomes leads 
to nuclear binding, complexed mAbs were incubated with cells. Internalization of 
antibodies was found after two hours, increasing with longer incubation times (5 and 
18 h). Antibodies were localized in cytoplasmic vesicles (Fig 3). In the pulse chase 
experiment after initial binding to the cell surface (Fig 4A), the antibody rapidly 
appeared in the cytoplasm (Fig 4B). After 18 h of incubation capping of residual 
mAb was observed. In none of these experiments, repeated several times, nuclear 
binding of internalized mAbs in living cells was seen. 
Effects of fixation on localization of mAb in-vivo 
Since in the previous experiments, where no nuclear binding was observed, fixation 
was carried out with paraformaldehyde, we questioned whether the in-vivo ANA was 
related to the fixation technique. To this end we analyzed in a separate experiment 
the effect of the different fixation procedures carried out on the same kidney. After 
ip administration of the hybridoma in mice, kidney tissue was fixed in parallel either 
by freezing in liquid N2, subsequent cutting of sections and acetone fixation or by 
initial in-vivo fixation with PLP and subsequent processing of tissue. After 
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Table 2: Binding of complexed and non-complexed mAb to cell surfaces of СЕМ, 
PEER and HL60 cells. 
mAb purification presence of СЕМ PEER HL60 
procedure* histones* DNA1 
2 
2 
2 
32 
32 
32 
34 
34 
34 
III 
II 
I 
III 
II 
I 
III 
II 
I 
— 
+ 
+ 
— 
++ 
++ 
— 
+-H-
++ 
— 
± 
+ 
— 
± 
-H-
— 
± 
+ 
22 
117 
88 
16 
166 
54 
16 
269 
94 
30 
356 
128 
34 
381 
38 
25 
326 
101 
17 
143 
55 
75 
600 
ND 
81 
529 
154 
WTl a - - 171 401 34 
1210" - - 4 5 ND 
The binding of complexed and non-complexed mAb on cell surfaces of 3 cell lines. 
The binding is expressed as mean fluorescence intensity. Data are derived from a 
representative experiment. # = for description of purification procedures see Table 
I. * = histone content as assessed on SDS-PAGE / = presence of DNA fragments as 
assessed after labelling with 32P (see text). 
a) WT1 is an IgG2a mouse mAb towards human CD7, which is expressed on СЕМ 
and PEER cells, but not on HL60. b) 1210 is an lgGla mouse mAb against human 
HLA class II, which is not expressed on СЕМ and PEER. ND = not determined. 
81 
Figure 3: Immuno electron microscopy of lymphoid cells incubated with antibodies 
(mAb #32) complexed to nucleosomal material. After 5 h gold particles, indicating 
antibody localization, can be found in cytoplasmic vesicles. The nuclear rim is 
indicated by arrows. No nuclear binding is observed (x 50000). 
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Figure 4: Incubation of 
antibodies (mAb #32) com­
plexed to nucleosomal material 
with lymphoid cells. By 
confocal laser microscopy in a 
pulse chase experiment after 
initial binding to the cell 
surface (4A χ 1200), the 
antibody rapidly appears in 
the cytoplasm (insert, 4B χ 
2400). Most importantly these 
studies did not reveal any 
nuclear binding in living cells. 
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cryopreservation and fixation with acetone in IF in-vivo ANA was observed identical 
to that shown in Fig 1. After fixation of the remaining part of the same kidney by 
perfusion with and immersion in PLP, no nuclear binding was found in this material 
by IF (data not shown), while by IEM the mAbs were localized in cytoplasmic 
vesicles (Fig 5), comparable to the localization found in the in-vitro experiments with 
living cells using confocal laser microscopy. 
Figure 5: Influence of fixation procedure on in-vivo ANA. A part of the same kidney 
used for IF in Fig 1, was fixed by in-vivo perfusion and subsequent immersion in 
PLP. By IEM no nuclear binding is observed. Antibodies are localized in cytoplasmic 
vesicles, one of which is indicated by an arrow (x 4800). 
DISCUSSION 
In-vivo ANA {in-vivo binding of auto-antibodies to the cell nucleus) as examined by 
IF has been described by numerous authors, in tissue sections of both patients with 
SLE (11-13) or other auto-immune diseases (14-16). Recently, it was reported that 
certain anti-dsDNA mAbs injected into experimental animals reproducibly show 
S3 
intranuclear localization, whereas others are deposited extracellularly within glomeruli 
and/or blood vessels (5). This intranuclear localization of anti-dsDNA mAbs was a 
time and ATP dependent phenomenon. Before internalization binding to a cell 
surface receptor was demonstrated (6). It was claimed that this in-vivo nuclear 
binding had major pathological consequences like decreased cell proliferation, 
increased protein synthesis (17), glomerular hypercellularity and proteinuria (5). We 
also observed nuclear binding when the hybridomas producing the anti-nucleosome 
mAb were inoculated ip in mice. Since in the ascites of these mice nuclear material 
is released from dying hybridoma cells, immune complexes are formed in-vivo ( 18). 
So, this in-vivo ANA might be a feature of anti-nucleosome antibodies complexed 
to nuclear antigens. Indeed, when we injected complexed anti-nucleosome antibodies 
iv into mice after 45 minutes strong in-vivo ANA was observed. After 5 minutes 
GBM binding was found which was similar to what we observed after renal 
perfusion of these complexed antibodies (10). We found that nuclear binding of mAb 
was not restricted to the kidney, but was also found in other organs such as liver and 
skin (data not shown). 
These observations provided evidence that in-vivo ANA was a feature of antibodies 
bound to nucleosomal material. Some of the discrepancies in the literature on this 
subject might therefore be explained by impurities of the antibody preparations 
containing variable amounts of nucleosomal antigens. This nucleosomal material can 
easily be copurified with anti-nuclear antibodies (10) and be missed on SDS-PAGE 
when Coomassie staining is used. 
Before in-vivo ANA can develop, auto-antibodies have to bind to the cell surface and 
have to be transported through the cytoplasm to the nucleus. Binding of anti-dsDNA 
mAbs to the cell surface, has been described before (19) and was attributed to the 
binding to the so-called "lupus associated membrane protein" (LAMP) (7). Later on, 
it was shown that this binding was not a direct cross reactivity of the mAb with 
LAMP, but that it occurred via histones and DNA (8,20). These findings were 
however, challenged by a more recent paper describing again that anti-dsDNA mAbs 
could directly bind to cell surfaces (3). However, one of the mAbs utilized in this 
latter study (PME 77) was used by Dr. Jacob et al to identify that binding occurred 
via histones and DNA (8). In line with our observations (10), this mAb shows only 
weak reactivity with DNA, and strong reactivity with nucleosomes (8). So this mAb 
resembles the anti-nucleosome mAbs used in this study. 
We found only very weak binding of pure non-complexed mAbs to cell surfaces 
while the complexed antibodies bound considerably stronger. For our experiments we 
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only used fresh cell cultures with a viability of >95%. This is important since cells 
in culture can be a rich source for nucleosomal material released in the supernatant 
and may mediate binding of purified Ig. Using cell cultures with a poor viability, we 
found indeed considerable binding of purified non-complexed mAbs (data not 
shown). 
The binding to cell surfaces that we observed of histones and DNA is in line with 
findings of others, showing binding of nucleosomes to cell surfaces, maybe via a 
DNA receptor (9). It is also possible that binding of complexed antibodies is a charge 
related phenomenon. This view is supported by our finding that complexed antibodies 
harboring less DNA bind better to the negatively charged cell surface. When we 
incubated complexed antibodies with cells we found cytoplasmic localization of 
mAb, but did not observe any nuclear binding despite 18 h of incubation. Therefore, 
we returned to the in-vivo experiments and found that in the same kidney nuclear 
binding can be detected when the tissue is processed conventionally for IF, whereas 
no nuclear localization is found when in-vivo PLP fixation is used. By IEM, 
localization in cytoplasmic vesicles was observed, resembling the picture found with 
the confocal laser microscopy in the in-vitro experiments. This suggests that, when 
tissue is processed for conventional IF the procedure leads to disruption of 
intracellular structures, which allows antibodies, present within the cytoplasm, to 
diffuse and to bind to the cell nucleus, which can occur after sections are cut before 
the acetone fixation. Another possibility is that acetone fixation is not sufficient and 
does not prevent migration of antibodies after the fixation procedure. This nuclear 
localization of mAb is prevented by PLP fixation. Therefore we had to conclude that 
in-vivo ANA is related to the fixation procedure. A similar phenomenon has been 
described for the p-ANCA due to antibodies to myeloperoxidase (21). 
Whether in-vivo ANA as found in SLE patients is due to in-vivo binding of auto-
antibodies to the nucleus or to a fixation related artefact, is not clear yet. However, 
our study raises serious doubts whether in-vivo ANA exists. It is claimed that in-vivo 
nuclear binding of auto-antibodies can lead to tissue damage (5). The fact that in-vivo 
ANA is often encountered in non-inflamed tissue (22) may be an argument that in 
these instances nuclear binding is a consequence of the fixation process. 
Although our results indicate that in-vivo ANA is an artefact, the phenomenon of in-
vivo ANA is a characteristic of pathogenic anti-nuclear auto-antibodies complexed 
to nucleosomal antigens. The same complexed auto-antibodies are able to bind to the 
GBM in-vivo and activate complement (10) and are related to onset (23) and 
exacerbations (24) of nephritis in SLE patients. A similar suggestion has been put 
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forward by Ohnishi and colleagues, who suggested that pathogenic anti-dsDNA 
antibodies are capable both of binding to nuclei in-vivo and to renal basement 
membranes via DNA/histone (25). Furthermore, cellular binding or intracytoplasmic 
uptake of these complexed auto-antibodies may be responsible for the derangement 
of cellular functions as observed by others like interference with apoptosis (4,26), 
cellular proliferation (5,17), protein synthesis (5) or proteinuria (17). Finally, our 
studies indicate that the analysis of in-vivo ANA is only valid, if the tissue is fixed 
properly. 
Acknowledgements: This study was supported by a grant from the Dutch Kidney 
Foundation (C91.1081), from the Dutch League Against Rheumatism (90/CR/287) 
and by a grant from the EC Biomed I program (BMH1-CT92-1766). 
REFERENCES 
1. Tan, E.M. 1982. Autoantibodies to nuclear antigens (ANA): their 
immunobiology and medicine. Adv. Immunol. 55:167. 
2. Bennett, R.M., J. Davis, and M. Merritt. 1986. Anti-DNA antibodies react 
with DNA expressed on the surface of monocytes and В lymphocytes. J. 
Rheumatol. /5:679. 
3. Raz, E., H. Ben-Bassat, T. Davidi, Ζ. Shlomai, and D. Eilat. 1993. 
Cross-reactions of anti-DNA autoantibodies with cell surface proteins. Eur. J. 
Immunol. 25:383. 
4. Tsai, C.Y., T. H. Wu, K. H. Sun, T. S. Liao, W. M. Lin, and С Yu. 1993. 
Polyclonal IgG anti-dsDNA antibodies exert cytotoxic effect on cultured rat 
mesangial cells by binding to cell membrane and augmenting apoptosis. 
Scand. J. Rheumatol. 22:162. 
5. Vlahakos, D., M. H. Foster, A. A. Ucci, К. J. Barrett, S. K. Datta, and M. P. 
Madaio. 1992. Murine monoclonal anti-DNA antibodies penetrate cells, bind 
to nuclei, and induce glomerular proliferation and proteinuria in vivo. J. Am. 
Soc. Nephrol. 2:1345. 
6. Yanase, K., R. M. Smith, B. Cizman, M. H. Foster, L. D. Peachey, L. Jarett, 
and M. P. Madaio. 1994. A subgroup of murine monoclonal 
anti-deoxuribonucleic acid antibodies traverse the cytoplasm and enter the 
nucleus in a time- and temperature- dependent manner. Lab. Invest. 71:52. 
86 
7. Jacob, L., F. Tron, J-F. Bach, and D. Louvard. 1984. A monoclonal anti-DNA 
antibody also binds to cell-surface protein(s). Proc. Natl. Acad. Sci. USA 
57:3843. 
8. Jacob, L., J. D. Viard, B. Allenet, M. F. Anin, F. B. H. Slama, J. 
Vanderkerckhove, J. Primo, J. Markovits, F Jacob, J. F. Bach, J. B. Le Peco, 
and D. Louvard. 1989. A monoclonal anti-double-stranded DNA autoantibody 
binds to a 94-kDa cell-surface protein on various cell types via nucleosomes 
or a DNA-histone complex. Proc. Natl. Acad. Sci. USA 86:4669. 
9. Hefeneider, S.H., К. A. Cornell, L. E. Brown, A. С. Bakke, S. L. McCoy, and 
R. M. Bennett. 1992. Nucleosomes and DNA bind to specific cell surface 
molecules on murine cells and induce cytokine production. Clin. Immunol. 
Immunopathol. 63:245. 
10. Kramers, C , M. N. Hylkema, M. C. J. van Bruggen, R. van de Lagemaat, H. 
В. P. M. Dijkman, К. J. M. Assmann, R. J. T. Smeenk, and J. H. M. Berden. 
1994. Anti-nucleosome antibodies complexed to nucleosomal antigens show 
anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. 
J. Clin. Invest. 94:568. 
11. Golan, T.D., A. E. Gharavi, and K. B. Elkon. 1993. Penetration of 
autoantibodies into living epithelial cells. J. Invest. Dermatol. 100:316. 
12. Shu, S., T. Provost, B. Croxdale, M. Reighlin, and E. H. Beutner. 1977. 
Nuclear deposits of immunoglobulins in skin of patients with systemic lupus 
erythematosus. Clin. Exp. Immunol. 27:238. 
13. McCoy, R.C. 1972. Nuclear localization of immunoglobulins in renal biopsies 
of patients with lupus nephritis. Am. J. Pathol. 65:469. 
14. Kallenberg, C.G.M., M. С. J. M. de Jong, T. M. Walstra, S. Kardaun, and T. 
H. The. 1983. In vivo antinuclear antibodies (ANA) in biopsies of normal 
skin: diagnostic significance and relation to serum ANA. J. Rheumatol. 
70:733. 
15. Bentley-Philips, C.B. and T. M. S. Geake. 1980. Mixed connective tissue 
disease characterized by speckled epidermal nuclear IgG deposition in normal 
skin. Br. J. Dermatol. 102:529. 
16. Velthuis, P.J., L. Kater, I. van der Tweel, F. Gmelig Meyling, R. H. W. M. 
Derksen, R. J. Hene, J. A. van Geutselaar, and H. Baart de la Faille. 1990. 
In-vivo ANA of the skin: its diagnostic significance and associations with 
selective antinuclear antibodies. Ann. Rheum. Dis. 49:163. 
87 
17. Cizman, В., G. S. Kunzio, M. H. Foster, and M. P. Madaio. 1993. Lupus 
anti-DNA antibodies that localize within nuclei in vivo, inhibit mesangial cell 
proliferation and induce protein synthesis. J. Am. Soc. Nephrol. 
4:597.(Abstract) 
18. Fournie, G.J. 1995. Detection of nucleosome:Ig immune complexes in ascites 
from mice transplanted with anti-DNA secreting hybridomas and in plasma 
from MRL-lpr/lpr mice. Lupus 4 (suppl 2) :49.(Abstract) 
19. Lerner, R.A., W. Meinke, and D. A. Goldstein. 1971. Membrane associated 
DNA in the cytoplasm of diploid human lymphocytes. Proc. Natl. Acad. Sci. 
USA 68:1212. 
20. Chan, T.M., G. Frampton, N. A. Staines, P. Hobby, G. J. Perry, and J. S. 
Cameron. 1992. Different mechanisms by which anti-DNA Moabs bind to 
human endothelial cells and glomerular mesangial cells. Clin. Exp. Immunol. 
88:68. 
21. Charles, L.A., R. J. Falk, and J. С Jennette. 1989. Reactivity of 
anti-neutrophil cytoplasmic autoantibodies with HL-60 cells. Clin. Immunol. 
Immunopathol. 55:243. 
22. Baart de la Faille-Kuyper, E.H. 1974. In-vivo nuclear localization of 
immunoglobulins in clinically normal skin in systemic and procainamide 
-induced lupus erythematosus. Neth. J. Med. 77:58. 
23. Termaat, R.M., K. Brinkman, J. С Nossent, A. J. G. Swaak, R. J. T. Smeenk, 
and J. H. M. Berden. 1990. Anti-heparan sulphate reactivity in sera from 
patients with systemic lupus erythematosus with renal or non-renal 
manifestations. Clin. Exp. Immunol. 82:268. 
24. Kramers, C , R. M. Termaat, E. J. ter Borg, M. С. J. van Bruggen, С. G. M. 
Kallenberg, and J. H. M. Berden. 1993. Higher anti-heparan sulphate reactivity 
during SLE exacerbations with renal manifestations. A long term prospective 
analysis. Clin. Exp. Immunol. 93:34. 
25. Ohnishi, K., F. M. Ebling, B. Mitchell, R. R. Sing, B. H. Hahn, and B. P. 
Tsao. 1994. Comparison of pathogenic and non-pathogenic murine antibodies 
to DNA: antigen binding and structural characteristics. Int. Immunol. 6:817. 
26. Tax, W.J.M., С Kramers, M. С J. van Bruggen, and J. H. M. Berden. 1995. 
Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. 
Kidney Int. 48:666. 
88 


CHAPTER 7 
Specificity of monoclonal anti-nucleosome auto-
antibodies derived from lupus mice. 
C. Kramers', C. Stemmer2, M. Monestier3, M.C.J, van Bruggen', T.P.M. Rijke 
Schilder', M.N. Hylkema", R.J.T. Smeenk\ S. Muller 2 and J.H.M. Berden'. 
'Division of Nephrology, University Hospital, Nijmegen, the Netherlands, 
institut de Biologie Moléculaire et Cellulaire, UPR 9021 CNRS, Strasbourg, 
France, 3Dept. of Microbiology and Immunology, Temple University School of 
Medicine, Philadelphia, PA, USA and "Dept. of Autoimmune Diseases, CLB, 
Amsterdam, The Netherlands. 
Submitted for publication. 

ABSTRACT 
Recently, anti-nucleosome antibodies, which do not bind to DNA or to individual 
histones have been identified in longitudinal studies in lupus mice. These anti-
nucleosome antibodies occur early in spontaneous SLE and are formed prior to other 
anti-nuclear specificities. However, nucleosomal epitopes are yet to be fully 
characterized. 
We selected a panel of 6 monoclonal anti-nucleosome antibodies (mAbs) (#2, #32, 
#34, PL2-6, LG8-1 and LG 10-1) derived from lupus mice. These mAbs were tested 
in ELISA on subnucleosome structures and on a panel of 53 histone peptides, 
covering the entire sequence of the five histones. Two mAbs reacted with one of 
these peptides, namely peptide 83-100 of H3 (mAb #2) and peptide 18-32 of H3 
(mAb #34). Based on the nucleosome and subnucleosome ELISA we identified 
different recognition patterns. Three mAbs showed the highest reactivity towards the 
intact nucleosome. For two of them (#32 and LG8-1) the nucleosomal epitope was 
primarily located on H2A/H2B-DNA, whereas for mAb #34 this primary epitope was 
located on H3/H4/DNA. Two mAbs (#2 and PL2-6) showed the highest reactivity 
with H2A/H2B-DNA and one mAb (LG 10-1) recognized an epitope on H3/H4-DNA. 
In the subnucleosome ELISA all but one (mAb #32) recognized more than one 
epitope including DNA complexed to a variety of cationic molecules. Comparing 
these reactivities we identified for all mAbs one specific nucleosomal epitope, 
whereas reactivity with other subnucleosomes was comparable to the reactivity 
towards DNA complexed with cationic molecules. In inhibition experiments both in 
ELISA and in immunofluorescence it was found that only one of the mAbs (i.e. PL2-
6), recognizing an epitope on H2A/H2B-DNA as primary epitope, could be inhibited 
by H2A/H2B-DNA in fluid phase. The two mAbs recognizing an epitope on H3/H4-
DNA as primary epitope could be inhibited by H3/H4-DNA in fluid phase. From 
these analyses, we conclude first that for these nucleosome specific mAbs linear 
histone peptides are not very important epitopes. Second, that these mAbs all 
recognize different epitopes on both H2A/H2B-DNA and H3/H4-DNA and third that 
some solid phase H2A/H2B-DNA epitopes are not expressed on fluid phase 
H2A/H2B-DNA. Our findings suggest that in SLE the nucleosome can act as auto-
antigen and that there is no immuno dominant epitope within the nucleosome. 
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INTRODUCTION 
In systemic lupus erythematosus (SLE) the formation of anti-nuclear antibodies is a 
characteristic feature and anti-double stranded DNA (dsDNA) antibodies are regarded 
as a serological hallmark (1). These anti-dsDNA antibodies have been assigned an 
important role in the pathogenesis of disease manifestations (2,3). In addition to 
antibodies to dsDNA also autoantibodies towards histones are formed (4). Recently, 
antibodies specific for the nucleosome, which do not bind to the constituents of the 
nucleosome i.e. DNA or histones have been identified (5,6). It has been suggested 
that the nucleosome is the major auto-immunogen and instrumental in the 
development of the whole spectrum of anti-nuclear antibodies (7,8). In longitudinal 
studies in MRL/lpr and BXSB mice, but not in experimentally induced lupus in GVH 
mice (9), it was found that anti-nucleosome antibodies appear very early in the 
disease, before the development of anti-dsDNA or anti-histone antibodies. Therefore, 
it was even postulated that in SLE the loss of tolerance for specific nucleosomal 
epitopes precedes the formation of anti-dsDNA and anti-histone antibodies (10). In 
vitro, helper T-cells specific for nucleosomes not only induced anti-nucleosome 
antibodies but also anti-dsDNA and anti-histone antibodies (7). However, data on the 
formation of nucleosome specific antibodies in SLE are still scarce. Further 
characterization of nucleosomal epitopes remains to be accomplished. To address this 
point we selected a panel of 6 monoclonal anti-nucleosome antibodies (mAbs) 
derived from lupus mice. By definition the reactivity of these mAbs towards DNA 
and to individual histones was absent or low compared to their reactivity towards the 
intact nucleosome. To define their antigenic specificity, these mAbs were tested in 
ELISA on 4 different subnucleosome structures, which are thought to harbor the 
epitopes which occur on the intact nucleosome. Furthermore, these mAbs were tested 
on a panel of 53 histone peptides, covering the entire sequence of the 5 histones. In 
order to further characterize these nucleosomal epitopes, inhibition experiments both 
in immunofluorescence (ANA) and in ELISA, were performed. Because we have 
shown previously (11,12) that the reactivity of monoclonal autoantibodies is strongly 
influenced by the binding of nuclear constituents to the auto-antibody during 
hybridoma culture, emphasis was given to the purification of the mAbs, and only 
purified mAbs were used for the analysis. 
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MATERIALS AND METHODS 
Monoclonal antibodies 
Mabs #2, #32, and #34 are from a panel of 60 mAbs, which were obtained by fusion 
of spleen cells from mice with spontaneous ((NZBxW)Fl, MRL/lpr) or experimen-
tally induced (parental-Fl chronic graft versus host (GVH) disease) SLE and scree-
ned for anti-dsDNA in ELISA (13). After removal of bound nucleosomal antigens 
these three mAbs lost their anti-dsDNA reactivity and appeared to be nucleosome 
specific antibodies (12). MAb #2 was derived from a GVH mouse and mAbs #32 and 
#34 from NZB/W mice. From the same panel mAb #56 was obtained, which is a is 
a "true" anti-dsDNA antibody since it still bound to dsDNA in purified non-
complexed form. Hybridomas of mAbs #2, #32, #34 and #56 were grown in serum 
free conditions (IMDM, Gibco BRL, Paisley, UK) supplemented with Serum Free 
Medium Supplement (SF1 (Costar, Cambridge, MA), 2% v/v). Purified non-
complexed mAbs #2, #32, #34 and #56 were obtained by purification on a protein 
A sepharose column (Pharmacia, Uppsala, Sweden) under high salt conditions, after 
DNase treatment of the culture supernatant (12). 
For comparison purposes and further characterization, we have also included 3 
previously reported mAbs. PL2-6 is a mAb derived from a MRL+/+ mouse (14). 
LG8-1 and LG 10-1 are mAbs derived from two different MRL/lpr mice (15). These 
mAbs were purified from culture supernatants by affinity chromatography on 
recombinant protein G-agarose (Pharmacia, Uppsala, Sweden). 
The immunoglobulin concentration was determined in ELISA (12). MAbs #2, #32 
and #34 belong to the IgG2a and mAbs PL2-6, LG8-1 and LG 10-1 to the IgG2b 
subclass. 
The purity of the mAbs (and of the antigens used in the subnucleosome ELISAs 
which are described below) was checked by SDS-PAGE (8-25%) analysis followed 
by silver staining (Phast gel system, Pharmacia). The presence of DNA was identified 
by extraction by phenol-chloroform, labeling with [32P]dATP and analysis on a 6% 
Polyacrylamide gel (Sequagel-6, National Diagnostics, Atlanta, GA) (12). 
Tests for antigen specificity of purified mAbs 
Purified antibodies were tested in ELISAs using the following antigens: dsDNA, 
histone, nucleosome, H2A/H2B dimer, H2A/H2B-DNA complex, H3/H4 tetramer and 
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H3/H4-DNA complex. 
- DsDNA. histone and nucleosome ELISA were performed as described before (12). 
- H2A/H2B. H2A/H2B-DNA. H3/H4 and H3/H4-DNA ELISAs were performed as 
described by Losman et al (14) with minor modifications. The individual core 
histones (purified from calf thymus) were purchased from Boehringer Mannheim. 
Before use all batches were checked for purity in SDS PAGE as described above and 
only pure batches were used. H2A/H2B dimers and H3/H4 tetramers were 
reconstituted by mixing H2A with H2B or H3 with H4 in phosphate buffered saline 
(PBS) at a final concentration of 1 mg/ml each for 1 hour at 4°C (16). Next Nunc 
immunoplates (maxisorp F96, Gibco) were coated overnight at 4°C with H2A/H2B 
or H3/H4 in a concentration of 10 μg/ml in 0.1 M glycine, 0.1 M NaCl, 0.1 M 
NaOH, pH 9. The plates were washed 5 times with PBS/0.05% Tween 20 (PBST) 
and blocked with 5% fetal calf serum (FCS) in PBS, 150 μΐ/well, for 1 hour at room 
temperature. The plates were washed again and samples serially diluted in PBST, 
containing 5% FCS, were incubated (100 μΐ/well) for 2 hours at 37°C. Next, the 
plates were washed again and 100 μΐ of peroxidase labeled rat monoclonal anti-
mouse Ig antibody (CLB-RM-19, CLB, Amsterdam, the Netherlands) diluted 1:1000 
in PBS were added per well. The plates were washed again and developed with 
3,5,3',5'-tetramethylbenzidine (Merck), 100 μg/ml in 0.11 M sodium acetate (pH 5.5) 
containing 0.003% H 2 0 2 . By adding 2M H2S04, 100 μΐ/well, color development was 
stopped after 15 min and the optical density (OD) at 450 nm was measured. When 
histone-DNA complexes were used as substrate, the ELISA plate was first coated 
with H2A/H2B or H3/H4 and after washing 5 times with PBS, DNA (Pharmacia) 
was added for 30 min at 50 μ^πιΐ in PBS at room temperature. Next, plates were 
washed and further procedures were identical to the anti-H2A/H2B ELISA. 
- Protamine/DNA and polv-L-lvsine/DNA ELISAs 
To analyze whether the reactivity towards DNA was influenced by binding to 
cations, the reactivity was also measured after precoating the ELISA plates with 
protamine or poly-L-lysine. Protamine (100 μΐ, 10 μg/ml) or poly-L-lysine (100 μΐ, 
10 μg/ml) were coated overnight at 4°C on Nunc Immunoplates. The plates were 
washed and DNA (100 μΐ, 50 μ&Ίη1 in PBS) was added for 30 minutes at room 
temperature. The ELISA was further developed as described for the H2A/H2B 
ELISA. 
The titer in all ELISAs was defined as the reciprocal of the dilution giving an OD 
of 1.0 at 450 nm and expressed per mg of Ig. 
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- Anti-histone peptide ELISA 
This ELISA using 53 synthetic peptides covering the entire sequence of the 4 bovine 
core histones and of human HI was performed as described previously (4,17). 
Inhibition experiments 
Inhibition experiments were performed in ELISA. In these experiments, each mAb 
was used in a concentration giving about 50% of the maximal OD. Several 
concentrations of inhibitor were pre-incubated for 20' at room temperature with these 
mAbs. Next mAb and inhibitor were transferred to a plate coated with the appropriate 
antigen and the ELISA was performed as described above for the various antigens. 
In addition, inhibition experiments were performed using nuclear fluorescence in 
kidney sections. The mAb concentration of the mAbs used was 2 μg/ml because this 
was the lowest concentration giving maximal nuclear fluorescence. The mAbs were 
mixed with different concentrations of inhibitor ranging from 0 to 25 μg/ml in two 
fold dilution steps. After incubation for 20 min at room temperature, mAb and 
inhibitor were transferred onto kidney sections and indirect immunofluorescence was 
performed as described before (12). Briefly, 2 μπι cryostat sections from BALB/c 
mouse kidneys were incubated with mAb alone or mAb with inhibitor in PBS 
containing 1% (wt/vol) BSA (PBS/BSA) for 30 min at room temperature. After 
rinsing with PBS, the sections were incubated with a F(ab)2 FITC labeled sheep anti 
mouse IgG (Cappel-Organon Teknika NV, Turnhout, Belgium) diluted 1:750 in 
PBS/BSA for 30 min at room temperature. After rinsing with PBS, the sections were 
embedded in Aquamount (BDH Ltd, Poole, England) and examined with a Zeiss 
fluorescence microscope. Anti-nuclear activity (ANA) was scored by two independent 
investigators on coded sections and intensity was scored semi-quantitatively on a 0-4 
scale. 
RESULTS 
Specificity of the anti-nucleosome mAbs 
Based on the nucleosome and subnucleosome ELISA we identified different 
recognition patterns (Table 1). Most mAbs showed reactivity with more than one 
subnucleosome structure, however for all mAbs a primary nucleosomal epitope could 
be identified. By definition all 6 mAbs reacted with whole nucleosomes, but they 
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Table 1: Reactivity of the various mAbs to nucleosomes and different subnucleosomal 
structures. 
mAb 
mouse origin 
nucleosome 
DNA 
H2A/H2B 
H2A/H2B-DNA 
H3/H4 
H3/H4-DNA 
#2 
GVH 
30002 
58 
<10 
5800 
<10 
1100 
#32 
BWF, 
8300 
<10 
<10 
1800 
<10 
<10 
#34 
BWF, 
12000 
<10 
80 
1600 
1300 
6000 
LG8-1 
MRL/1 
12800 
455 
<10 
6400 
<10 
1200 
LG10-1 
MRL/1 
12800 
1000 
<10 
1600 
<10 
20500 
PL2-6 
MRL/n 
19200 
250 
24000 
51200 
<10 
10200 
WT1 
<10 
<10 
<10 
<10 
<10 
<10 
' WT1 is a mouse IgG2a anti-human CD7 mAb used as control 2Titer per mg Ig. 
Table 2: Reactivity of mAbs #2 , PL2-6, LG8-1, LG10-1 and #56 (a specific anti-
dsDNA mAb) to free non-complexed DNA and to DNA complexed to various 
positively charged molecules. 
#2 
58' 
364 
364 
5800 
1100 
PL2-6 
250 
7500 
4000 
51200 
10200 
LG8-1 
500 
1400 
1500 
7200 
1600 
LG10-1 
1200 
1600 
1200 
3600 
40000 
56 
4000 
4000 
4000 
4000 
4000 
'Titer per mg Ig. 
DNA 
protamine/DNA 
poly-L-lysine/DNA 
H2A/H2B-DNA 
H3/H4-DNA 
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differed in their binding pattern with nucleosome subparticles. MAbs #2 and PL2-6 
are anti-H2A/H2B-DNA antibodies since they react better with this antigen than with 
the whole nucleosome. PL2-6 also shows considerable reactivity with the H2A/H2B 
dimer. For mAbs #32 and LG8-1, the nucleosomal epitope appears to be primarily 
located on the H2A/H2B-DNA subparticle, however since these two mAbs reacted 
better with the whole nucleosome than with H2A/H2B-DNA, additional epitopes 
seem to be involved. Likewise, LG 10-1 has an anti-H3/H4-DNA specificity whereas, 
for mAb #34 the primary but not exclusive nucleosomal epitope is on the H3/H4-
DNA subparticle. 
Mabs #2, LG8-1, LG 10-1 and PL2-6 hardly bound to DNA, but showed considerable 
reactivity with both H2A/H2B-DNA and H3/H4-DNA, be it that for each of the 
mAbs one of these reactivities could be identified as the primary epitope while the 
other was considerably lower. Since histones are cationic proteins, we questioned 
whether these antibodies bound to DNA after complexation with a cationic molecule 
or preferentially to epitopes generated after complexation of DNA to either H2A/H2B 
or H3/H4, forming its primary epitope. Therefore, we complexed DNA with 
protamine or poly-L-lysine on the plate, and found an increase in reactivity against 
cationic complexed DNA compared to DNA alone (Table 2). However, the binding 
was lower than to the primary histone/DNA epitopes described above. The reactivity 
of the mAb towards the histone/DNA complex, which was not the primary epitope 
was comparable to the reactivities found towards DNA complexed to the other 
cationic molecules. The use of the different precoats did not influence the reactivity 
of the "true" anti-dsDNA mAb #56, which indicates that the use of cationic precoats 
did not lead to a different coating of DNA. These experiments indicate that 
complexation of DNA to a cation can partially mimic but is not identical to the 
epitope generated after binding of DNA to histones. This suggests that these 
nucleosome specific mAbs do recognize charge dependent epitopes within the 
DNA/cation complex molecule but preferentially react with specific epitopes 
harbored within the histone/DNA complex of the primary epitope. The reactivity of 
some mAbs towards other DNA complexes than the primary recognized epitope can 
thus be considered as less specific. 
None of the mAbs showed any reactivity when tested in ELISA on individual 
histones, except for mAb #34 which showed a moderate reactivity towards H3. In the 
histone peptide ELISA, mAb #2 bound to the 83-100 peptide of H3 and not with any 
other peptide tested. MAb #34 bound to the 18-32 peptide of H3. However, the OD 
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Table 3. Binding of mAbs histone to synthetic peptides (2μΜ). Only results of mAbs 
#2, #34 and a control mAb WT1 are shown. The other 4 anti-nucleosome mAbs were 
negative on all histone peptides. 
Antigen 
HI peptides 
H2A peptides 
H2B peptides 
H3 
1-21 
18-32 
30-45 
40-55 
53-70 
68-85 
83-100 
98-112 
107-123 
111-130 
118-135 
130-135 
H4 peptides 
#2 
neg2 
neg 
neg 
0.05 
0.00 
0.00 
0.14 
0.07 
0.08 
0.40 
0.08 
0.03 
0.09 
0.12 
0.04 
neg 
#34 
neg 
neg 
neg 
0.06 
0.40 
0.05 
0.10 
0.04 
0.00 
0.04 
0.01 
0.04 
0.07 
0.05 
0.01 
neg 
WT1 
neg 
neg 
neg 
0.11 
0.02 
0.04 
0.08 
0.04 
0.00 
0.00 
0.01 
0.01 
0.07 
0.04 
0.01 
neg 
Results are expressed as OD values and positive results (OD>0.30) are underlined, 
"neg: negative (OD < 0.30) for all peptides tested. 
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Table 4: Results of inhibition experiments in ELISA and IF. In both experiments the 
inhibitor was the antigen which was the primary epitope which the mAb recognized. 
In ELISA inhibition of binding of the mAb to this primary epitope and in IF 
inhibition of ANA was tested. 
mAb 
#2 
#32 
LG8-1 
PL2-6 
#34 
LG10-1 
specificity 
H2A/H2B-DNA 
H2A/H2B-DNA 
H2A/H2B-DNA 
H2A/H2B-DNA 
H3/H4-DNA 
H3/H4-DNA 
ELISA 
>50' 
>50 
>50 
12.5 
1 
25 
IF 
>252 
>25 
>25 
2 
1 
10 
'The concentration of inhibitor fog/ml) giving 50% inhibition of OD in ELISA or 
250% reduction of ANA scored semiquantitatively in IF. 
found on these two histone peptides was low. The other mAbs did not bind to histone 
peptides in this assay. The results of these experiments are given in Table 3. 
Inhibition experiments 
For all mAbs was tested whether the primary antigen recognized by these mAbs was 
able to inhibit in fluid phase the binding of these mAbs to the same antigen in solid 
phase ELISA or to nuclei in IF. The results found in ELISA and in IF were 
comparable (Table 4). From the mAbs recognizing H2A/H2B-DNA as primary 
nucleosomal epitope, only for PL2-6 the binding to H2A/H2B-DNA in ELISA and 
to nuclei in IF was inhibited by H2A/H2B-DNA in fluid phase. For mAbs #2, #32 
and LG 10-1 fluid phase H2A/H2B-DNA could not inhibit this binding. In contrast, 
for both mAbs recognizing H3/H4-DNA as primary epitope (i.e. #34 and LG 10-1), 
this binding could be inhibited by fluid phase H3/H4-DNA. From these experiments 
we conclude that the nucleosomal H2A/H2B-DNA epitope recognized by mAbs #2, 
#32 and LG 10-1 is not expressed by fluid phase H2A/H2B-DNA and that it is 
different from the epitope recognized by PL2-6. 
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DISCUSSION 
In recent years more and more evidence has emerged that the nucleosome plays an 
important role in the development of the auto-antibody repertoire in SLE. Already 
more than a decade ago, it was found that when rabbits were immunized with 
chicken erythrocyte nucleosomes, antibodies to the various individual histones were 
formed, in a striking similar pattern as found in the sera of SLE patients. However, 
antibodies against dsDNA could not be detected (18). Later it was found, that when 
New Zealand white rabbits were immunized with RNA-complexed to histones, they 
developed an autoimmune-like response including antibodies against dsDNA and 
peptides of the Sm-D antigen (19). In this study it was concluded that altered 
nucleosome particles, rather than native nucleosomes may represent the antigenic 
stimulus giving rise to autoantibodies in SLE. Recently, it was shown that not DNA 
but the nucleosome is the antigen which is recognized by pathogenic auto-antibody 
inducing T-helper cells (7). It was also found that anti-nucleosome antibodies are 
seen early in spontaneous murine lupus, before the occurrence of anti-dsDNA and 
anti-histone antibodies (10,20) and that in human SLE the prevalence of anti-
nucleosome antibodies is very high (6,21). However, the study of anti-nucleosome 
antibodies in polyclonal sera is hampered by the fact that anti-dsDNA and anti-
histone antibodies are also able to bind to the nucleosome and will contribute to the 
total anti-nucleosome reactivity in serum. Analysis of nucleosome specific antibodies 
in serum or plasma can therefore only be performed after removal of anti-dsDNA and 
anti-histone antibodies. Using this approach the existence of nucleosome specific 
auto-antibodies was recently demonstrated in human lupus (22). 
The existence of antibodies specific for (sub)nucleosomes not reactive with either 
DNA or histones separately, was also shown in studies analyzing monoclonal 
antibodies (5,12,14,23). Until now the fine specificities of these antibodies have not 
been studied in full detail. 
In this study we describe 6 monoclonal anti-nucleosome antibodies, which do not or 
only weakly bind to DNA or individual histones. When these were tested in ELISA 
with subnucleosome structures they all appeared to be different. For each mAb a 
major epitope could be identified, being either H2A/H2B-DNA or H3/H4-DNA on 
the intact nucleosome (mAbs #32, #34, LG8-1), H2A/H2B-DNA (mAbs #2, PL2-6) 
or H3/H4-DNA (LG 10-1). However, most mAbs recognize more than this major 
nucleosomal epitope. In experiments using DNA complexed to a variety of cationic 
molecules we could show that the binding to the other "minor" nucleosomal epitopes 
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is comparable to the binding to DNA complexée! to cationic molecules and can thus 
be considered as less specific. In contrast to mAbs #2, LG8-1 and LG 10-1, mAb 
PL2-6 also binds to H2A/H2B dimer. This reactivity was first described in patients 
with procainamide induced lupus (24). For this mAb H2A/H2B-DNA binding can be 
explained by its reactivity towards H2A/H2B. MAb #34 not only binds to H3/H4-
DNA, but also to a lesser extent to H3/H4 and H3. 
The finding that DNA complexed with positively charged molecules can mimic 
nucleosomal epitopes has clinical consequences, since the majority of the routinely 
performed anti-dsDNA ELISA's use a protamine or poly-L-lysine precoat to catch 
DNA. These assays therefore may not only detect anti-dsDNA but also anti-
nucleosome specificities. 
Four out of these six mAbs recognize an epitope located on H2A/H2B-DNA as 
primary nucleosomal epitope. That H2A/H2B-DNA comprises major epitopes of the 
nucleosome is underlined by the observation that the prevalence of anti-H2A/H2B-
DNA reactivity in human lupus was found to be very high and comparable to anti-
chromatin (« anti-nucleosome) reactivity (21). Since it was found that anti-
nucleosome and anti-H2A/H2B-DNA reactivity was found early in spontaneous 
murine lupus, before the occurrence of anti-dsDNA antibodies, it has even been 
postulated that tolerance against H2A/H2B-DNA is lost early in the disease and that 
reactivities against other epitopes on the nucleosome (like dsDNA and H3/H4-DNA) 
develop later (10). So it seems that H2A/H2B-DNA is a central and major epitope 
for lupus auto-antibodies. 
Until now little is known about the pathogenic potential of anti-nucleosome 
antibodies. Recently, we described for mAbs #2, #32 and #34, that when these 
antibodies are complexed to nucleosomal antigens, they can bind via the histone-part 
to the GBM in vivo and activate complement (12). As we describe in this paper, #2 
and #32 recognize an epitope located on H2A/H2B-DNA and #34 on H3/H4-DNA. 
It was recently reported in human lupus that the presence of anti-H2A/H2B-DNA 
reactivity correlates with kidney disease (21). In a study in graft versus host mice, 
levels of antibodies against chromatin core particles decreased significantly before 
the appearance of proteinuria, suggesting their involvement in glomerular injury (9). 
On the other hand anti-H2A/H2B-DNA was first described in patients with 
procainamide induced lupus (25), and in these patients renal disease is very rare (26). 
It is therefore tempting to speculate that the H2A/H2B-DNA complex harbors 
different epitopes, which define the nephritogenic potential of the various anti-
H2A/H2B-DNA antibodies. In our view (27) antibodies which bind the positive 
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charges on the N-terminal ends of H2A/H2B will prevent the subsequent binding to 
the GBM, while antibodies which will neutralize the DNA associated negative 
charges will render the complex more nephritogenic. 
MAb #2 also recognizes the 83-100 peptide of H3 in the histone peptide ELISA. 
Since binding to H2A/H2B-DNA is stronger than to H3/H4-DNA and the OD found 
in the histone peptide ELISA is low, these data suggest that this linear epitope is not 
very important in the binding of the mAb to the nucleosome. A linear epitope (18-32 
H3) on H3 was identified for mAb #34 which might explain its reactivity towards 
H3. 
Inhibition experiments in IF and ELISA showed that preincubation of mAbs #2, #32 
and LG8-1 with H2A/H2B-DNA did not inhibit ANA in IF nor H2A/H2B-DNA 
binding in ELISA. We conclude that the nucleosomal epitope recognized by these 
mAbs is not expressed by H2A/H2B-DNA in fluid phase. It appears therefore that 
conformational changes which take place during coating are necessary for binding. 
The fact that most H2A/H2B-DNA reactive antibodies could not be inhibited by fluid 
phase H2A/H2B-DNA has implications for absorption studies on polyclonal sera with 
fluid phase H2A/H2B-DNA, which have been performed in the past (25). In view of 
our results it is possible that not all H2A/H2B-DNA reactive antibodies will be 
absorbed by fluid phase H2A/H2B-DNA. 
In summary, we tested 6 anti-nucleosome mAbs on subnucleosomal structures and 
histone peptides. Some linear histone epitopes were identified, but these seem to be 
of minor importance. After detailed analysis, all mAbs appeared to be different. They 
all recognize different nucleosomal epitopes on both H2A/H2B-DNA and H3/H4-
DNA. We conclude that nucleosomes evoke auto-autobodies in lupus which are 
directed against a multitude of epitopes on the nucleosome. Our findings support the 
view that in SLE different parts of the nucleosome can act as auto-antigens which 
trigger the formation of anti-nucleosome antibodies. 
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Antibodies against double stranded DNA (dsDNA) are viewed as the hallmark for 
systemic lupus erythematosus (SLE) (1). The trigger for the formation of these 
antibodies, however, has always been puzzling. It is now generally accepted that the 
auto-antibody response in lupus is antigen driven since somatic mutation and affinity 
maturation occur and T-cell help is required (2,3). Although immunization of normal 
mice with bacterial DNA can induce anti-single stranded DNA antibodies, anti-
dsDNA antibodies are not formed and in general mammalian DNA is non-
immunogenic (4,5). Since antigen presenting cells (APCs) present peptides and not 
nucleotides after processing of the antigen, DNA itself is an unlikely candidate to 
evoke the anti-dsDNA response. In the nucleus DNA is closely associated with 
histones, which have a function in the first steps of packaging the DNA into 
chromatin and in gene transcription. The nucleosome consists of a histone octamer 
(two histone H2A/H2B dimers and a histone H3/H4 tetramer), 146 base pairs (bp) 
of DNA wrapped twice around the octamer (forming the so called core particle), and 
the linker DNA (between 20 and 60 bp) joining adjacent core particles to form the 
nucleosomal array. Histone HI binds outside the core particle to the linker DNA 
region (6). 
The nucleosome has been proposed recently as an important immunogen in lupus, 
both at the Τ and В cell level, which may induce the formation of anti-dsDNA 
antibodies (7). When we tested a series of anti-nuclear antibodies on a panel of 
histone peptides, we found that not only anti-histone and anti-nucleosome antibodies 
could bind to certain histone peptides (data not shown), but unexpectedly also anti-
dsDNA antibodies. We then raised the question whether more anti-dsDNA antibodies 
recognized (in addition to DNA) non-DNA nucleosomal epitopes and tested 6 
monoclonal anti-dsDNA antibodies (mAbs) for their reactivity towards a series of 
overlapping synthetic peptides of the five histones HI, H2A, H2B H3 and H4. 
The mAbs used in this study were obtained from two different lupus mouse strains, 
namely mAb #2 from experimentally induced lupus mouse with parental-Fl chronic 
graft versus host (GVH) disease, and the other five mAbs (#36, #42, #51, #53 and 
#56) from different NZB/W mice. All selected mAbs belong to the IgG2a subclass 
except for mAb #51 which carries the IgG2b isotype. 
The mAbs were produced, purified and characterized as described previously (8). As 
it is known that DNA and histones can be copurified with anti-dsDNA antibodies (8), 
particular care was given to the purification of the mAbs. For the analysis only 
highly purified mAbs were used, not complexed to nucleosomal antigens, which was 
checked as described (8). One of these (i.e. mAb #2) showed only weak binding to 
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Table 1. Binding of mAbs to dsDNA, individual whole histones and synthetic histone 
peptides. 
Monoclonal antibodies 
neg 
0.04 
neg 
0.16 
neg 
0.21 
neg 
0.07 
neg 
0.19 
neg 
0.12 
#2 #36 #42 #51 #53 #56 
dsDNA OM >3.00 >3.00 >3.00 >3.00 >3.00 
Hl 
peptides neg' neg neg neg neg neg 
Whole Hl 0.12 0.22 0.15 0.17 0.26 0.07 
H2A 
peptides 
Whole H2A 
H2B 
peptides 
Whole H2B 
НЗ 
1-21 
18-32 
30-45 
40-55 
53-70 
68-85 
neg 
0.08 
neg 
0.10 
neg 
0.29 
neg 
0.10 
neg 
0.13 
neg 
0.18 
0.05 
0.00 
0.00 
0.14 
0.07 
0.08 
0.10 
0.04 
0.07 
0.19 
0.14 
0.05 
0.24 
0.09 
0.10 
0.29 
0.18 
0.13 
0.10 
0.05 
0.06 
0.10 
0.13 
0.02 
0.27 
0.14 
0.29 
0.19 
0.23 
0.09 
0.10 
0.00 
0.04 
0.28 
0.18 
0.01 
112 
83-100 
91-104 
98-112 
107-123 
111-130 
118-135 
130-135 
Whole НЗ 
0.40 
ND 
0.08 
0.03 
0.09 
0.12 
0.04 
0.06 
0.06 
0.10 
0.05 
0.05 
0.04 
0.06 
0.02 
0.06 
>3.00 
0.14 
0.17 
0.16 
0.25 
0.15 
0.19 
0.22 
0.12 
0.13 
0.01 
0.02 
0.03 
0.00 
0.00 
0.04 
1.45 
ND 
0.04 
0.06 
0.04 
0.05 
0.02 
0.09 
1.94 
0.13 
0.02 
0.05 
0.12 
0.05 
0.03 
0.05 
H4 
1-29 
27-44 
42-59 
57-74 
72-89 
85-102 
Whole H4 
0.12 
0.06 
0.08 
0.02 
0.06 
0.05 
0.06 
0.27 
0.12 
0.02 
0.01 
0.03 
0.00 
0.06 
0.38 
0.28 
0.18 
0.19 
0.20 
0.14 
0.22 
0.06 
0.13 
0.00 
0.00 
0.00 
0.00 
0.05 
0.21 
0.27 
0.03 
0.00 
0.02 
0.03 
0.10 
0.29 
0.19 
0.07 
0.00 
0.03 
0.00 
0.02 
Results are expressed as OD values and positive results (OD>0.30) are underlined, 
'neg = negative (OD<0.30) for all peptides tested. ND = not determined. 
DNA and a strong reactivity with the intact nucleosome, while the other five mAbs 
were "true" anti-dsDNA antibodies. In purified form two out of these five antibodies 
(i.e. mAbs #42 and #56) showed high titers in the Farr assay, which is regarded as 
the "golden standard" for the detection of anti-dsDNA antibodies. These antibodies 
were tested for their reactivity in ELISA towards whole histones and towards 53 
synthetic histone peptides, covering the entire sequences of the 4 bovine core histones 
and human HI (9,10). 
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None of the six mAbs reacted with any of the whole histones. In contrast, four out 
of six mAbs bound to one and the same histone peptide, i.e. the H3 83-100 peptide. 
In addition, mAb #42 recognized the H4 1-29 peptide, although the OD value found 
in this ELISA was just above the cut-off and low compared to the OD value 
observed with H3 83-100 (Table 1). 
By ELISA inhibition experiments, we were able to show that the binding of mAbs 
#2, #42, #53 and #56 to dsDNA could be efficiently inhibited by peptide H3 83-100 
and vice-versa, although in all experiments DNA was a more powerful inhibitor than 
H3 83-100 (data not shown). In control experiments, neighboring histone peptides 
(i.e. H3 91-104 and H3 98-112) could not inhibit the antibody binding to DNA. 
As outlined already the nucleosome has been assigned an important role in SLE. 
Firstly, antibodies exclusively reactive with the intact nucleosome and not with its 
components DNA or histones were identified (11,12). Secondly, in longitudinal 
studies in spontaneous lupus mouse models, tolerance for the nucleosomal epitopes 
seems to be lost first since antibodies to chromatin appear first, while later on anti-
dsDNA and anti-histone antibodies are formed (3,13). More importantly, some 
nucleosome-specific T-helper clones from SNF1 lupus mice were found to be able 
to induce anti-dsDNA and anti-histone antibodies in vitro (7). It has also been shown 
that immunization of animals with altered nucleosome particles induced a variety of 
anti-nuclear antibodies which are also found in patients with SLE (14). Lastly, we 
have provided evidence that nucleosomes are able to mediate the binding of auto­
antibodies to the glomerular basement membrane (8,15). 
The observed reactivity towards the H3 83-100 peptide is not an unique property of 
a single lupus strain, since mAb #2 was derived from a GVH mouse and the others 
from NZB/W Fl mice. 
The finding that these murine anti-dsDNA mAbs bind to H3 83-100 may contribute 
to the understanding of the nature of the В cell epitope involved in the production 
ofauto-anti-dsDNA antibodies. We postulate that the nucleosomal epitope recognized 
by these mAbs is composed of both dsDNA and the H3 83-100 peptide, but that the 
mAbs can also show reactivity against a part of this epitope, i.e. dsDNA and the H3 
83-100 peptide. A similar mechanism has been proposed for mAbs binding both 
H2A/H2B dimer and DNA (16). In this regard, it is interesting to know that native 
mammalian DNA itself is non-immunogenic, but when it was coupled to certain 
proteins (Fus 1) an anti-dsDNA response emerges after immunization of normal mice 
(17). 
Although it is rather uncommon that the same peptide of an antigen serves both as 
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а В- and T-cell epitope, it might be possible that this H3 peptide is generated during 
processing of the nucleosome by the antigen presenting cell (APC), and that it may 
be part of the antigen presented to the T-cell. In this view this H3 peptide could act 
as a cryptic nucleosomal T-cell epitope (18) postulated by Mohan et al (7). Further 
research is needed to analyse whether this H3 83-100 peptide coupled to DNA of 
restricted length is indeed recognized by lupus derived T-cells. Preliminary studies 
have shown that immunization of rabbits with this peptide alone does not evoke an 
anti-dsDNA response (C Stemmer and S Muller, unpublished data). If further 
research will indeed identify this peptide as an important part of the antigen inducing 
anti-dsDNA antibodies, this raises the possibility to interfere with the anti-dsDNA 
auto-antibody formation with T-cell vaccination using a modified form/presentation 
of this antigen. A similar approach has been shown to be effective in other auto­
immune diseases like adjuvant arthritis (19). 
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EDITORIAL REVIEW 
Apoptosis, nucleosomes, and nephritis in 
systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is an autoimmune disease 
that is characterized by the production of antmuclear autoanti­
bodies. The serological hallmark of SLE is the presence of 
antibodies against double-stranded DNA. It is generally assumed 
that these anti-DNA antibodies participate in the development of 
lesions in this disease. The primary event inducing the formation 
of anti-DNA antibodies has always been puzzling, since it has 
been very difficult to demonstrate the presence of free DNA in 
serum of SLE patients [1]. Furthermore, native DNA is usually 
considered non-immunogenic [2, 3]. In recent years, several 
studies have been published which suggest that not DNA itself, 
but DNA complexed to histones (nucleosomes) is the immuno­
genic particle involved both in the induction of pathogenic 
anli-DNA antibodies, and in the pathophysiology of SLE 
In eukaryotic cells, DNA is packed in the nucleus in the form of 
chromatin. In chromatin, adjacent nucleosomes are linked by 
about 60 bp of DNA. Nucleosomes are the fundamental repeating 
units of the chromatin string, and are responsible for the compac­
tion of DNA Each nucleosome is built up by eight core histone 
molecules (forming the histone octamer), one histone HI mole­
cule and 146 bp of DNA [4], as shown in Figure 1. 
Lately, it has become evident that at least in certain murine 
models of SLE (Ipr and gld mice), and perhaps also in SLE 
patients as well, the process of apoptosis is aberrant Apoptosis 
(programmed cell death) results in fragmentation of the nucleus 
by intemucleosomal cleavage of the chromatin. Normally, these 
apoptotic cells are phagocytosed rapidly, but if this does not occur 
nucleosomes may be released. On the other hand, apoptosis of 
maturing Τ cells is involved in establishing and maintaining 
tolerance, and therefore a disturbed apoptosis may cause a 
breakdown of tolerance. These recent data provide elements for a 
new concept of SLE, both for the induction as well as for the 
effector phase of the disease. We will first review the evidence for 
disturbed apoptosis in SLE, and then discuss how this relates to 
the immune response against nucleosomes. Subsequently, the 
significane« of nucleosomes for the disease manifestations of SLE 
(with emphasis on glomerulonephritis) will be discussed. 
Dysregulalion of apoptosis in SLE 
The term "apoptosis" was first used in 1972 to describe the 
process in which cells undergo several morphological changes, 
including condensation and fragmentation of the nucleus without 
disruption of the plasma membrane [5] It was later shown that 
activation of an endogenous nuclease is involved in the intemu-
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cleosomal cleavage of chromatin [6]. The induction of apoptosis is 
under strict regulation by a variety of factors, including signals 
from surrounding cells With respect to Τ cells, for example, both 
cytokines (such as interleukin-1, interleukin-2, interferon-γ) and 
costimulatory molecules (like ICAM-1, VCAM-1, LFA-3 and B7) 
present on antigen-presenting cells determine whether a Τ cell is 
driven to apoptosis or to cell proliferation [7-10]. Once a cell has 
become apoptotic, it should be removed in a rapid and efficient 
manner while still intact, to prevent the release of potentially toxic 
cell contents. This removal of apoptotic cells occurs by phagocy­
tosis. Macrophages are the most important effector cell in this 
respect, but other cell types like epithelial cells apparently can 
also ingest neighboring cells undergoing apoptosis. Several differ­
ent receptors on the phagocyte surface may be involved in this 
process, such as phosphatidylsenne receptor and thrombospondin 
receptors [11]. The morphology of apoptotic cells in tissues and in 
vitro has been described in detail [12, 13]. 
It has been very difficult to demonstrate the presence of free 
DNA in serum from SLE patients, but when DNA was found it 
occurred in the form of (oligo)nucleosomes [1]. A potential 
source for these nucleosomes are apoptotic cells, since nucleo­
somes were spontaneously released from cultured normal murine 
spleen cells, whereas this process did not occur when apoptosis 
was blocked with zinc sulfate [14]. Also during culture of human 
lymphocytes nucleosome release occurred, which was strongly 
correlated with the degree of lymphocyte apoptosis [15]. It is, 
however, not precisely known how nucleosomes are released from 
apoptotic cells. It is conceivable that in some cases these nucleo­
somes derive from apoptotic bodies. These appear at the cell 
surface of several cell types during apoptosis as a result of 
packaging of cellular components as membrane-bounded blebs. 
After their budding from the cell, apoptotic bodies are usually 
rapidly ingested by phagocytes. Some of these apoptotic bodies 
contain chromatin [13) In a recent study on UV-injured kerati-
nocytes, it was demonstrated that some of the apoptotic bodies 
contained nucleosomes, ribonucleoproteins (that are also targets 
of autoantibodies in SLE), and in addition fragments of the 
endoplasmatic reticulum or the nuclear membrane [16]. Nucleo­
somes may, after their release from apoptotic cells, also adhere to 
specific "nucleosome receptors" present on the surface of viable 
cells [17, 18]. In contrast to the programmed process of apoptosis, 
cell death by necrosis is a more random process of cellular 
destruction [12, 13] that is not expected to yield intact nucleoso-
mal particles. 
In recent years it has become evident that, at least in certain 
murine models, SLE is directly linked to a defect in apoptosis. We 
will first discuss the data obtained in lupus-prone and transgenic 
mice, and then address this question for human SLE. In mice, the 
Ipr and gld genes provide single gene models of systemic autoim­
munity (including the formation of anti-dsDNA antibodies). 
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Fig. 1. Diagram showing how the nucleosome is built up by eight histone 
proteins (4 homodimers of И2А, H2B, ИЗ, and H4) and two superhelical 
turns of 146 bp of DNA. The N-terminal parts of the histone molecules 
(approximately one third of the total molecule) contain positively charged 
residues which are located on the outside of the nucleosome. Histone HI, 
which is located on the outside of the nucleosome, is not shown in this 
diagram. 
Although expression of the Ipr gene in both В and Τ cells is 
required for autoantibody production in Ipr mice [19, 20], the 
molecular basis of the Ipr syndrome became only apparent when 
Watanabe-Fukunaga et al [21] demonstrated that Ipr mice lack the 
expression of the Fas antigen. The Fas molecule (also known as 
APO-1, and designated CD95) belongs to the TNF receptor 
family, and is a cell-surface receptor that mediates apoptosis. The 
aberrant transcription of the Fas gene in Ipr mice is caused by the 
insertion of a retroviral sequence in an intron [22-24]. Early 
replacement of the Ipr gene by the normal Fas gene will correct 
the accelerated autoimmune disease in these mice [25]. These 
tindings demonstrate that in this model there is a causal relation­
ship between dysregulation of apoptosis and autoimmune disease. 
The natural ligand for Fas has recently been cloned; it is a 
transmembrane protein and a member of the TNF family [26]. 
The gld mouse strain has a mutation of the Fas ligand gene [27]. 
It therefore appears that either a defect in the receptor (Ipr) or its 
ligand (gld) causes systemic autoimmunity. How does the defect in 
the Fas antigen cause autoimmunity in Ipr mice? In view of the 
important role of apoptosis in shaping the Τ cell repertoire by 
negative selection, one is inclined to think that a defective Fas 
antigen would cause aberrant thymic selection. It appears, how­
ever, that thymic selection of CD4+ or CD8+ Τ cells in these 
mice proceeds normally [28]. In contrast, both subsets of mature 
Τ cells exhibit decreased apoptosis in response to antigen stimu­
lation and therefore it has been suggested that autoimmunity in 
this model results from a failure of peripheral tolerance [29, 30]. 
Also in gld mice, the Τ cell defect apparently is contained within 
the compartment of activated, mature Τ cells rather than in the 
thymus [31]. It seems probable that the defective Fas gene in Ipr 
mice may also cause a decreased antigen-induced apoptosis of 
mature autoimmune В cells [21]. It is important, however, to 
realize that even in Ipr mice other genes are involved as well [32]. 
Since MRL/+ mice (which lack the Ipr gene) also develop lupus 
(although to a lesser extent, and later in life), it must be concluded 
that Ipr accelerates rather than causes the disease. In other murine 
models of SLE, such as NZB/W mice, no abnormalities of the Fas 
gene have been detected [22]. 
Apart from the Fas gene, there are several other genes involved 
in the regulation of apoptosis. There are pathways for the 
induction of apoptosis which are independent of the Fas antigen, 
such as the TNF receptor [33]. Furthermore, there are genes that 
decrease the susceptibility for apoptosis, such as the bcl-2 gene 
[34]. The bcl-2 gene was first discovered in В cell lymphomas, 
which have a permanent high expression of the bcl-2 protein. 
When in transgenic mice bcl-2 was brought under the control of 
an immunoglobulin promotor, the number of В cells increased, 
and autoantibodies against nuclear antigens (including histone 
and DNA) were produced, resulting in immune complex glomer­
ulonephritis [35]. In another study with transgenic mice, it could 
be demonstrated that bcl-2 inhibits the clonal deletion of autore­
active В cells in the periphery but not in bone marrow [36]. In 
bcl-2 knockout mice, fulminant lymphoid apoptosis was observed, 
causing disappearance of the lymphoid system within four weeks 
after birth [37, 38]. Recent studies have revealed that the bcl-2 
gene is a member of an expanding family of similar genes, some of 
which have the same effect as bcl-2 (protection against apoptosis), 
whereas others like box will increase the susceptibility for apop­
tosis [39]. The box protein can form a heterodimer with the bcl-2 
protein and in this way neutralise the effect of bcl-2. The bcl-2 
protein apparently exerts its protective effect by activating an 
anti-oxidant pathway in the cell [40]. Many stimuli inducing 
apoptosis are known to generate reactive oxygen species. The 
relative amounts of box and bcl-2 in a cell may therefore deter­
mine the susceptibility of the cell for apoptosis. 
In human SLE, no defects in expression or function of the Fas 
antigen have been found [41]. This does not imply, however, that 
apoptosis is completely normal in human SLE. Two phenomena 
have been described that may contribute to disturbed apoptosis in 
human SLE. First, serum levels of soluble Fas were found to be 
elevated in several SLE patients. Due to alternative splicing, the 
Fas encoded protein can also occur in a soluble form. Soluble Fas 
can inhibit apoptosis, since after injection in normal mice, it 
causes increased numbers of В cells and autoimmune features 
[42]. Secondly, in lymphocytes from SLE patients the expression 
of bcl-2 is increased [43]. This may be a reflection of in vivo 
activation, since lymphocyte activation is known to increase the 
transcription of bcl-2 [44]. Despite these increases of soluble Fas 
and intracellular bcl-2, lymphocytes from SLE patients display an 
increased rate of "spontaneous" apoptosis in vitro [15], as do 
lymphocytes from Ipr mice [45]. One should be cautious, however, 
to extrapolate from these in vitro findings to the in vivo situation. 
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It has been postulated that lymphocytes from Ipr mice may be 
"primed" for apoptosis, but prevented from dying in vivo. Once 
placed in culture in vitro, such cells would then rapidly die [45]. 
With respect to lymphocytes from SLE patients, the protective 
effect of soluble Fas in serum will be diminished or absent when 
cells are cultured in vitro. Furthermore, as mentioned above, the 
rate of apoptosis of SLE lymphocytes in response to antigenic 
stimulation is decreased [29, 30] instead of increased. It may be 
important in this respect to precisely define the subset of lympho­
cytes that is being studied (double-negative Τ cells, or CD4-
positive Τ cells, or В cells), and their antigen specificity. It is 
conceivable that some cells in SLE patients (or lupus-prone mice) 
display an increased rate of apoptosis whereas for other cells 
(depending on cell type, activation state, and specificity) apoptosis 
may proceed at a decreased rate, or at the same rate as in normal 
individuals. Therefore, although the Fas antigen is normal in 
human SLE, apoptosis appears to be abnormal, as evidenced by 
an increased concentration of soluble Fas, an increased expression 
of bcl-2, and an increased rate of apoptosis when lymphocytes 
from SLE patients are cultured in vitro. It remains to be proven 
that the abnormalities of apoptosis observed in human SLE are a 
cause of disease (as appears to be the case in the murine SLE 
models discussed above) rather than a consequence 
Dysregulation of apoptosis can contribute to the pathogenesis 
of lupus nephritis in two different ways. First, apoptosis appears to 
be an important mechanism to induce tolerance of Τ cells towards 
self-antigens [46,47]. This implies that a disturbance in apoptosis 
may cause persistence of autoreactive Τ cells and in this way affect 
the magnitude of the anti-nucleosomal immune response. As 
discussed above, one of the consequences of a defective Fas 
antigen is breakdown of peripheral Τ cell tolerance. Secondly, 
autoreactive lymphocytes that have escaped apoptosis in response 
to autoantigen may be "primed" for apoptosis. Some of these cells 
may be induced to become apoptotic by other mechanisms 
(unrelated to Fas). Removal of such apoptotic lymphocytes may 
be less effective (depending on the microenvironment) than when 
apoptosis occurs by the "normal" (antigen-induced) mechanism. 
In this respect it may be relevant that within tissues phagocytosis 
of apoptotic bodies occurs rapidly, but not when they are formed 
in a fluid medium [13]. A possibility that deserves further inves­
tigation is that in SLE patients phagocytosis of apoptotic cells 
(and apoptotic bodies) might be decreased. Although there are no 
published data yet on this subject, it has been known for a long 
time that in SLE there are profound defects in other forms of 
phagocytosis (such as complement-mediated phagocytosis in lu­
pus-prone mice [48], and Fc receptor-dependent phagocytosis in 
SLE patients [49]). If phagocytosis of apoptotic cells is indeed 
defective in SLE, this could also affect the persistence of non-
lymphoid apoptotic cells (such as UV-injured keratinocytes [16]). 
Nucleosomes as immunogenic particles in SLE 
In what way can dysregulation of apoptosis contribute to 
autoimmunity against nucleosomal antigens in SLE? What is the 
role of nucleosomes, and how are Τ lymphocytes (double-nega­
tive, or CD4+ cells) and В cells involved in this process? As 
discussed above, apoptosis is the most likely source of nucleo­
somes. Lymphocytes from SLE patients demonstrated an in­
creased rate of apoptosis m vitro, and the number of apoptotic 
cells in freshly isolated lymphocytes was also slightly increased 
[15]. If this reflects the in vivo situation, the increased number of 
apoptotic lymphocytes might lead to the release of increased 
amounts of nucleosomes. One way that nucleosomes can evoke an 
immune response is by polyclonal activation of В cells. Both with 
murine and human lymphocytes, polyclonal В cell activation by 
nucleosomes has been demonstrated [14, 50]. The secretion of 
interleukin-6 that was observed after interaction of nucleosomes 
with murine spleen cells [18] may further enhance this polyclonal 
В cell activation. 
Although polyclonal В cell activation by nucleosomes may 
occur, there are many arguments in favor of the hypothesis that 
pathogenic anti-DNA antibodies are the result of an antigen-
driven immune response (such as clonal expansion, IgG class 
switch, somatic mutations). T-helper (Th) cells are required for 
the production of these anti-DNA autoantibodies. Since there is 
an expanded population of double-negative Τ cells (CD3+, 
CD4-, CD8-) in SLE [51, 52], and because these cells exhibit a 
preferential use of distinct V(3 genes both in Ipr mice [51] and in 
humans [53], these cells might be involved in the initiation of 
autoimmune disease. Indeed, aß CD4-CD8— (as well as γδ 
CD4-CD8-) Τ helper cell lines could be isolated from patients 
with active lupus nephritis [52, 54]. The large majority, however, 
of Th cells supplying help for production of pathogenic anti-DNA, 
are CD4+ cells and not double-negative cells [54]. Furthermore, 
recent experiments with MHC class Il-deficient Ipr mice have 
demonstrated an important role for CD4+ Th cells, whereas 
double-negative Τ cells did not appear to be essential for initiating 
disease [55] It was found in lupus-prone mice that only a fraction 
of autoreactive Τ cell clones can induce anti-DNA autoantibodies 
m vitro, and accelerate the development of lupus nephritis when 
transferred in vivo. The specificity of these pathogenic Th cells has 
been studied in some detail Approximately 50% of them were 
specific for nucleosomal antigens. Importantly, nucleosome-spe-
cific CD4+ Τ cells were not detectable in normal mice, but they 
were found in the spleens of lupus-prone mice as early as one 
month of age, long before any autoimmune manifestation. These 
nucleosome-specific Th cells not only augmented the anti-nucleo-
some response of syngeneic В cells, but also the anti-histone and 
anti-DNA response. The importance of nucleosomes as immuno­
genic particles was underlined by the finding that injection of 
purified nucleosomes into preautoimmune mice could signifi­
cantly accelerate the development of glomerulonephritis [56]. 
An intriguing question in this respect is the nature of the 
epitope recognized by the pathogenic Th cell. These nucleosome-
specific Th clones were not activated by free DNA or histones, the 
two components of nucleosomes. This result suggests that either 
nucleosomes are taken up more efficiently by antigen-presenting 
cells, or that critical Th cell epitopes in the histones are protected 
from degradation by being bound to DNA [56]. Another possibil­
ity is that after antigen processing of nucleosomes, MHC class II 
molecules present self-peptides that were previously cryptic. The 
possible significance of such cryptic epitopes for the induction of 
autoimmunity has recently been reviewed [57] It has also been 
suggested that the presence of endoplasmatic reticulum or nu­
clear membrane within the apoptotic bodies causes an increased 
generation of reactive oxygen species which may induce oxidative 
modification of autoantigens. The unique peptide fragments 
generated in this way could then, in genetically susceptible 
individuals, be presented to Th cells and induce an autoimmune 
response [16]. 
Whatever the precise nature of the epitope recognized by the 
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Fig. 2. Immunoelectron microscopy after perfusion of a monoclonal anti-
body complexée! to nucleosomal antigens. Throughout the width of the 
GBM, binding of the complexed antibody is seen (the noncomplexed, pure 
antibody did not bind at alt). 
pathogenic Th cells, it is obvious that nucleosome-specific Th cells 
were only present in lupus-prone and not in normal mice [56]. In 
normal individuals, apoptosis also occurs but no anti-DNA anti-
bodies are found. Furthermore, injection of nucleosomes into 
normal mice does not result in formation of anti-DNA autoanti-
bodies or nephritis [58]. It is apparent then that apart from the 
extracellular presence of nuclear antigens, there must be other 
factors involved in the induction of such autoreactive Τ cells. It is 
well known that susceptibility to SLE is influenced by genes 
encoded within the MHC complex [2, 55]. Furthermore, in Ipr 
mice the virtually absent expression of Fas may cause breakdown 
of (peripheral) tolerance, as discussed above. This may result in 
the prolonged survival in vivo of autoimmune Τ and В cells. 
Anti-nucleosome antibodies 
The occurrence of antibodies specific for nucleosomes or 
subnucleosomal structures in SLE provides further evidence that 
nucleosomes are immunogenic particles in SLE. These antibodies, 
which only react with the intact nucleosome or subnucleosomal 
structures, but not with its components DNA or individual 
histones, have first been noted in drug induced lupus. In procain­
amide induced lupus not only antibodies to H2A-H2B complex 
were found [59], but also to (H2A-H2B)DNA complexes [60]. 
Further analysis revealed that the antibodies recognize an epitope 
created by the monomeric, trimolecular histone-DNA complex 
[61]. Studies in lupus prone mice revealed that antibodies against 
chromatin (such as nucleosomes) are the result of an antigen 
driven response and precede the occurrence of anti-DNA or 
anti-histone antibodies [62]. The authors concluded that anti-
DNA antibodies are a subset of the wide spectrum of anti-
chromatin (nucleosome) antibodies, which is also favored by the 
observation that nucleosome specific Τ helper cells cannot only 
induce an anti-nucleosome response, but also reactivity towards 
DNA [56]. Recently, it was shown that the prevalence of anti-
nucleosome antibodies is very high (88%) in human lupus [63] 
and that the titers of anti-nucleosome reactivity correlate with 
disease severity [64]. One should realize, however, that the study 
of these reactivities in polyclonal SLE sera is hampered by the fact 
that anti-DNA and anti-histone antibodies will also bind to 
nucleosomes. This problem is circumvented if one studies the 
specificity of monoclonal antibodies derived from lupus prone 
mice or SLE patients. Indeed, reactivity against histone/DNA 
complexes has been found in such monoclonal antibodies (mAbs). 
From MRL/Mp +/+ mice mAbs were obtained which exerted 
reactivity against the (H2A-H2B)DNA complex [65], and recently 
a murine mAb directed against the intact nucleosome, which did 
not recognize any subnucleosomal structure, was described [66]. 
Also in mAbs derived from SLE patients reactivity against a 
mixture of DNA and histones has been detected [67]. We recently 
found that anti-nucleosome antibodies complexed to nucleosomal 
material exerted anti-DNA reactivity both in ELISA and Farr 
assay. After removal of the bound nucleosomal material the 
anti-DNA reactivity disappeared and only anti-nucleosome reac­
tivity remained [68]. This indicates that in SLE sera reactivity 
towards DNA can be a feature of anti-nucleosome antibodies. In 
fact, we now have preliminary data that after purification of 
anti-DNA positive SLE sera, a substantial part of the anti-DNA 
reactivity is lost, whereas reactivity against other, nominal anti­
gens (for instance anti-EBV) is unaltered. This suggests that the 
occurrence of anti-nucleosome antibodies in SLE might be more 
prevalent than is assumed until now. 
Relevance of nucleosomes for the pathophysiology of 
SLE nephritis 
Classically, not nucleosomes but DNA has been thought to play 
a role in the development of tissue lesions in lupus through the 
formation and subsequent deposition of DNA/anti-DNA im­
mune-complexes [69]. However, formal proof for this assumption 
is rather lacking. It has been very difficult to detect circulating free 
DNA or DNA complexed to anti-DNA antibodies [70-72]. Ru­
more and Steinman [1] showed that DNA in the circulation of 
SLE patients was present in the form of (oligo)nucleosomes. 
Based on these observations it is likely that DNA is not present in 
naked form in the circulation but complexed in (oligo)nucleo-
somes. In addition, it is difficult to envisage how the anionic 
charged DNA can have affinity for the anionic charged GBM. 
The first notion, that nucleosomes might play a role in the 
pathophysiology of glomerular disease in lupus, came from exper­
iments with cross reactive anti-DNA antibodies. Working with 
anti-DNA mAbs which bound to heparan sulfate (HS) we found 
that this cross reactivity was not exerted by the antibody itself, but 
was mediated by nucleosomal material complexed to the antibody 
[73]. HS is an intrinsic constituent of the GBM, and the negatively 
charged side chain of heparan sulfate proteoglycan. It is respon­
sible for the negative charge of the GBM, and thus for the 
charge-dependent permselectivity of the GBM [74]. Neutraliza­
tion of this HS associated charge, or antibody binding to HS leads 
to albuminuria [75, 76]. We postulated that the positively charged 
histones within the nucleosomal part of the immune complex 
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Dysregulation of apoptosis 
Decreased phagocytosis? 
Quantitative/qualitative 
changes in nucleosomes 
In situ binding of 
nucleosomes to GBM (HS7) 
-*• Persistence of autoreactive Τ cells 
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Fig. J. Proposed mechanisms linking 
dysregulation of apoptosis to lupus nephritis 
Nucleosomes can be released from 
apoptotic cells (decreased phagocytosis 
might be a contributing factor) Persisting 
nucleosome-specifìc Τ cells can provide help 
for production of anti-nucleosome 
antibodies Nucleosomes can mediate the 
binding of such antibodies to anionic 
structures in the GBM, such as heparan 
sulfate (HS) 
could interact with HS and that this interaction might lead to 
albuminuria by neutralization of charge or by eliciting an inflam­
matory reaction [73]. At the same time Schmiedeke et al [77] 
indeed showed that histone aggregates have a high affinity for the 
GBM. We subsequently showed in a rat kidney perfusion system 
that histones can mediate binding of subsequent perfused DNA 
and anti-DNA and induce subepithelial or subendothelial local­
ization of the antibody depending on the perfusion protocol [78]. 
We propose that nucleosomes act as planted antigens or as 
mediators for binding of autoantibodies to the GBM. Although 
nucleosomes have a pi of about 7, they contain many positively 
charged N-terminal regions which are located on the outside of 
the particle It has even been shown that molecules with a net 
negative charge, but with canonie regions can bind to the GBM 
[79] Indeed, we could show that nucleosome containing immune 
complexes are able to bind to the GBM, whereas the punned 
antibodies do not bind. Binding of such complexes to the GBM is 
illustrated at the ultrastructural level in Figure 2. The pathogenic 
potential of this binding was underlined by the fact that comple­
ment activation took place. Using heparinase perfusion prior to 
perfusion of nucleosome containing immune complexes, we could 
show that the ligand in the GBM was partly but not solely HS [68]. 
The exact composition of the nucleosomal material in the immune 
complex which mediates the binding to the GBM in vivo is not 
clear yet. In our studies we obtained immune complexes from 
hybndoma culture supernatants and found that the four core 
histones but not HI were present, and DNA in the complexes 
were predominantly the size of about 120 bp The presence of 
antibody bound to the nucleosome seems to be a critical deter­
minant, since we found that perfusion of naked nucleosomes did 
not lead to a comparable binding to the GBM. Furthermore, the 
specificity of the bound antibody could be important for the 
overall pi of the complex, for instance anti-DNA and anti-
nucleosome antibodies increase the pi of the complex and thereby 
the nephntogemcity This concept is supported by the recent 
finding that pathogenic anti-DNA antibodies, which are able to 
bind to HS in the GBM via nucleosomes, harbor more charged 
amino acids (like arginine) than non-pathogenic anti-DNA anti­
bodies [80]. In this concept binding of anti-histone antibodies, by 
binding to the histone part of the nucleosome would both 
decrease the pi and the nephntogemcity of the complex This 
latter hypothesis is in line with the clinical observation that renal 
disease is rare in SLE-like syndromes characterized by the occur­
rence of predominantly anti-histone antibodies as in drug induced 
lupus 
What are the data to support the significance of nucleosomes in 
vivo'' Since HS reactivity is a feature of immune complexes 
consisting of anti-nuclear autoantibodies and nucleosomal anti­
gens, anti-HS reactivity in plasma is an indirect way to identify the 
presence of these immune complexes. Anti-HS reactivity has been 
found to correlate with renal symptoms in lupus patients [81-83], 
although anti-HS reactivity was not present in every episode with 
renal manifestations [83]. Further evidence for the role of these 
immune complexes comes from our observation that the staining 
for glomerular HS in both human [84] and murine [85] lupus 
nephritis is strongly reduced or even absent. Despite a nearly 
complete loss of HS staining in mice with heavy and prolonged 
albuminuria, glomerular HS content was unaltered. Therefore, we 
had to conclude that HS was masked by immunoreactants pre­
sumably containing nucleosomal antigens. More direct evidence 
for the involvement of nucleosomes in lupus nephritis is provided 
by studies showing both histones [86, 87] and DNA [88] in 
glomerular immune deposits in human and murine lupus nephri­
tis. In one study the deposition of histones was almost exclusively 
found in albuminuric mice [87], underlining the role of histones 
and nucleosomes in the development of albuminuria in these 
mice. These in vivo data therefore support the concept that 
nucleosomal material may mediate antibody binding to the GBM 
for which HS is a ligand 
In conclusion, both in human and murine lupus abnormalities 
in apoptosis have been described This aberrant apoptosis may 
contribute to lupus nephritis by mechanisms that have been 
summarized in Figure 3. Binding of nucleosome containing com­
plexes to other basement membranes might lead to other organ 
manifestations of the disease. However, many questions remain to 
be answered. Future studies have to clarify the exact contribution 
of disturbed apoptosis in SLE. In addition studies are needed to 
identify the precise nature of the epitopes within the nucleosome 
recognized by auto-reactive Τ cells. Furthermore, the possibility 
should be studied that different epitopes within the nucleosome 
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dic ta te t he p roduc t ion of different au toan t ibod ie s (such as ant i -
h is tone , a n t i - D N A , an t i -nuc leosome) . Finally t he exact compos i -
t ion of t he n u c l e o s o m e and the n u c l e o s o m e / a u t o a n t i b o d y c o m -
plex d e t e r m i n i n g affinity for t he G B M should b e clarified. 
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CHAPTER 10 
Summary. 
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Antibodies against double stranded DNA (dsDNA) are a serological marker for the 
autoimmune disease systemic lupus erythematosus (SLE). They have always been 
thought to play an important role in the etiopathogenesis of many organ 
manifestations of the disease. Especially nephritis, one of the most serious 
complications of SLE, has in the past been linked to the occurrence of anti-dsDNA 
antibodies. Classically, it was thought that DNA/anti-dsDNA complexes are trapped 
passively in the glomerular basement membrane (GBM), leading to local 
inflammation. 
We challenged this concept and showed in previous work, described in chapter two, 
that anti-dsDNA antibodies may cross-react with heparan sulfate (HS), which is an 
intrinsic constituent of the GBM and responsible for its negative charge. This cross-
reactivity is not a property of the antibodies themselves but is based on histones and 
DNA (nucleosomes) bound to the antibodies. In our concept nucleosomes bridge the 
binding of antibodies to the anionic HS via the cationic histones within the 
nucleosome. 
In chapter three in a prospective analysis in 72 consecutive SLE patients the 
correlation between plasma anti-HS reactivity and the occurrence of exacerbations 
with renal manifestations was studied. From these 72 patients 22 experienced 40 
exacerbations. In 20 of these exacerbations renal symptoms were present. During 
exacerbations with renal manifestations both anti-HS and anti-dsDNA titers were 
higher than in exacerbations without renal symptoms. Anti-HS titers correlated 
significantly with anti-dsDNA antibody titers (rs = 0.57; p<0.05). In some patients 
a high anti-dsDNA titer without anti-HS reactivity was detected, whereas anti-HS 
reactivity without anti-dsDNA reactivity was never found. These findings suggest that 
anti-HS reactivity is dependent of the presence of anti-dsDNA antibodies, whereas 
not all anti-dsDNA antibodies are complexed to nucleosomes and thus exhibit anti-
HS reactivity. 
In chapter four complexed monoclonal anti-nuclear antibodies, showing anti-HS 
reactivity, were prepared using various purification procedures. In this way antibody 
preparations containing nucleosomal material and pure non-complexed antibodies 
were obtained. Pure and complexed antibodies were tested in vitro for antigen 
specificity and were perfused into a rat kidney to study glomerular binding. In ELISA 
pure antibodies could not bind to HS (as expected) but surprisingly also DNA 
reactivity was lost after removal of nucleosomal material. In purified form only the 
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intact nucleosome was recognized. When the antibodies were complexed to 
nucleosomes they bound to DNA (both in ELISA and Farr assay), to HS and to 
histones. 
When pure non-complexed antibodies were perfused into a rat kidney no binding was 
observed, whereas after perfusion of antibodies complexed to nucleosomal material 
binding of antibodies through the whole width of the GBM was observed. Histones 
could be detected in these GBM deposits and when after the renal perfusion, the 
blood circulation of the rat was restored for 15 minutes, deposition of rat complement 
was detected. In order to show that HS in the GBM was the ligand for the observed 
binding, HS was removed by renal perfusion of the HS degrading enzyme heparinase. 
When complexed antibodies were perfused after removal of HS by this procedure, 
binding was considerably reduced, showing that HS is an important but not the only 
ligand for the complexed antibodies in the GBM. 
Since in chapter four it was shown that anti-nucleosome antibodies complexed to 
nucleosomes were able to bind to the GBM and initiate inflammation, in chapter five 
we studied whether histones and nucleosomes could actually be detected in biopsies 
of patients with lupus nephritis. We also studied whether the presence of 
nucleosomes and histones in these biopsies correlated with loss of HS staining in the 
GBM. This was done since in a recent study from our laboratories we found that HS 
staining was decreased in albuminuric MRL/1 and NZB/W Fl lupus mice, while 
glomerular HS content was intact, suggesting that HS was masked by immune 
deposits. We studied kidney biopsies of 11 lupus patients with diffuse proliferative 
SLE glomerulonephritis (DPGN, WHO class IV) and 6 patients with membranous 
SLE glomerulonephritis (MGN, WHO class V). Sections of all biopsies were stained 
for the presence of histones, nucleosomes, DNA and IgG in the immune deposits and 
for the presence of HS and heparan sulfate proteoglycan (HSPG) core protein (which 
is the glycoprotein to which HS is linked) in the GBM. Histones were present in all 
patients with DPGN and in two out of six patients with MGN (p<0.02, Fisher exact 
test). Nucleosomes were detected in five patients with DPGN and in none of the 
MGN patients. HS staining was nearly absent in DPGN and only moderately reduced 
in MGN. A significant correlation between presence of histones and decrease of HS 
staining was found (rs = -0.77). Staining of HSPG core protein was normal in all 
biopies. It is at present unclear whether the nucleosomal particle in the glomerular 
deposits consists mainly of histones or whether in vivo binding of anti-dsDNA and/or 
anti-nucleosome antibodies leads to masking of nucleosome specific epitopes. 
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In chapter six another possible pathogenic mechanism of anti-nucleosome antibodies 
is described. When the hybridomas producing monoclonal anti-nucleosome antibodies 
(mAbs) are inoculated intraperitoneally in mice, in immunofluorescence (IF) not only 
glomerular binding is observed but also binding to cell nuclei is found. This 
phenomenon is called in vivo anti-nuclear activity (in vivo ANA). Recently, it was 
described that some anti-DNA antibodies are able to bind to the cell surface, 
subsequently are internalized in the cytoplasm and thereafter are transported to the 
nucleus (in vivo ANA), which leads to pathological consequences like decreased cell 
proliferation, increased protein synthesis, glomerular hypercellularity and proteinuria. 
We could show that when antibodies complexed to nucleosomes are injected 
intravenously in naive mice, after 45 minutes in vivo ANA is observed, whereas after 
injection of pure non-complexed antibodies hardly any nuclear binding is seen. In 
additional experiments using well defined human cell lines, cell surface binding of 
antibodies also appeared to be a property of anti-nucleosome antibodies complexed 
to nucleosomes, whereas pure non-complexed antibodies did not bind. However, 
when complexed antibodies were incubated up to 24 hours with living cells, only 
internalization of antibodies in cytoplasmic vesicles was found and no nuclear 
binding. We hypothesized that in vivo ANA observed in IF may be related to the 
fixation procedure. To study this, from mice bearing the hybridoma producing the 
anti-nucleosome mAbs intraperitoneally, a small part of the kidney was processed for 
standard IF using acetone fixation after cutting of the sections, whereas the remaining 
part was in vivo fixed with a mixture of 0.01 M sodium periodate, 0.075 M lysine 
HCl, 0.0375 M Na2HP04 and 2% paraformaldehyde (PLP) and studied in both IF and 
IEM. After standard IF, as anticipated, in vivo ANA was observed, whereas after in 
vivo fixation with PLP only localization of antibodies in cytoplasmic vesicles and no 
nuclear binding was found. From these experiments we conclude that anti-
nucleosome antibodies complexed to nucleosomes can bind to the cell surface and 
are subsequently internalized. In vivo ANA however, is a fixation related 
phenomenon. 
Until now little is known about the characteristics of the epitopes on the intact 
nucleosome which are recognized by anti-nucleosome antibodies. In chapter seven 
a panel of six anti-nucleosome mAbs derived from lupus mice was characterized in 
ELISA on nucleosomes and subnucleosome structures (H2A/H2B dimer, H3/H4 
tetramer, H2A/H2B-DNA complex and H3/H4-DNA complex) and on a panel of 53 
overlapping synthetic histone peptides covering the entire sequence of the five 
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histones. By definition these antibodies showed no or low reactivity towards DNA 
or the individual histones compared to their reactivity towards nucleosomes. In the 
histone peptide ELISA we found that only two mAbs recognized one of the 53 
peptides. Since the reactivity found hardly exceeded background levels, we concluded 
that linear histone epitopes are not important for the binding of these anti-nucleosome 
antibodies. In the nucleosome and subnucleosome ELISAs all mAbs showed different 
reactivity patterns. Three mAbs showed higher reactivity towards the intact 
nucleosome than to subnucleosome structures. For two of them the primary 
nucleosomal epitope was located on H2A/H2B-DNA, whereas for the other mAb 
this primary epitope was located on H3/H4/DNA. From the remaining three, two 
mAbs were directed against an epitope on H2A/H2B-DNA and one mAb recognized 
an epitope on H3/H4-DNA. In the subnucleosome ELISA all but one recognized 
more than one epitope. When DNA was coated with a variety of cationic molecules 
for all mAbs one specific nucleosomal epitope could be identified, whereas the 
reactivity with other subnucleosomes was comparable to the reactivity towards DNA 
coated with these cationic molecules. In inhibition experiments both in ELISA and 
in immunofluorescence (IF) it was found that only one of the mAbs recognizing an 
epitope on H2A/H2B-DNA as primary epitope could be inhibited by H2A/H2B-DNA 
in fluid phase. The two mAbs recognizing an epitope on H3/H4-DNA as primary 
epitope could be inhibited by H3/H4-DNA in fluid phase. From these experiments 
we conclude that some epitopes on H2A/H2B-DNA recognized by certain anti-
nucleosome mAbs are not expressed by H2A/H2B-DNA in fluid phase. 
These mAbs all recognize different nucleosomal epitopes on both H2A/H2B-DNA 
and H3/H4-DNA. Our findings support the view that in SLE the whole nucleosome 
is the auto-antigen which triggers the formation of anti-nucleosome antibodies. 
It is now generally accepted that the auto-immune response in SLE is antigen driven 
and T-cell dependent. The nucleosome has been proposed as an important 
immunogen leading to the formation of not only anti-nucleosome, but also anti-
dsDNA and anti-histone antibodies. In this view a nucleosomal epitope is involved 
in the formation of anti-dsDNA antibodies. We therefore hypothesized that anti-
dsDNA antibodies might recognize more than DNA alone and tested in chapter eight 
6 monoclonal anti-dsDNA antibodies derived from lupus mice on the panel of 53 
overlapping synthetic histone peptides described above. We found that four out of six 
mAbs recognized one and the same histone peptide, i.e. the H3 83-100 peptide. Both 
DNA and H3 83-100 were able to inhibit the binding of these mAbs to DNA and H3 
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83-100. We hypothesize that this peptide, together with DNA forms a nucleosomal 
epitope, which evokes the formation of auto-antibodies capable of binding to DNA 
and H3 83-100 separately. It has recently been postulated that the nucleosome is 
processed by antigen presenting cells and that cryptic nucleosomal peptides are 
presented to T-cells, which help B-cells in the production of anti-dsDNA antibodies. 
Maybe H3 83-100 is one of these cryptic epitopes. 
Since the most likely source of nucleosomes in the circulation is from apoptotic cells 
and disturbances in apoptosis have been described in both murine and human lupus, 
in chapter nine the literature concerning apoptosis, nucleosomes and nephritis in SLE 
is reviewed. Disturbances in apoptosis can lead to both the persistance of autoreactive 
Τ cells and to release of nucleosomes which may be altered (and become more 
immunogenic). Decreased phagocytosis, which has been described in SLE, may lead 
to prolonged survival of nucleosomes in the circulation. These altered nucleosomes 
than may be a target for autoreactive T-cells, which leads to the production of anti-
nucleosome, anti-dsDNA and anti-histone antibodies. As already described in 
chapters 2 and 3, nucleosomes may mediate the binding of these antibodies to the 
GBM. So the nucleosome seems to play a central role in SLE, both in the induction 
and in the effector phase of the disease. 
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CHAPTER 11 
Samenvatting. 

Antistoffen tegen dubbelstrengs DNA (dsDNA) zijn kenmerkend voor de 
autoimmuun ziekte systemische lupus erythematosus (SLE). Men is er altijd van 
uitgegaan dat deze antistoffen een belangrijke rol spelen in de ontstaanswijze van 
vele verschijnselen van deze ziekte. Met name voor het optreden van nefritis, één van 
de ernstigste complicaties van SLE, is een verband met anti-dsDNA antistoffen 
beschreven. Van oudsher is er gedacht dat DNA/anti-dsDNA complexen vastlopen 
in de glomerulaire basaal membraan (GBM), hetgeen tot een locale ontstekingsreactie 
zou leiden. 
Wij vroegen ons af of deze zienswijze juist was en toonden in vroeger werk aan, 
(beschreven in hoofdstuk twee) dat anti-dsDNA antistoffen kunnen kruisreageren met 
heparaan sulfaat (HS). HS is een onderdeel van de GBM en verantwoordelijk voor 
diens negatieve lading. Deze kruisreactiviteit wordt niet door de antistoffen zelf 
veroorzaakt, maar door histonen en DNA (nucleosomen) gebonden aan de antistoffen. 
In onze visie vormen nucleosomen een brug voor de binding van antistoffen aan het 
negatief geladen HS in de GBM, waarbij de positief geladen histonen in het 
nucleosoom aan HS binden. 
In hoofdstuk drie werd in een prospectieve analyse bij 72 SLE patiënten de correlatie 
tussen plasma anti-HS reactiviteit en het optreden van exacerbaties met renale 
verschijnselen bestudeerd. Van deze 72 patiënten kregen er 22 gezamenlijk 40 
exacerbaties. Bij 20 van deze exacerbaties waren er onder andere renale symptomen. 
Gedurende exacerbaties met renale verschijnselen waren zowel anti-HS als anti-
dsDNA hoger dan in exacerbaties zonder renale symptomen. De anti-HS titers 
toonden een significante correlatie met anti-dsDNA antistof titers (rs = 0,57; p<0,05). 
Bij sommige patiënten werd een hoge anti-dsDNA titer zonder anti-HS gevonden, 
terwijl anti-HS reactiviteit zonder anti-dsDNA reactiviteit niet gezien werd. Deze 
bevindingen maken het aannemelijk dat anti-HS reactiviteit afhankelijk is van de 
aanwezigheid van anti-dsDNA antistoffen, terwijl niet alle anti-dsDNA antistoffen 
gecomplexeerd zijn aan nucleosomen en zo anti-HS reactiviteit vertonen. 
In hoofdstuk vier werden 3 anti-nucleaire monoclonale antistoffen die in kweek 
supernatant anti-HS reactiviteit vertoonden, op verschillende manieren opgezuiverd. 
Op deze wijze werden antistoffen gecomplexeerd aan nucleosomaal materiaal en 
zuivere niet-gecomplexeerde antistoffen verkregen. Van deze zuivere en 
gecomplexeerde antistoffen werd in vitro de antigene specificiteit bepaald. Daarnaast 
werden rattenieren geperfundeerd met deze antistof preparaten om zo de binding in 
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de glomerulus te bestuderen. In ELISA bleken zuivere antistoffen niet aan HS te 
binden (hetgeen ook voorspeld was), maar onverwachts ging ook de DNA reactiviteit 
verloren na verwijdering van het gecomplexeerde nucleosomale materiaal. In zuivere 
toestand herkenden deze antistoffen slechts het intacte nucleosoom. Alleen als de 
antistoffen gecomplexeerd waren aan nucleosomen konden ze aan DNA (in ELISA 
en Fair assay), HS en histonen binden. 
Na renale perfusie van zuivere niet-gecomplexeerde antistoffen werd geen binding 
gezien, terwijl na perfusie van antistoffen gecomplexeerd aan nucleosomaal materiaal 
binding van antistoffen door de gehele breedte van de GBM gevonden werd. 
Histonen werden in deze GBM deposities aangetoond. Als na renal perfusie de 
circulatie van de rat gedurende 15 minuten hersteld werd, werd depositie van rat 
complement waargenomen. Teneinde aan te tonen dat HS in de GBM de ligand voor 
de binding van deze gecomplexeerde antistoffen was, werd HS van de GBM 
verwijderd door renale perfusie van het enzym heparinase, hetgeen in staat is HS af 
te breken. Als na deze procedure gecomplexeerde antistoffen werden geperfundeerd, 
bleek de binding van antistoffen aan de GBM aanzienlijk verminderd. 
Uit deze proeven concluderen we dat anti-nucleosoom antistoffen gecomplexeerd aan 
nucleosomaal materiaal kunnen binden aan de GBM en dat HS een belangrijke, doch 
niet de enige ligand in de GBM is waaraan deze gecomplexeerde antistoffen binden. 
Daar in hoofdstuk 4 aangetoond was dat anti-nucleosoom antistoffen gecomplexeerd 
aan nucleosomen aan de GBM konden binden en ontsteking konden veroorzaken, 
analyseerden we in hoofdstuk vijf of histonen en nucleosomen ook daadwerkelijk in 
nierbiopsie ën van patiënten met lupus nefritis aantoonbaar waren. Bovendien 
bestudeerden we of de aanwezigheid van nucleosomen en histonen correleerde met 
verlies van HS kleuring in de GBM. In een recente studie hebben we namelijk 
gevonden dat de HS kleuring is afgenomen in MRL/1 muizen met een eiwitlek, 
terwijl het glomerulaire HS gehalte niet veranderd is, hetgeen doet vermoeden dat HS 
is afgedekt door immuun deposities. We bestudeerden nierbiopsie ën van 11 lupus 
patiënten met diffuus proliferatieve glomerulonefritis (DPGN, WHO klasse IV) en 
6 patiënten met membraneuze glomerulonefritis (MGN, WHO klasse V). Coupes van 
alle nierbiopsie ën werden gekleurd op de aanwezigheid van histonen, nucleosomen, 
DNA en IgG in de immuun deposities. Bovendien werd de kleurbaarheid van HS en 
eiwitdeel van heparaan sulfaat proteoglycaan (HSPG) (het glycoproteine waarvan HS 
een zijketen is) in de GBM getest. Histonen waren aanwezig in de glomerulaire 
deposities van alle patiënten met DPGN en in 2 van de 6 patiënten met MGN 
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(p<0,02; Fisher exact test). Nucleosomen werden aangetoond in de biopsieën van 5 
patiënten met DPGN en in geen van de MGN patiënten. De HS kleuring was vrijwel 
verdwenen in de GBM van DPGN patiënten, terwijl deze slechts in lichte mate 
verminderd was bij MGN patiënten. Er was een significante correlatie tussen de 
aanwezigheid van histonen en de afname van HS kleuring (rs = -0,77). De 
kleurbaarheid van het eiwitdeel van HSPG was normaal in alle biopsiëen. Het is 
onduidelijk of het nucleosomale partikel wat aanwezig is in glomerulaire immuun 
deposities voornamelijk uit histonen bestaat, of dat in vivo binding van anti-dsDNA 
en/of anti-nucleosoom antistoffen bepaalde nucleosomale epitopen afdekt. 
In hoofdstuk zes wordt een ander mechanisme beschreven waardoor anti-nucleosoom 
antistoffen pathogeen kunnen zijn. Als hybridomen die monoclonale anti-nucleosoom 
antistoffen produceren intraperitoneaal bij muizen worden geplaatst, wordt met 
immunofluorescentie (IF) niet alleen glomerulaire binding gezien maar ook binding 
van antistoffen aan de cel kernen. Dit fenomeen heet in vivo anti-nucleaire activiteit 
(in vivo ANA). Onlangs werd beschreven dat bepaalde anti-dsDNA antistoffen aan 
het cel oppervlak kunnen binden, vervolgens in het cytoplasma opgenomen worden 
en daarna naar de celkern getransporteerd worden (in vivo ANA), hetgeen pathogeen 
zou zijn en zou leiden tot verminderde cel proliferatie, toegenomen eiwit synthese, 
glomerulaire hypercellulariteit en proteinuric 
Als wij antistoffen gecomplexeerd aan nucleosomen intraveneus aan normale muizen 
toedienden, werd na 45 minuten in vivo ANA gezien, terwijl injectie van zuivere 
niet-gecomplexeerde antistoffen niet tot binding van antistoffen leidde. Vervolgens 
bleek in experimenten met humane cellijnen dat ook binding aan het cel oppervlak 
een eigenschap van antistoffen gecomplexeerd aan nucleosomen was, terwijl niet-
gecomplexeerde antistoffen niet bonden. Echter, incubatie van levende cellen met 
gecomplexeerde antistoffen gedurende 24 uur leidde slechts tot opname van 
antistoffen in cytoplasmatische vesikels en niet tot binding aan de kern. Wij 
veronderstelden dat in vivo ANA zoals die in IF gezien werd, wellicht samenhing met 
de methode van fixeren. Om dit aan te tonen, werd van muizen bij wie het 
hybridoom wat de anti-nucleosoom antistoffen produceerde intraperitoneaal geplaatst 
was, een klein deel van de nier genomen en verwerkt voor standaard IF met aceton 
fixatie na het snijden van coupes. Een ander deel van dezelfde nier werd in vivo 
gefixeerd met een oplossing van 0,01 M perjodaat, 0,075 M lysine HCl, 0,0375 M 
NajHPO,, en 2% paraformaldedyde (PLP) en bestudeerd in zowel IF als immuno 
electronen microscopie. Na standaard IF werd, zoals te verwachten was, in vivo ANA 
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gezien, terwijl na in vivo fixatie met PLP geen kembinding, maar slechts opname in 
cytoplasmatische vesikels gevonden werd. Uit deze experimenten concluderen we dat 
anti-nucleosoom antistoffen gecomplexeerd aan nucleosomen aan het cel oppervlak 
kunnen binden en dat de antistoffen vervolgens in het cytoplasma worden 
opgenomen. Het optreden van in vivo ANA echter is afhankelijk van de fixatie 
methode. 
Op dit moment is er betrekkelijk weinig bekend over de epitopen op het nucleosoom 
welke door anti-nucleosoom antistoffen herkend worden. In hoofdstuk zeven wordt 
een panel van 6 anti-nucleosoom antistoffen welke zijn verkregen uit lupus muizen, 
gekarakteriseerd in ELISA door ze te testen op nucleosomen en subnucleosomale 
structuren (H2A/H2B dimeer, H3/H4 tetrameer, H2A/H2B-DNA complex en H3/H4-
DNA complex) en op een panel van 53 overlappende synthetische histon peptiden 
die de volledige aminozuur sequentie van de 5 histonen omvatten. Per definitie had-
den deze antistoffen geen of een lage reactiviteit met DNA of de individuele histonen 
ten opzichte van de reactiviteit met het intacte nucleosoom. In de histon peptide 
ELISA vonden we dat slechts 2 monoclonale antistoffen één van de 53 peptiden 
herkenden. Deze reactiviteit kwam nauwelijks boven de achtergrond uit, waaruit we 
concludeerden dat lineaire histon epitopen van ondergeschikt belang zijn voor de 
binding van deze anti-nucleosomale antistoffen. In de nucleosoom en subnucleosoom 
ELISAs vonden we dat alle 6 antistoffen verschillend reageerden. Drie antistoffen 
toonden een hogere reactiviteit met het intacte nucleosoom dan met subnucleosomale 
structuren. Voor twee van hen bevond het primaire nucleosomale epitoop zich op 
H2A/H2B-DNA en voor de derde op H3/H4-DNA. Twee van de overige antistoffen 
waren gericht tegen een epitoop op H2A/H2B-DNA en de laatste tegen een epitoop 
op H3/H4-DNA. In de subnucleosoom ELISA herkenden alle antistoffen op één na 
meer dan één epitoop. Wanneer DNA met verschillende cationische moleculen gecoat 
werd, bleek voor alle antistoffen één specifiek nucleosomaal epitoop te identificeren 
te zijn, terwijl de reactiviteit met het andere subnucleosoom vergelijkbaar was met 
de reactiviteit met DNA gecoat met willekeurige cationische moleculen. In inhibitie 
experimenten werd zowel in ELISA als in IF gevonden dat slechts één antistof die 
een epitoop op H2A/H2B-DNA herkende, geremd kon worden door H2A/H2B-DNA 
in vloeibare fase. De twee antistoffen die een epitoop op H3/H4-DNA herkenden 
konden beiden wel door H3/H4-DNA in vloeibare fase geremd worden. Uit deze 
experimenten concluderen we dat sommige epitopen op H2A/H2B-DNA die door 
bepaalde anti-nucleosomale antistoffen in ELISA herkend worden, niet op H2A/H2B-
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DNA in vloeibare fase voorkomen. 
Deze 6 monoclonale antistoffen herkennen allen verschillende epitopen op zowel 
H2A/H2B-DNA en H3/H4-DNA. Deze bevindigen bevestigen de veronderstelling dat 
in SLE het hele nucleosoom het auto-antigen is dat de vorming van deze anti-
nucleosoom antistoffen veroorzaakt. 
Op dit moment wordt verondersteld dat de auto-immuun reactie in SLE antigeen en 
T-cel afhankelijk is. Het nucleosoom zou een belangrijk immunogeen zijn, hetgeen 
uiteindelijk leidt tot de vorming van niet alleen anti-nucleosoom, maar ook anti-
dsDNA en anti-histon antistoffen. Volgens deze visie is een nucleosomaal epitoop 
betrokken bij de vorming van anti-dsDNA antistoffen. Daarom veronderstelden we 
dat anti-dsDNA wellicht meer dan DNA alleen herkennen en testten we in hoofdstuk 
acht 6 monoclonale antistoffen welke waren verkregen van lupus muizen op het 
panel van 53 overlappende synthetische histon peptiden, zoals dat in hoofdstuk 7 
beschreven is. Wij vonden dat 4 van deze 6 antistoffen één en hetzelfde histon 
peptide herkenden namelijk het 83-100 peptide van histon H3. Zowel DNA als H3 
83-100 waren in staat om de binding van deze antistoffen aan DNA en H3 83-100 
en vice versa te remmen. We hypothetiseren dat dit peptide samen met DNA een 
nucleosomaal epitoop vormt, waartegen antistoffen ontstaan, die zowel DNA als H3 
83-100 apart kunnen binden. Recent is gepostuleerd dat het nucleosoom wordt 
verwerkt door antigeen presenterende cellen en dat cryptische nucleosomale peptiden 
aan de T-cellen aangeboden worden, welke de B-cellen bijstaan bij de productie van 
anti-dsDNA antistoffen. Wellicht is H3 83-100 één van deze cryptische epitopen. 
Daar apoptotische cellen de meest voor de hand liggende bron voor nucleosomen in 
de circulatie zijn en verstoring van apoptose zowel bij mensen als bij muizen 
beschreven is in SLE, hebben we in hoofdstuk negen de literatuur betreffende 
apoptose, nucleosomen en nefritis in SLE samengevat. Verstoring van apoptose kan 
zowel tot langdurige overleving van autoreactieve T-cellen leiden, als tot het 
vrijkomen van nucleosomen die wellicht veranderd en zo immunogeen zijn. 
Verminderde fagocytose, hetgeen ook bij SLE beschreven is, kan leiden tot een 
verlengde overleving van nucleosomen in de circulatie. Deze veranderde 
nucleosomen kunnen het doelwit zijn van autoreactieve T-cellen, hetgeen leidt tot de 
vorming van anti-nucleosoom, anti-dsDNA en anti-histon antistoffen. Zoals 
beschreven in de hoofdstukken 2 en 3, kunnen nucleosomen de binding van deze 
antistoffen aan de GBM bewerkstelligen. Aldus lijken nucleosomen een centrale rol 
in SLE te spelen, zowel bij de inductie als in de effector-fase van de ziekte. 
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STELLINGEN 
behorende bij het proefschrift 
Anti-nucleosome auto-antibodies 
in systemic lupus erythematosus 
Kees Kramers 
12-12-1995 
1. Nucleosomaal materiaal kan de binding van anti-nucleosoom antistoffen 
aan de GBM mediè'ren en speelt op deze manier een rol in de initiatie van 
lupus nefritis. 
(dit proefschrift) 
2. Anti-nucleosoom antistoffen, zoals die bij SLE worden aangetroffen, zijn 
zeer heterogeen en herkennen verschillende nucleosomale epitopen. 
(dit proefschrift) 
3. Het feit dat in glomerulaire deposities van lupus patiënten histonen en 
nucleosomen aantoonbaar zijn, terwijl DNA niet aankleurt, suggereert dat 
DNA is afgedekt door antistoffen. 
(dit proefschrift) 
4. Het feit dat sommige anti-DNA antistoffen een histon peptide herkennen, 
suggereert dat nucleosomen van belang zijn voor de vorming van deze 
antistoffen. 
(dit proefschrift, Mohan et al J.Exp.Med. 1993;177:1367) 
5. Apoptose speelt een belangrijke rol in de Pathogenese van SLE, zowel in 
de initiatie als in de effector fase van de ziekte. 
6. Het is tot op heden onmogelijk alle antistoffen uit plasma of glomerulaire 
eluaten op te zuiveren zonder selectief reactiviteit te verliezen. 
7. De polyreactiviteit van glomerulaire eluaten zoals beschreven door Sabbaga 
et al (J.Autoimmunity 1990;3:215) is ongetwijfeld veroorzaakt door 
antistoffen gecomplexeerd aan nucleosomaal materiaal. 
8. De bestudering van anti-nucleosomale antistoffen in SLE en drug-induced 
lupus zal inzicht kunnen verschaffen over de eigenschappen die de 
nefritogeniciteit bepalen. 
9. Bij de selectie voor geschikte kandidaten voor de opleiding tot internist zou 
een meting van het kukel moeten geschieden. 
(vrij naar Marten Toonder) 
10. Voor de zuiverheid van beoordeling van onderzoek door paraklinische 
specialismen zoals radiodiagnostiek en pathologie zou vermelding van 
klinische gegevens achterwege moeten blijven. 
11. Een goede onderzoeker heeft een goede analist. 
12. Door condooms en geboortebeperking te verbieden, werkt het Vaticaan 
mee aan een catastrofe in Afrika. 
13. Principiële tegenstanders van actieve euthanasie begeleiden geen patiënten. 
14. Het is met moraal, zoals met invoegen in de file. Degene die eerder 
invoegt is een sukkel, degene die later invoegt een schon. 
15. A small step for a man, a giant leap for mankind, 
(dit proefschrift) 



